#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Progressive Symptom-Associated Prefrontal Volume Loss Occurs in First-Episode Schizophrenia but not in Affective Psychosis
#Text=Although smaller gray matter volumes (GMV) in the prefrontal cortex (PFC) in schizophrenia and bipolar disorder have been reported cross-sectionally, there are, to our knowledge, no reports of longitudinal comparisons using manually drawn, gyrally-based ROI, and their associations with symptoms.
1-1	0-11	Progressive	_
1-2	12-30	Symptom-Associated	_
1-3	31-41	Prefrontal	_
1-4	42-48	Volume	_
1-5	49-53	Loss	_
1-6	54-60	Occurs	_
1-7	61-63	in	_
1-8	64-77	First-Episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]
1-9	78-91	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
1-10	92-95	but	_
1-11	96-99	not	_
1-12	100-102	in	_
1-13	103-112	Affective	_
1-14	113-122	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
1-15	123-131	Although	_
1-16	132-139	smaller	_
1-17	140-144	gray	_
1-18	145-151	matter	_
1-19	152-159	volumes	_
1-20	160-161	(	_
1-21	161-164	GMV	_
1-22	164-165	)	_
1-23	166-168	in	_
1-24	169-172	the	_
1-25	173-183	prefrontal	_
1-26	184-190	cortex	_
1-27	191-192	(	_
1-28	192-195	PFC	_
1-29	195-196	)	_
1-30	197-199	in	_
1-31	200-213	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-32	214-217	and	_
1-33	218-225	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[3]
1-34	226-234	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[3]
1-35	235-239	have	_
1-36	240-244	been	_
1-37	245-253	reported	_
1-38	254-271	cross-sectionally	_
1-39	271-272	,	_
1-40	273-278	there	_
1-41	279-282	are	_
1-42	282-283	,	_
1-43	284-286	to	_
1-44	287-290	our	_
1-45	291-300	knowledge	_
1-46	300-301	,	_
1-47	302-304	no	_
1-48	305-312	reports	_
1-49	313-315	of	_
1-50	316-328	longitudinal	_
1-51	329-340	comparisons	_
1-52	341-346	using	_
1-53	347-355	manually	_
1-54	356-361	drawn	_
1-55	361-362	,	_
1-56	363-376	gyrally-based	_
1-57	377-380	ROI	_
1-58	380-381	,	_
1-59	382-385	and	_
1-60	386-391	their	_
1-61	392-404	associations	_
1-62	405-409	with	_
1-63	410-418	symptoms	_
1-64	418-419	.	_

#Text=The object of this study was to determine whether first-episode schizophrenia (FESZ) and first-episode affective psychosis (FEAFF) patients show initial and progressive PFC GMV reduction in bilateral frontal pole, superior frontal gyrus (SFG), middle frontal gyrus (MFG), and inferior frontal gyrus (IFG) and examine their symptom associations.
2-1	420-423	The	_
2-2	424-430	object	_
2-3	431-433	of	_
2-4	434-438	this	_
2-5	439-444	study	_
2-6	445-448	was	_
2-7	449-451	to	_
2-8	452-461	determine	_
2-9	462-469	whether	_
2-10	470-483	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]
2-11	484-497	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]
2-12	498-499	(	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]
2-13	499-503	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]
2-14	503-504	)	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]
2-15	505-508	and	_
2-16	509-522	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]
2-17	523-532	affective	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]
2-18	533-542	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[7]
2-19	543-544	(	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]
2-20	544-549	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]
2-21	549-550	)	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]
2-22	551-559	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]
2-23	560-564	show	_
2-24	565-572	initial	_
2-25	573-576	and	_
2-26	577-588	progressive	_
2-27	589-592	PFC	_
2-28	593-596	GMV	_
2-29	597-606	reduction	_
2-30	607-609	in	_
2-31	610-619	bilateral	_
2-32	620-627	frontal	_
2-33	628-632	pole	_
2-34	632-633	,	_
2-35	634-642	superior	_
2-36	643-650	frontal	_
2-37	651-656	gyrus	_
2-38	657-658	(	_
2-39	658-661	SFG	_
2-40	661-662	)	_
2-41	662-663	,	_
2-42	664-670	middle	_
2-43	671-678	frontal	_
2-44	679-684	gyrus	_
2-45	685-686	(	_
2-46	686-689	MFG	_
2-47	689-690	)	_
2-48	690-691	,	_
2-49	692-695	and	_
2-50	696-704	inferior	_
2-51	705-712	frontal	_
2-52	713-718	gyrus	_
2-53	719-720	(	_
2-54	720-723	IFG	_
2-55	723-724	)	_
2-56	725-728	and	_
2-57	729-736	examine	_
2-58	737-742	their	_
2-59	743-750	symptom	_
2-60	751-763	associations	_
2-61	763-764	.	_

#Text=Twenty-one FESZ, 24 FEAFF and 23 healthy control subjects (HC) underwent 1.5T MRI with follow-up imaging on the same scanner ~ 1.5 years later.
3-1	765-775	Twenty-one	_
3-2	776-780	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-3	780-781	,	_
3-4	782-784	24	_
3-5	785-790	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
3-6	791-794	and	_
3-7	795-797	23	_
3-8	798-805	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]
3-9	806-813	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]
3-10	814-822	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]
3-11	823-824	(	_
3-12	824-826	HC	_
3-13	826-827	)	_
3-14	828-837	underwent	_
3-15	838-842	1.5T	_
3-16	843-846	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument
3-17	847-851	with	_
3-18	852-861	follow-up	_
3-19	862-869	imaging	_
3-20	870-872	on	_
3-21	873-876	the	_
3-22	877-881	same	_
3-23	882-889	scanner	_
3-24	890-891	~	_
3-25	892-895	1.5	_
3-26	896-901	years	_
3-27	902-907	later	_
3-28	907-908	.	_

#Text=Groups were strikingly different in progressive GMV loss.
4-1	909-915	Groups	_
4-2	916-920	were	_
4-3	921-931	strikingly	_
4-4	932-941	different	_
4-5	942-944	in	_
4-6	945-956	progressive	_
4-7	957-960	GMV	_
4-8	961-965	loss	_
4-9	965-966	.	_

#Text=FESZ showed significant progressive GMV loss in the left SFG, bilateral MFG, and bilateral IFG.
5-1	967-971	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[10]
5-2	972-978	showed	_
5-3	979-990	significant	_
5-4	991-1002	progressive	_
5-5	1003-1006	GMV	_
5-6	1007-1011	loss	_
5-7	1012-1014	in	_
5-8	1015-1018	the	_
5-9	1019-1023	left	_
5-10	1024-1027	SFG	_
5-11	1027-1028	,	_
5-12	1029-1038	bilateral	_
5-13	1039-1042	MFG	_
5-14	1042-1043	,	_
5-15	1044-1047	and	_
5-16	1048-1057	bilateral	_
5-17	1058-1061	IFG	_
5-18	1061-1062	.	_

#Text=In addition, left MFG and/or IFG GMV loss was associated with worsening of withdrawal-retardation and total BPRS symptoms scores.
6-1	1063-1065	In	_
6-2	1066-1074	addition	_
6-3	1074-1075	,	_
6-4	1076-1080	left	_
6-5	1081-1084	MFG	_
6-6	1085-1088	and	_
6-7	1088-1089	/	_
6-8	1089-1091	or	_
6-9	1092-1095	IFG	_
6-10	1096-1099	GMV	_
6-11	1100-1104	loss	_
6-12	1105-1108	was	_
6-13	1109-1119	associated	_
6-14	1120-1124	with	_
6-15	1125-1134	worsening	_
6-16	1135-1137	of	_
6-17	1138-1160	withdrawal-retardation	_
6-18	1161-1164	and	_
6-19	1165-1170	total	_
6-20	1171-1175	BPRS	_
6-21	1176-1184	symptoms	_
6-22	1185-1191	scores	_
6-23	1191-1192	.	_

#Text=In contrast, FEAFF showed no significant difference in GMV compared with HC, either cross-sectionally or longitudinally.
7-1	1193-1195	In	_
7-2	1196-1204	contrast	_
7-3	1204-1205	,	_
7-4	1206-1211	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[11]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[12]
7-5	1212-1218	showed	_
7-6	1219-1221	no	_
7-7	1222-1233	significant	_
7-8	1234-1244	difference	_
7-9	1245-1247	in	_
7-10	1248-1251	GMV	_
7-11	1252-1260	compared	_
7-12	1261-1265	with	_
7-13	1266-1268	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]
7-14	1268-1269	,	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]
7-15	1270-1276	either	_
7-16	1277-1294	cross-sectionally	_
7-17	1295-1297	or	_
7-18	1298-1312	longitudinally	_
7-19	1312-1313	.	_

#Text=Of note, FreeSurfer run on the same images showed no significant changes longitudinally.
8-1	1314-1316	Of	_
8-2	1317-1321	note	_
8-3	1321-1322	,	_
8-4	1323-1333	FreeSurfer	_
8-5	1334-1337	run	_
8-6	1338-1340	on	_
8-7	1341-1344	the	_
8-8	1345-1349	same	_
8-9	1350-1356	images	_
8-10	1357-1363	showed	_
8-11	1364-1366	no	_
8-12	1367-1378	significant	_
8-13	1379-1386	changes	_
8-14	1387-1401	longitudinally	_
8-15	1401-1402	.	_

#Text=Introduction
#Text=The prefrontal cortex (PFC) has been associated with the pathophysiology of schizophrenia.
9-1	1403-1415	Introduction	_
9-2	1416-1419	The	_
9-3	1420-1430	prefrontal	_
9-4	1431-1437	cortex	_
9-5	1438-1439	(	_
9-6	1439-1442	PFC	_
9-7	1442-1443	)	_
9-8	1444-1447	has	_
9-9	1448-1452	been	_
9-10	1453-1463	associated	_
9-11	1464-1468	with	_
9-12	1469-1472	the	_
9-13	1473-1488	pathophysiology	_
9-14	1489-1491	of	_
9-15	1492-1505	schizophrenia	_
9-16	1505-1506	.	_

#Text=Cross-sectional voxel-based morphometry (VBM) studies revealed PFC volume reduction and several studies manually parcellating the PFC into subregions showed smaller volumes in the superior frontal gyrus (SFG), middle frontal gyrus (MFG), and inferior frontal gyrus (IFG).
10-1	1507-1522	Cross-sectional	_
10-2	1523-1534	voxel-based	_
10-3	1535-1546	morphometry	_
10-4	1547-1548	(	_
10-5	1548-1551	VBM	_
10-6	1551-1552	)	_
10-7	1553-1560	studies	_
10-8	1561-1569	revealed	_
10-9	1570-1573	PFC	_
10-10	1574-1580	volume	_
10-11	1581-1590	reduction	_
10-12	1591-1594	and	_
10-13	1595-1602	several	_
10-14	1603-1610	studies	_
10-15	1611-1619	manually	_
10-16	1620-1632	parcellating	_
10-17	1633-1636	the	_
10-18	1637-1640	PFC	_
10-19	1641-1645	into	_
10-20	1646-1656	subregions	_
10-21	1657-1663	showed	_
10-22	1664-1671	smaller	_
10-23	1672-1679	volumes	_
10-24	1680-1682	in	_
10-25	1683-1686	the	_
10-26	1687-1695	superior	_
10-27	1696-1703	frontal	_
10-28	1704-1709	gyrus	_
10-29	1710-1711	(	_
10-30	1711-1714	SFG	_
10-31	1714-1715	)	_
10-32	1715-1716	,	_
10-33	1717-1723	middle	_
10-34	1724-1731	frontal	_
10-35	1732-1737	gyrus	_
10-36	1738-1739	(	_
10-37	1739-1742	MFG	_
10-38	1742-1743	)	_
10-39	1743-1744	,	_
10-40	1745-1748	and	_
10-41	1749-1757	inferior	_
10-42	1758-1765	frontal	_
10-43	1766-1771	gyrus	_
10-44	1772-1773	(	_
10-45	1773-1776	IFG	_
10-46	1776-1777	)	_
10-47	1777-1778	.	_

#Text=However, results were not consistent in the longitudinal studies.
11-1	1779-1786	However	_
11-2	1786-1787	,	_
11-3	1788-1795	results	_
11-4	1796-1800	were	_
11-5	1801-1804	not	_
11-6	1805-1815	consistent	_
11-7	1816-1818	in	_
11-8	1819-1822	the	_
11-9	1823-1835	longitudinal	_
11-10	1836-1843	studies	_
11-11	1843-1844	.	_

#Text=In schizophrenia compared with healthy controls (HC), one study found that the frontal region showed longitudinal cortical thinning and our VBM study also showed progressive gray matter volume (GMV) reduction in the prefrontal region, but another VBM study reported no reduction in the FESZ group.
12-1	1845-1847	In	_
12-2	1848-1861	schizophrenia	_
12-3	1862-1870	compared	_
12-4	1871-1875	with	_
12-5	1876-1883	healthy	_
12-6	1884-1892	controls	_
12-7	1893-1894	(	_
12-8	1894-1896	HC	_
12-9	1896-1897	)	_
12-10	1897-1898	,	_
12-11	1899-1902	one	_
12-12	1903-1908	study	_
12-13	1909-1914	found	_
12-14	1915-1919	that	_
12-15	1920-1923	the	_
12-16	1924-1931	frontal	_
12-17	1932-1938	region	_
12-18	1939-1945	showed	_
12-19	1946-1958	longitudinal	_
12-20	1959-1967	cortical	_
12-21	1968-1976	thinning	_
12-22	1977-1980	and	_
12-23	1981-1984	our	_
12-24	1985-1988	VBM	_
12-25	1989-1994	study	_
12-26	1995-1999	also	_
12-27	2000-2006	showed	_
12-28	2007-2018	progressive	_
12-29	2019-2023	gray	_
12-30	2024-2030	matter	_
12-31	2031-2037	volume	_
12-32	2038-2039	(	_
12-33	2039-2042	GMV	_
12-34	2042-2043	)	_
12-35	2044-2053	reduction	_
12-36	2054-2056	in	_
12-37	2057-2060	the	_
12-38	2061-2071	prefrontal	_
12-39	2072-2078	region	_
12-40	2078-2079	,	_
12-41	2080-2083	but	_
12-42	2084-2091	another	_
12-43	2092-2095	VBM	_
12-44	2096-2101	study	_
12-45	2102-2110	reported	_
12-46	2111-2113	no	_
12-47	2114-2123	reduction	_
12-48	2124-2126	in	_
12-49	2127-2130	the	_
12-50	2131-2135	FESZ	_
12-51	2136-2141	group	_
12-52	2141-2142	.	_

#Text=Another study reported that the FESZ group showed greater longitudinal brain surface contraction in the anterior parts of the SFG and MFG bilaterally.
13-1	2143-2150	Another	_
13-2	2151-2156	study	_
13-3	2157-2165	reported	_
13-4	2166-2170	that	_
13-5	2171-2174	the	_
13-6	2175-2179	FESZ	_
13-7	2180-2185	group	_
13-8	2186-2192	showed	_
13-9	2193-2200	greater	_
13-10	2201-2213	longitudinal	_
13-11	2214-2219	brain	_
13-12	2220-2227	surface	_
13-13	2228-2239	contraction	_
13-14	2240-2242	in	_
13-15	2243-2246	the	_
13-16	2247-2255	anterior	_
13-17	2256-2261	parts	_
13-18	2262-2264	of	_
13-19	2265-2268	the	_
13-20	2269-2272	SFG	_
13-21	2273-2276	and	_
13-22	2277-2280	MFG	_
13-23	2281-2292	bilaterally	_
13-24	2292-2293	.	_

#Text=However, progressive gyrus-level changes may play a role in the pathophysiology of the onset and of post-onset progression in FESZ, since each of the SFG, MFG, and IFG has been associated with specific functions.
14-1	2294-2301	However	_
14-2	2301-2302	,	_
14-3	2303-2314	progressive	_
14-4	2315-2326	gyrus-level	_
14-5	2327-2334	changes	_
14-6	2335-2338	may	_
14-7	2339-2343	play	_
14-8	2344-2345	a	_
14-9	2346-2350	role	_
14-10	2351-2353	in	_
14-11	2354-2357	the	_
14-12	2358-2373	pathophysiology	_
14-13	2374-2376	of	_
14-14	2377-2380	the	_
14-15	2381-2386	onset	_
14-16	2387-2390	and	_
14-17	2391-2393	of	_
14-18	2394-2404	post-onset	_
14-19	2405-2416	progression	_
14-20	2417-2419	in	_
14-21	2420-2424	FESZ	_
14-22	2424-2425	,	_
14-23	2426-2431	since	_
14-24	2432-2436	each	_
14-25	2437-2439	of	_
14-26	2440-2443	the	_
14-27	2444-2447	SFG	_
14-28	2447-2448	,	_
14-29	2449-2452	MFG	_
14-30	2452-2453	,	_
14-31	2454-2457	and	_
14-32	2458-2461	IFG	_
14-33	2462-2465	has	_
14-34	2466-2470	been	_
14-35	2471-2481	associated	_
14-36	2482-2486	with	_
14-37	2487-2495	specific	_
14-38	2496-2505	functions	_
14-39	2505-2506	.	_

#Text=Given the fact that none of the previously used longitudinal methods accurately measured gyral volume we thus used gyrally based manual tracing methodology, and included a psychotic first episode affective psychosis group (FEAFF) for comparison.
15-1	2507-2512	Given	_
15-2	2513-2516	the	_
15-3	2517-2521	fact	_
15-4	2522-2526	that	_
15-5	2527-2531	none	_
15-6	2532-2534	of	_
15-7	2535-2538	the	_
15-8	2539-2549	previously	_
15-9	2550-2554	used	_
15-10	2555-2567	longitudinal	_
15-11	2568-2575	methods	_
15-12	2576-2586	accurately	_
15-13	2587-2595	measured	_
15-14	2596-2601	gyral	_
15-15	2602-2608	volume	_
15-16	2609-2611	we	_
15-17	2612-2616	thus	_
15-18	2617-2621	used	_
15-19	2622-2629	gyrally	_
15-20	2630-2635	based	_
15-21	2636-2642	manual	_
15-22	2643-2650	tracing	_
15-23	2651-2662	methodology	_
15-24	2662-2663	,	_
15-25	2664-2667	and	_
15-26	2668-2676	included	_
15-27	2677-2678	a	_
15-28	2679-2688	psychotic	_
15-29	2689-2694	first	_
15-30	2695-2702	episode	_
15-31	2703-2712	affective	_
15-32	2713-2722	psychosis	_
15-33	2723-2728	group	_
15-34	2729-2730	(	_
15-35	2730-2735	FEAFF	_
15-36	2735-2736	)	_
15-37	2737-2740	for	_
15-38	2741-2751	comparison	_
15-39	2751-2752	.	_

#Text=Clinically, positive symptoms are present in the acute psychotic state, with post-psychotic depression and negative symptoms becoming more apparent after the initial acute psychotic state in FESZ.
16-1	2753-2763	Clinically	_
16-2	2763-2764	,	_
16-3	2765-2773	positive	_
16-4	2774-2782	symptoms	_
16-5	2783-2786	are	_
16-6	2787-2794	present	_
16-7	2795-2797	in	_
16-8	2798-2801	the	_
16-9	2802-2807	acute	_
16-10	2808-2817	psychotic	_
16-11	2818-2823	state	_
16-12	2823-2824	,	_
16-13	2825-2829	with	_
16-14	2830-2844	post-psychotic	_
16-15	2845-2855	depression	_
16-16	2856-2859	and	_
16-17	2860-2868	negative	_
16-18	2869-2877	symptoms	_
16-19	2878-2886	becoming	_
16-20	2887-2891	more	_
16-21	2892-2900	apparent	_
16-22	2901-2906	after	_
16-23	2907-2910	the	_
16-24	2911-2918	initial	_
16-25	2919-2924	acute	_
16-26	2925-2934	psychotic	_
16-27	2935-2940	state	_
16-28	2941-2943	in	_
16-29	2944-2948	FESZ	_
16-30	2948-2949	.	_

#Text=Of further relevance, the severity of withdrawal-retardation subscale scores of the Brief Psychiatric Rating Scale (BPRS) in FESZ were found to be inversely correlated with fMRI activation of the frontal operculum.
17-1	2950-2952	Of	_
17-2	2953-2960	further	_
17-3	2961-2970	relevance	_
17-4	2970-2971	,	_
17-5	2972-2975	the	_
17-6	2976-2984	severity	_
17-7	2985-2987	of	_
17-8	2988-3010	withdrawal-retardation	_
17-9	3011-3019	subscale	_
17-10	3020-3026	scores	_
17-11	3027-3029	of	_
17-12	3030-3033	the	_
17-13	3034-3039	Brief	_
17-14	3040-3051	Psychiatric	_
17-15	3052-3058	Rating	_
17-16	3059-3064	Scale	_
17-17	3065-3066	(	_
17-18	3066-3070	BPRS	_
17-19	3070-3071	)	_
17-20	3072-3074	in	_
17-21	3075-3079	FESZ	_
17-22	3080-3084	were	_
17-23	3085-3090	found	_
17-24	3091-3093	to	_
17-25	3094-3096	be	_
17-26	3097-3106	inversely	_
17-27	3107-3117	correlated	_
17-28	3118-3122	with	_
17-29	3123-3127	fMRI	_
17-30	3128-3138	activation	_
17-31	3139-3141	of	_
17-32	3142-3145	the	_
17-33	3146-3153	frontal	_
17-34	3154-3163	operculum	_
17-35	3163-3164	.	_

#Text=We thus hypothesized that FESZ would display progressive structural abnormalities in gyrally defined ROI and that gyral loss of GMV might be associated with emergent depression and negative symptoms after the acute psychotic state.
18-1	3165-3167	We	_
18-2	3168-3172	thus	_
18-3	3173-3185	hypothesized	_
18-4	3186-3190	that	_
18-5	3191-3195	FESZ	_
18-6	3196-3201	would	_
18-7	3202-3209	display	_
18-8	3210-3221	progressive	_
18-9	3222-3232	structural	_
18-10	3233-3246	abnormalities	_
18-11	3247-3249	in	_
18-12	3250-3257	gyrally	_
18-13	3258-3265	defined	_
18-14	3266-3269	ROI	_
18-15	3270-3273	and	_
18-16	3274-3278	that	_
18-17	3279-3284	gyral	_
18-18	3285-3289	loss	_
18-19	3290-3292	of	_
18-20	3293-3296	GMV	_
18-21	3297-3302	might	_
18-22	3303-3305	be	_
18-23	3306-3316	associated	_
18-24	3317-3321	with	_
18-25	3322-3330	emergent	_
18-26	3331-3341	depression	_
18-27	3342-3345	and	_
18-28	3346-3354	negative	_
18-29	3355-3363	symptoms	_
18-30	3364-3369	after	_
18-31	3370-3373	the	_
18-32	3374-3379	acute	_
18-33	3380-3389	psychotic	_
18-34	3390-3395	state	_
18-35	3395-3396	.	_

#Text=Subgenual PFC volume reduction has been shown in patients with affective disorder, and smaller IFG correlated with the lifetime number of manic episodes in bipolar disorder (BD).
19-1	3397-3406	Subgenual	_
19-2	3407-3410	PFC	_
19-3	3411-3417	volume	_
19-4	3418-3427	reduction	_
19-5	3428-3431	has	_
19-6	3432-3436	been	_
19-7	3437-3442	shown	_
19-8	3443-3445	in	_
19-9	3446-3454	patients	_
19-10	3455-3459	with	_
19-11	3460-3469	affective	_
19-12	3470-3478	disorder	_
19-13	3478-3479	,	_
19-14	3480-3483	and	_
19-15	3484-3491	smaller	_
19-16	3492-3495	IFG	_
19-17	3496-3506	correlated	_
19-18	3507-3511	with	_
19-19	3512-3515	the	_
19-20	3516-3524	lifetime	_
19-21	3525-3531	number	_
19-22	3532-3534	of	_
19-23	3535-3540	manic	_
19-24	3541-3549	episodes	_
19-25	3550-3552	in	_
19-26	3553-3560	bipolar	_
19-27	3561-3569	disorder	_
19-28	3570-3571	(	_
19-29	3571-3573	BD	_
19-30	3573-3574	)	_
19-31	3574-3575	.	_

#Text=These findings suggest that patients with affective disorder might show volume reduction in PFC, and abnormalities in the PFC might be associated with clinical features.
20-1	3576-3581	These	_
20-2	3582-3590	findings	_
20-3	3591-3598	suggest	_
20-4	3599-3603	that	_
20-5	3604-3612	patients	_
20-6	3613-3617	with	_
20-7	3618-3627	affective	_
20-8	3628-3636	disorder	_
20-9	3637-3642	might	_
20-10	3643-3647	show	_
20-11	3648-3654	volume	_
20-12	3655-3664	reduction	_
20-13	3665-3667	in	_
20-14	3668-3671	PFC	_
20-15	3671-3672	,	_
20-16	3673-3676	and	_
20-17	3677-3690	abnormalities	_
20-18	3691-3693	in	_
20-19	3694-3697	the	_
20-20	3698-3701	PFC	_
20-21	3702-3707	might	_
20-22	3708-3710	be	_
20-23	3711-3721	associated	_
20-24	3722-3726	with	_
20-25	3727-3735	clinical	_
20-26	3736-3744	features	_
20-27	3744-3745	.	_

#Text=Longitudinally, when compared with their HC group, a FEAFF group did not show progressive volume reduction, although progressive volume reduction in the prefrontal area was found in a different BD group.
21-1	3746-3760	Longitudinally	_
21-2	3760-3761	,	_
21-3	3762-3766	when	_
21-4	3767-3775	compared	_
21-5	3776-3780	with	_
21-6	3781-3786	their	_
21-7	3787-3789	HC	_
21-8	3790-3795	group	_
21-9	3795-3796	,	_
21-10	3797-3798	a	_
21-11	3799-3804	FEAFF	_
21-12	3805-3810	group	_
21-13	3811-3814	did	_
21-14	3815-3818	not	_
21-15	3819-3823	show	_
21-16	3824-3835	progressive	_
21-17	3836-3842	volume	_
21-18	3843-3852	reduction	_
21-19	3852-3853	,	_
21-20	3854-3862	although	_
21-21	3863-3874	progressive	_
21-22	3875-3881	volume	_
21-23	3882-3891	reduction	_
21-24	3892-3894	in	_
21-25	3895-3898	the	_
21-26	3899-3909	prefrontal	_
21-27	3910-3914	area	_
21-28	3915-3918	was	_
21-29	3919-3924	found	_
21-30	3925-3927	in	_
21-31	3928-3929	a	_
21-32	3930-3939	different	_
21-33	3940-3942	BD	_
21-34	3943-3948	group	_
21-35	3948-3949	.	_

#Text=A critical feature of the present study is evaluating patients longitudinally in the immediate post-onset time period to reveal any structural change differences among FESZ, FEAFF and HC groups.
22-1	3950-3951	A	_
22-2	3952-3960	critical	_
22-3	3961-3968	feature	_
22-4	3969-3971	of	_
22-5	3972-3975	the	_
22-6	3976-3983	present	_
22-7	3984-3989	study	_
22-8	3990-3992	is	_
22-9	3993-4003	evaluating	_
22-10	4004-4012	patients	_
22-11	4013-4027	longitudinally	_
22-12	4028-4030	in	_
22-13	4031-4034	the	_
22-14	4035-4044	immediate	_
22-15	4045-4055	post-onset	_
22-16	4056-4060	time	_
22-17	4061-4067	period	_
22-18	4068-4070	to	_
22-19	4071-4077	reveal	_
22-20	4078-4081	any	_
22-21	4082-4092	structural	_
22-22	4093-4099	change	_
22-23	4100-4111	differences	_
22-24	4112-4117	among	_
22-25	4118-4122	FESZ	_
22-26	4122-4123	,	_
22-27	4124-4129	FEAFF	_
22-28	4130-4133	and	_
22-29	4134-4136	HC	_
22-30	4137-4143	groups	_
22-31	4143-4144	.	_

#Text=It is now being widely recognized that such early evaluation is critical as this is the time of most pronounced change in cognitive variables, implying a consequent critical need for structural MRI studies in the immediate post-onset period.
23-1	4145-4147	It	_
23-2	4148-4150	is	_
23-3	4151-4154	now	_
23-4	4155-4160	being	_
23-5	4161-4167	widely	_
23-6	4168-4178	recognized	_
23-7	4179-4183	that	_
23-8	4184-4188	such	_
23-9	4189-4194	early	_
23-10	4195-4205	evaluation	_
23-11	4206-4208	is	_
23-12	4209-4217	critical	_
23-13	4218-4220	as	_
23-14	4221-4225	this	_
23-15	4226-4228	is	_
23-16	4229-4232	the	_
23-17	4233-4237	time	_
23-18	4238-4240	of	_
23-19	4241-4245	most	_
23-20	4246-4256	pronounced	_
23-21	4257-4263	change	_
23-22	4264-4266	in	_
23-23	4267-4276	cognitive	_
23-24	4277-4286	variables	_
23-25	4286-4287	,	_
23-26	4288-4296	implying	_
23-27	4297-4298	a	_
23-28	4299-4309	consequent	_
23-29	4310-4318	critical	_
23-30	4319-4323	need	_
23-31	4324-4327	for	_
23-32	4328-4338	structural	_
23-33	4339-4342	MRI	_
23-34	4343-4350	studies	_
23-35	4351-4353	in	_
23-36	4354-4357	the	_
23-37	4358-4367	immediate	_
23-38	4368-4378	post-onset	_
23-39	4379-4385	period	_
23-40	4385-4386	.	_

#Text=The present study meets this need and, to our knowledge, this approach is not present in any other longitudinal PFC manually parcellated ROI evaluation of either FESZ or FEAFF.
24-1	4387-4390	The	_
24-2	4391-4398	present	_
24-3	4399-4404	study	_
24-4	4405-4410	meets	_
24-5	4411-4415	this	_
24-6	4416-4420	need	_
24-7	4421-4424	and	_
24-8	4424-4425	,	_
24-9	4426-4428	to	_
24-10	4429-4432	our	_
24-11	4433-4442	knowledge	_
24-12	4442-4443	,	_
24-13	4444-4448	this	_
24-14	4449-4457	approach	_
24-15	4458-4460	is	_
24-16	4461-4464	not	_
24-17	4465-4472	present	_
24-18	4473-4475	in	_
24-19	4476-4479	any	_
24-20	4480-4485	other	_
24-21	4486-4498	longitudinal	_
24-22	4499-4502	PFC	_
24-23	4503-4511	manually	_
24-24	4512-4523	parcellated	_
24-25	4524-4527	ROI	_
24-26	4528-4538	evaluation	_
24-27	4539-4541	of	_
24-28	4542-4548	either	_
24-29	4549-4553	FESZ	_
24-30	4554-4556	or	_
24-31	4557-4562	FEAFF	_
24-32	4562-4563	.	_

#Text=Herein, as what we believe to be a distinct contribution to the literature, we report cross-sectional and longitudinal GMV findings for PFC subregions in FESZ, FEAFF, and HC and the associations between progressive volume reduction in PFC subregions and symptom severity.
25-1	4564-4570	Herein	_
25-2	4570-4571	,	_
25-3	4572-4574	as	_
25-4	4575-4579	what	_
25-5	4580-4582	we	_
25-6	4583-4590	believe	_
25-7	4591-4593	to	_
25-8	4594-4596	be	_
25-9	4597-4598	a	_
25-10	4599-4607	distinct	_
25-11	4608-4620	contribution	_
25-12	4621-4623	to	_
25-13	4624-4627	the	_
25-14	4628-4638	literature	_
25-15	4638-4639	,	_
25-16	4640-4642	we	_
25-17	4643-4649	report	_
25-18	4650-4665	cross-sectional	_
25-19	4666-4669	and	_
25-20	4670-4682	longitudinal	_
25-21	4683-4686	GMV	_
25-22	4687-4695	findings	_
25-23	4696-4699	for	_
25-24	4700-4703	PFC	_
25-25	4704-4714	subregions	_
25-26	4715-4717	in	_
25-27	4718-4722	FESZ	_
25-28	4722-4723	,	_
25-29	4724-4729	FEAFF	_
25-30	4729-4730	,	_
25-31	4731-4734	and	_
25-32	4735-4737	HC	_
25-33	4738-4741	and	_
25-34	4742-4745	the	_
25-35	4746-4758	associations	_
25-36	4759-4766	between	_
25-37	4767-4778	progressive	_
25-38	4779-4785	volume	_
25-39	4786-4795	reduction	_
25-40	4796-4798	in	_
25-41	4799-4802	PFC	_
25-42	4803-4813	subregions	_
25-43	4814-4817	and	_
25-44	4818-4825	symptom	_
25-45	4826-4834	severity	_
25-46	4834-4835	.	_

#Text=Finally, considering that many recent structural MRI studies have adopted automatic voxel-based analysis such as FreeSurfer (https://surfer.nmr.mgh.harvard.edu), we compare FreeSurfer results on the same images and the same ROIs as those used in our manual ROI analysis.
26-1	4836-4843	Finally	_
26-2	4843-4844	,	_
26-3	4845-4856	considering	_
26-4	4857-4861	that	_
26-5	4862-4866	many	_
26-6	4867-4873	recent	_
26-7	4874-4884	structural	_
26-8	4885-4888	MRI	_
26-9	4889-4896	studies	_
26-10	4897-4901	have	_
26-11	4902-4909	adopted	_
26-12	4910-4919	automatic	_
26-13	4920-4931	voxel-based	_
26-14	4932-4940	analysis	_
26-15	4941-4945	such	_
26-16	4946-4948	as	_
26-17	4949-4959	FreeSurfer	_
26-18	4960-4961	(	_
26-19	4961-4966	https	_
26-20	4966-4967	:	_
26-21	4967-4968	/	_
26-22	4968-4969	/	_
26-23	4969-4995	surfer.nmr.mgh.harvard.edu	_
26-24	4995-4996	)	_
26-25	4996-4997	,	_
26-26	4998-5000	we	_
26-27	5001-5008	compare	_
26-28	5009-5019	FreeSurfer	_
26-29	5020-5027	results	_
26-30	5028-5030	on	_
26-31	5031-5034	the	_
26-32	5035-5039	same	_
26-33	5040-5046	images	_
26-34	5047-5050	and	_
26-35	5051-5054	the	_
26-36	5055-5059	same	_
26-37	5060-5064	ROIs	_
26-38	5065-5067	as	_
26-39	5068-5073	those	_
26-40	5074-5078	used	_
26-41	5079-5081	in	_
26-42	5082-5085	our	_
26-43	5086-5092	manual	_
26-44	5093-5096	ROI	_
26-45	5097-5105	analysis	_
26-46	5105-5106	.	_

#Text=Methods
#Text=Participants
#Text=The participants were twenty-one patients with FESZ and 24 with FEAFF (22 BD in a manic phase and 2 with a unipolar depression diagnosis at the time of the scans who later showed a manic phase) and 23 HCs (Table 1).
27-1	5107-5114	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
27-2	5115-5127	Participants	_
27-3	5128-5131	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-4	5132-5144	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-5	5145-5149	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-6	5150-5160	twenty-one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-7	5161-5169	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-8	5170-5174	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-9	5175-5179	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[15]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[16]
27-10	5180-5183	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-11	5184-5186	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-12	5187-5191	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-13	5192-5197	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[17]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[18]
27-14	5198-5199	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-15	5199-5201	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-16	5202-5204	BD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-17	5205-5207	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-18	5208-5209	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-19	5210-5215	manic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-20	5216-5221	phase	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-21	5222-5225	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-22	5226-5227	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-23	5228-5232	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-24	5233-5234	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-25	5235-5243	unipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-26	5244-5254	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-27	5255-5264	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-28	5265-5267	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-29	5268-5271	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-30	5272-5276	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-31	5277-5279	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-32	5280-5283	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-33	5284-5289	scans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-34	5290-5293	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-35	5294-5299	later	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-36	5300-5306	showed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-37	5307-5308	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-38	5309-5314	manic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-39	5315-5320	phase	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-40	5320-5321	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-41	5322-5325	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-42	5326-5328	23	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
27-43	5329-5332	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]
27-44	5333-5334	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
27-45	5334-5339	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
27-46	5340-5341	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
27-47	5341-5342	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
27-48	5342-5343	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=Briefly, the criteria of the subjects are as follows.
28-1	5344-5351	Briefly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-2	5351-5352	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-3	5353-5356	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-4	5357-5365	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-5	5366-5368	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-6	5369-5372	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-7	5373-5381	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-8	5382-5385	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-9	5386-5388	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-10	5389-5396	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
28-11	5396-5397	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=Patients and HCs met criteria for age (18–45 years), IQ ( > 75), right-handedness (handedness was assessed using the Edinburgh inventory), and a negative history for seizures, head trauma with loss of consciousness, neurologic disorder, and no history of drug dependence in the past 5 years.
29-1	5398-5406	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-2	5407-5410	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-3	5411-5414	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
29-4	5415-5418	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-5	5419-5427	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-6	5428-5431	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-7	5432-5435	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-8	5436-5437	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-9	5437-5439	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-10	5439-5440	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-11	5440-5442	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-12	5443-5448	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-13	5448-5449	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-14	5449-5450	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-15	5451-5453	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-16	5454-5455	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-17	5456-5457	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-18	5458-5460	75	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-19	5460-5461	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-20	5461-5462	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-21	5463-5479	right-handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-22	5480-5481	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-23	5481-5491	handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-24	5492-5495	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-25	5496-5504	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-26	5505-5510	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-27	5511-5514	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-28	5515-5524	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[22]
29-29	5525-5534	inventory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[22]
29-30	5534-5535	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-31	5535-5536	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-32	5537-5540	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-33	5541-5542	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-34	5543-5551	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-35	5552-5559	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-36	5560-5563	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-37	5564-5572	seizures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-38	5572-5573	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-39	5574-5578	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-40	5579-5585	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-41	5586-5590	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-42	5591-5595	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-43	5596-5598	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-44	5599-5612	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-45	5612-5613	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-46	5614-5624	neurologic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-47	5625-5633	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-48	5633-5634	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-49	5635-5638	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-50	5639-5641	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-51	5642-5649	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-52	5650-5652	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-53	5653-5657	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-54	5658-5668	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-55	5669-5671	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-56	5672-5675	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-57	5676-5680	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-58	5681-5682	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-59	5683-5688	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
29-60	5688-5689	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=Patient diagnosis was based on the Structured Clinical Interview for DSM (SCID)–Patient Version for DSM-III-R or DSM-IV criteria.
30-1	5690-5697	Patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-2	5698-5707	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-3	5708-5711	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-4	5712-5717	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-5	5718-5720	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-6	5721-5724	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-7	5725-5735	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
30-8	5736-5744	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
30-9	5745-5754	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
30-10	5755-5758	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
30-11	5759-5762	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
30-12	5763-5764	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
30-13	5764-5768	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
30-14	5768-5769	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-15	5769-5770	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-16	5770-5777	Patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-17	5778-5785	Version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-18	5786-5789	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-19	5790-5799	DSM-III-R	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-20	5800-5802	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-21	5803-5809	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-22	5810-5818	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
30-23	5818-5819	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]

#Text=The HCs had no Axis I or Axis II disorder according to the SCID-Non-Patient Version and SCID II Personality Disorders, and no Axis I disorder in their first-degree relatives per self-report.
31-1	5820-5823	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-2	5824-5827	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
31-3	5828-5831	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-4	5832-5834	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-5	5835-5839	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-6	5840-5841	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-7	5842-5844	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-8	5845-5849	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-9	5850-5852	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-10	5853-5861	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-11	5862-5871	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-12	5872-5874	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-13	5875-5878	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-14	5879-5895	SCID-Non-Patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
31-15	5896-5903	Version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-16	5904-5907	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-17	5908-5912	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-18	5913-5915	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-19	5916-5927	Personality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-20	5928-5937	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-21	5937-5938	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-22	5939-5942	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-23	5943-5945	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-24	5946-5950	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-25	5951-5952	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-26	5953-5961	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-27	5962-5964	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-28	5965-5970	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-29	5971-5983	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-30	5984-5993	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-31	5994-5997	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-32	5998-6009	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
31-33	6009-6010	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=All the subjects were longitudinally re-scanned approximately 1.5 years later (Table 2).
32-1	6011-6014	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-2	6015-6018	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-3	6019-6027	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-4	6028-6032	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-5	6033-6047	longitudinally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-6	6048-6058	re-scanned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-7	6059-6072	approximately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-8	6073-6076	1.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-9	6077-6082	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-10	6083-6088	later	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-11	6089-6090	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-12	6090-6095	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-13	6096-6097	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-14	6097-6098	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-15	6098-6099	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Excluding the 2 subjects initially diagnosed as unipolar but later found to be manic did not change the statistical results in the cross-sectional or the longitudinal sample.
33-1	6100-6109	Excluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-2	6110-6113	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-3	6114-6115	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-4	6116-6124	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-5	6125-6134	initially	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-6	6135-6144	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-7	6145-6147	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-8	6148-6156	unipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-9	6157-6160	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-10	6161-6166	later	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-11	6167-6172	found	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-12	6173-6175	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-13	6176-6178	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-14	6179-6184	manic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-15	6185-6188	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-16	6189-6192	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-17	6193-6199	change	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-18	6200-6203	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-19	6204-6215	statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-20	6216-6223	results	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-21	6224-6226	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-22	6227-6230	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-23	6231-6246	cross-sectional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-24	6247-6249	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-25	6250-6253	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-26	6254-6266	longitudinal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-27	6267-6273	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
33-28	6273-6274	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=The cross-sectional and longitudinal groups were matched for age, sex, handedness, and parental socioeconomic status (SES).
34-1	6275-6278	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-2	6279-6294	cross-sectional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-3	6295-6298	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-4	6299-6311	longitudinal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-5	6312-6318	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-6	6319-6323	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-7	6324-6331	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-8	6332-6335	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-9	6336-6339	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-10	6339-6340	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-11	6341-6344	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-12	6344-6345	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-13	6346-6356	handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-14	6356-6357	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-15	6358-6361	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-16	6362-6370	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
34-17	6371-6384	socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[28]
34-18	6385-6391	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[28]
34-19	6392-6393	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[28]
34-20	6393-6396	SES	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[28]
34-21	6396-6397	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[28]
34-22	6397-6398	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Medication history, if present, was assessed by patient report and through medical chart review.
35-1	6399-6409	Medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-2	6410-6417	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-3	6417-6418	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-4	6419-6421	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-5	6422-6429	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-6	6429-6430	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-7	6431-6434	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-8	6435-6443	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-9	6444-6446	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-10	6447-6454	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-11	6455-6461	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-12	6462-6465	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-13	6466-6473	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-14	6474-6481	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-15	6482-6487	chart	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-16	6488-6494	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
35-17	6494-6495	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=Dosage (Table 1 and Table 3) of antipsychotics did not correlate with any initial volume or volume change.
36-1	6496-6502	Dosage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-2	6503-6504	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-3	6504-6509	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-4	6510-6511	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-5	6512-6515	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-6	6516-6521	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-7	6522-6523	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-8	6523-6524	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-9	6525-6527	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-10	6528-6542	antipsychotics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-11	6543-6546	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-12	6547-6550	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-13	6551-6560	correlate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-14	6561-6565	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-15	6566-6569	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-16	6570-6577	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-17	6578-6584	volume	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-18	6585-6587	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-19	6588-6594	volume	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-20	6595-6601	change	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
36-21	6601-6602	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=Patients were recruited at McLean Hospital, a Harvard Medical School affiliate.
37-1	6603-6611	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-2	6612-6616	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-3	6617-6626	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-4	6627-6629	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-5	6630-6636	McLean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-6	6637-6645	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-7	6645-6646	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-8	6647-6648	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-9	6649-6656	Harvard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-10	6657-6664	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-11	6665-6671	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-12	6672-6681	affiliate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
37-13	6681-6682	.	_

#Text=The HCs were recruited through newspaper advertisements.
38-1	6683-6686	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
38-2	6687-6690	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[31]
38-3	6691-6695	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
38-4	6696-6705	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
38-5	6706-6713	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
38-6	6714-6723	newspaper	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
38-7	6724-6738	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
38-8	6738-6739	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]

#Text=Consistent with the literature and our previous studies, a first episode was operationally defined as the first hospitalization for psychosis.
39-1	6740-6750	Consistent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-2	6751-6755	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-3	6756-6759	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-4	6760-6770	literature	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-5	6771-6774	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-6	6775-6778	our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-7	6779-6787	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-8	6788-6795	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-9	6795-6796	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-10	6797-6798	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-11	6799-6804	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-12	6805-6812	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-13	6813-6816	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-14	6817-6830	operationally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-15	6831-6838	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-16	6839-6841	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-17	6842-6845	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-18	6846-6851	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-19	6852-6867	hospitalization	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-20	6868-6871	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-21	6872-6881	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
39-22	6881-6882	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]

#Text=Subjects had not been previously hospitalized for any psychiatric reason.
40-1	6883-6891	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-2	6892-6895	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-3	6896-6899	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-4	6900-6904	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-5	6905-6915	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-6	6916-6928	hospitalized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-7	6929-6932	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-8	6933-6936	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-9	6937-6948	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-10	6949-6955	reason	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]
40-11	6955-6956	.	_

#Text=We believe this criterion is consistent and robust based on a consequent objective record of symptoms; moreover as judged by the onset of antipsychotic medication, our subjects had a short potential psychosis duration prior to our study, 2 weeks for the FESZ and 1 week for FEAFF.
41-1	6957-6959	We	_
41-2	6960-6967	believe	_
41-3	6968-6972	this	_
41-4	6973-6982	criterion	_
41-5	6983-6985	is	_
41-6	6986-6996	consistent	_
41-7	6997-7000	and	_
41-8	7001-7007	robust	_
41-9	7008-7013	based	_
41-10	7014-7016	on	_
41-11	7017-7018	a	_
41-12	7019-7029	consequent	_
41-13	7030-7039	objective	_
41-14	7040-7046	record	_
41-15	7047-7049	of	_
41-16	7050-7058	symptoms	_
41-17	7058-7059	;	_
41-18	7060-7068	moreover	_
41-19	7069-7071	as	_
41-20	7072-7078	judged	_
41-21	7079-7081	by	_
41-22	7082-7085	the	_
41-23	7086-7091	onset	_
41-24	7092-7094	of	_
41-25	7095-7108	antipsychotic	_
41-26	7109-7119	medication	_
41-27	7119-7120	,	_
41-28	7121-7124	our	_
41-29	7125-7133	subjects	_
41-30	7134-7137	had	_
41-31	7138-7139	a	_
41-32	7140-7145	short	_
41-33	7146-7155	potential	_
41-34	7156-7165	psychosis	_
41-35	7166-7174	duration	_
41-36	7175-7180	prior	_
41-37	7181-7183	to	_
41-38	7184-7187	our	_
41-39	7188-7193	study	_
41-40	7193-7194	,	_
41-41	7195-7196	2	_
41-42	7197-7202	weeks	_
41-43	7203-7206	for	_
41-44	7207-7210	the	_
41-45	7211-7215	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[32]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[33]
41-46	7216-7219	and	_
41-47	7220-7221	1	_
41-48	7222-7226	week	_
41-49	7227-7230	for	_
41-50	7231-7236	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[34]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[35]
41-51	7236-7237	.	_

#Text=This study was approved by the McLean Hospital, Veterans Affairs Boston Healthcare System, and Harvard Medical School institutional review boards.
42-1	7238-7242	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-2	7243-7248	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-3	7249-7252	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-4	7253-7261	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-5	7262-7264	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-6	7265-7268	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-7	7269-7275	McLean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-8	7276-7284	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-9	7284-7285	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-10	7286-7294	Veterans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-11	7295-7302	Affairs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-12	7303-7309	Boston	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-13	7310-7320	Healthcare	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-14	7321-7327	System	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-15	7327-7328	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-16	7329-7332	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-17	7333-7340	Harvard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-18	7341-7348	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-19	7349-7355	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-20	7356-7369	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-21	7370-7376	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-22	7377-7383	boards	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
42-23	7383-7384	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]

#Text=Written informed consent was obtained from all subjects before study participation.
43-1	7385-7392	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-2	7393-7401	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-3	7402-7409	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-4	7410-7413	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-5	7414-7422	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-6	7423-7427	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-7	7428-7431	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-8	7432-7440	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-9	7441-7447	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-10	7448-7453	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-11	7454-7467	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
43-12	7467-7468	.	_

#Text=Clinical evaluations at times 1 and 2 included the BPRS and the Wechsler Adult Intelligence Scale–Revised (WAIS-R).
44-1	7469-7477	Clinical	_
44-2	7478-7489	evaluations	_
44-3	7490-7492	at	_
44-4	7493-7498	times	_
44-5	7499-7500	1	_
44-6	7501-7504	and	_
44-7	7505-7506	2	_
44-8	7507-7515	included	_
44-9	7516-7519	the	_
44-10	7520-7524	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
44-11	7525-7528	and	_
44-12	7529-7532	the	_
44-13	7533-7541	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[37]
44-14	7542-7547	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[37]
44-15	7548-7560	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[37]
44-16	7561-7574	Scale–Revised	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[37]
44-17	7575-7576	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[37]
44-18	7576-7582	WAIS-R	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[37]
44-19	7582-7583	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[37]
44-20	7583-7584	.	_

#Text=MRI processing
#Text=The MRI protocol used 2 pulse sequences on a 1.5T MRI system (GE Medical Systems, Milwaukee, Wisconsin), as described by and our supplementary text.
45-1	7585-7588	MRI	_
45-2	7589-7599	processing	_
45-3	7600-7603	The	_
45-4	7604-7607	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument
45-5	7608-7616	protocol	_
45-6	7617-7621	used	_
45-7	7622-7623	2	_
45-8	7624-7629	pulse	_
45-9	7630-7639	sequences	_
45-10	7640-7642	on	_
45-11	7643-7644	a	_
45-12	7645-7649	1.5T	_
45-13	7650-7653	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument
45-14	7654-7660	system	_
45-15	7661-7662	(	_
45-16	7662-7664	GE	_
45-17	7665-7672	Medical	_
45-18	7673-7680	Systems	_
45-19	7680-7681	,	_
45-20	7682-7691	Milwaukee	_
45-21	7691-7692	,	_
45-22	7693-7702	Wisconsin	_
45-23	7702-7703	)	_
45-24	7703-7704	,	_
45-25	7705-7707	as	_
45-26	7708-7717	described	_
45-27	7718-7720	by	_
45-28	7721-7724	and	_
45-29	7725-7728	our	_
45-30	7729-7742	supplementary	_
45-31	7743-7747	text	_
45-32	7747-7748	.	_

#Text=The segmented voxel volumes of gray and white matter and cerebrospinal fluid were summed to yield the total intracranial contents (ICC).
46-1	7749-7752	The	_
46-2	7753-7762	segmented	_
46-3	7763-7768	voxel	_
46-4	7769-7776	volumes	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-5	7777-7779	of	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-6	7780-7784	gray	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-7	7785-7788	and	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-8	7789-7794	white	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-9	7795-7801	matter	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-10	7802-7805	and	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-11	7806-7819	cerebrospinal	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-12	7820-7825	fluid	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]
46-13	7826-7830	were	_
46-14	7831-7837	summed	_
46-15	7838-7840	to	_
46-16	7841-7846	yield	_
46-17	7847-7850	the	_
46-18	7851-7856	total	_
46-19	7857-7869	intracranial	_
46-20	7870-7878	contents	_
46-21	7879-7880	(	_
46-22	7880-7883	ICC	_
46-23	7883-7884	)	_
46-24	7884-7885	.	_

#Text=Region of interest (ROI)
#Text=The PFC subregions of frontal pole (FP), and the superior, middle and inferior frontal gyri (SFG, MFG, and IFG respectively) are displayed in Fig. 1.
47-1	7886-7892	Region	_
47-2	7893-7895	of	_
47-3	7896-7904	interest	_
47-4	7905-7906	(	_
47-5	7906-7909	ROI	_
47-6	7909-7910	)	_
47-7	7911-7914	The	_
47-8	7915-7918	PFC	_
47-9	7919-7929	subregions	_
47-10	7930-7932	of	_
47-11	7933-7940	frontal	_
47-12	7941-7945	pole	_
47-13	7946-7947	(	_
47-14	7947-7949	FP	_
47-15	7949-7950	)	_
47-16	7950-7951	,	_
47-17	7952-7955	and	_
47-18	7956-7959	the	_
47-19	7960-7968	superior	_
47-20	7968-7969	,	_
47-21	7970-7976	middle	_
47-22	7977-7980	and	_
47-23	7981-7989	inferior	_
47-24	7990-7997	frontal	_
47-25	7998-8002	gyri	_
47-26	8003-8004	(	_
47-27	8004-8007	SFG	_
47-28	8007-8008	,	_
47-29	8009-8012	MFG	_
47-30	8012-8013	,	_
47-31	8014-8017	and	_
47-32	8018-8021	IFG	_
47-33	8022-8034	respectively	_
47-34	8034-8035	)	_
47-35	8036-8039	are	_
47-36	8040-8049	displayed	_
47-37	8050-8052	in	_
47-38	8053-8056	Fig	_
47-39	8056-8057	.	_
47-40	8058-8059	1	_
47-41	8059-8060	.	_

#Text=The details of the criteria used for parcellation are also described in our supplementary text.
48-1	8061-8064	The	_
48-2	8065-8072	details	_
48-3	8073-8075	of	_
48-4	8076-8079	the	_
48-5	8080-8088	criteria	_
48-6	8089-8093	used	_
48-7	8094-8097	for	_
48-8	8098-8110	parcellation	_
48-9	8111-8114	are	_
48-10	8115-8119	also	_
48-11	8120-8129	described	_
48-12	8130-8132	in	_
48-13	8133-8136	our	_
48-14	8137-8150	supplementary	_
48-15	8151-8155	text	_
48-16	8155-8156	.	_

#Text=All manual ROI parcellations were performed by investigators blind to diagnoses and the date of scan.
49-1	8157-8160	All	_
49-2	8161-8167	manual	_
49-3	8168-8171	ROI	_
49-4	8172-8185	parcellations	_
49-5	8186-8190	were	_
49-6	8191-8200	performed	_
49-7	8201-8203	by	_
49-8	8204-8217	investigators	_
49-9	8218-8223	blind	_
49-10	8224-8226	to	_
49-11	8227-8236	diagnoses	_
49-12	8237-8240	and	_
49-13	8241-8244	the	_
49-14	8245-8249	date	_
49-15	8250-8252	of	_
49-16	8253-8257	scan	_
49-17	8257-8258	.	_

#Text=To assess inter-rater reliability, 3 blind raters (T.O., T.A., and T.R.) independently delineated the ROIs for 5 randomly selected cases.
50-1	8259-8261	To	_
50-2	8262-8268	assess	_
50-3	8269-8280	inter-rater	_
50-4	8281-8292	reliability	_
50-5	8292-8293	,	_
50-6	8294-8295	3	_
50-7	8296-8301	blind	_
50-8	8302-8308	raters	_
50-9	8309-8310	(	_
50-10	8310-8313	T.O	_
50-11	8313-8314	.	_
50-12	8314-8315	,	_
50-13	8316-8319	T.A	_
50-14	8319-8320	.	_
50-15	8320-8321	,	_
50-16	8322-8325	and	_
50-17	8326-8329	T.R	_
50-18	8329-8330	.	_
50-19	8330-8331	)	_
50-20	8332-8345	independently	_
50-21	8346-8356	delineated	_
50-22	8357-8360	the	_
50-23	8361-8365	ROIs	_
50-24	8366-8369	for	_
50-25	8370-8371	5	_
50-26	8372-8380	randomly	_
50-27	8381-8389	selected	_
50-28	8390-8395	cases	_
50-29	8395-8396	.	_

#Text=Intra-class correlation coefficients for the volume were 0.97 for the left FP, 0.98 for the right FP, 0.97 for the left SFG, 0.95 for the right SFG, 0.96 for the left MFG, 0.96 for the right MFG, 0.95 for the left IFG, 0.96 for the right IFG.
51-1	8397-8408	Intra-class	_
51-2	8409-8420	correlation	_
51-3	8421-8433	coefficients	_
51-4	8434-8437	for	_
51-5	8438-8441	the	_
51-6	8442-8448	volume	_
51-7	8449-8453	were	_
51-8	8454-8458	0.97	_
51-9	8459-8462	for	_
51-10	8463-8466	the	_
51-11	8467-8471	left	_
51-12	8472-8474	FP	_
51-13	8474-8475	,	_
51-14	8476-8480	0.98	_
51-15	8481-8484	for	_
51-16	8485-8488	the	_
51-17	8489-8494	right	_
51-18	8495-8497	FP	_
51-19	8497-8498	,	_
51-20	8499-8503	0.97	_
51-21	8504-8507	for	_
51-22	8508-8511	the	_
51-23	8512-8516	left	_
51-24	8517-8520	SFG	_
51-25	8520-8521	,	_
51-26	8522-8526	0.95	_
51-27	8527-8530	for	_
51-28	8531-8534	the	_
51-29	8535-8540	right	_
51-30	8541-8544	SFG	_
51-31	8544-8545	,	_
51-32	8546-8550	0.96	_
51-33	8551-8554	for	_
51-34	8555-8558	the	_
51-35	8559-8563	left	_
51-36	8564-8567	MFG	_
51-37	8567-8568	,	_
51-38	8569-8573	0.96	_
51-39	8574-8577	for	_
51-40	8578-8581	the	_
51-41	8582-8587	right	_
51-42	8588-8591	MFG	_
51-43	8591-8592	,	_
51-44	8593-8597	0.95	_
51-45	8598-8601	for	_
51-46	8602-8605	the	_
51-47	8606-8610	left	_
51-48	8611-8614	IFG	_
51-49	8614-8615	,	_
51-50	8616-8620	0.96	_
51-51	8621-8624	for	_
51-52	8625-8628	the	_
51-53	8629-8634	right	_
51-54	8635-8638	IFG	_
51-55	8638-8639	.	_

#Text=FreeSurfer analysis
#Text=In order to compare the ability of detecting subtle structural changes and the validity of manual parcellation with the use of automated methodology, we also analyzed the ROI volumes using FreeSurfer version 5.3 (https://surfer.nmr.mgh.harvard.edu).
52-1	8640-8650	FreeSurfer	_
52-2	8651-8659	analysis	_
52-3	8660-8662	In	_
52-4	8663-8668	order	_
52-5	8669-8671	to	_
52-6	8672-8679	compare	_
52-7	8680-8683	the	_
52-8	8684-8691	ability	_
52-9	8692-8694	of	_
52-10	8695-8704	detecting	_
52-11	8705-8711	subtle	_
52-12	8712-8722	structural	_
52-13	8723-8730	changes	_
52-14	8731-8734	and	_
52-15	8735-8738	the	_
52-16	8739-8747	validity	_
52-17	8748-8750	of	_
52-18	8751-8757	manual	_
52-19	8758-8770	parcellation	_
52-20	8771-8775	with	_
52-21	8776-8779	the	_
52-22	8780-8783	use	_
52-23	8784-8786	of	_
52-24	8787-8796	automated	_
52-25	8797-8808	methodology	_
52-26	8808-8809	,	_
52-27	8810-8812	we	_
52-28	8813-8817	also	_
52-29	8818-8826	analyzed	_
52-30	8827-8830	the	_
52-31	8831-8834	ROI	_
52-32	8835-8842	volumes	_
52-33	8843-8848	using	_
52-34	8849-8859	FreeSurfer	_
52-35	8860-8867	version	_
52-36	8868-8871	5.3	_
52-37	8872-8873	(	_
52-38	8873-8878	https	_
52-39	8878-8879	:	_
52-40	8879-8880	/	_
52-41	8880-8881	/	_
52-42	8881-8907	surfer.nmr.mgh.harvard.edu	_
52-43	8907-8908	)	_
52-44	8908-8909	.	_

#Text=Thus, the MRI scans used for manual parcellation were reprocessed using FreeSurfer v. 5.3.
53-1	8910-8914	Thus	_
53-2	8914-8915	,	_
53-3	8916-8919	the	_
53-4	8920-8923	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument
53-5	8924-8929	scans	_
53-6	8930-8934	used	_
53-7	8935-8938	for	_
53-8	8939-8945	manual	_
53-9	8946-8958	parcellation	_
53-10	8959-8963	were	_
53-11	8964-8975	reprocessed	_
53-12	8976-8981	using	_
53-13	8982-8992	FreeSurfer	_
53-14	8993-8994	v	_
53-15	8994-8995	.	_
53-16	8996-8999	5.3	_
53-17	8999-9000	.	_

#Text=One of the coronal slice parcellated by FreeSurfer v. 5.3 is displayed in our supplementary Fig.
54-1	9001-9004	One	_
54-2	9005-9007	of	_
54-3	9008-9011	the	_
54-4	9012-9019	coronal	_
54-5	9020-9025	slice	_
54-6	9026-9037	parcellated	_
54-7	9038-9040	by	_
54-8	9041-9051	FreeSurfer	_
54-9	9052-9053	v	_
54-10	9053-9054	.	_
54-11	9055-9058	5.3	_
54-12	9059-9061	is	_
54-13	9062-9071	displayed	_
54-14	9072-9074	in	_
54-15	9075-9078	our	_
54-16	9079-9092	supplementary	_
54-17	9093-9096	Fig	_
54-18	9096-9097	.	_

#Text=S1.
55-1	9098-9100	S1	_
55-2	9100-9101	.	_

#Text=The detailed procedures for volumetric measurements of FP, SFG, caudal and rostral MFG, and IFG (i.e. pars opercularis, pars orbitalis, and pars pars orbitalis) have been described in several publications.
56-1	9102-9105	The	_
56-2	9106-9114	detailed	_
56-3	9115-9125	procedures	_
56-4	9126-9129	for	_
56-5	9130-9140	volumetric	_
56-6	9141-9153	measurements	_
56-7	9154-9156	of	_
56-8	9157-9159	FP	_
56-9	9159-9160	,	_
56-10	9161-9164	SFG	_
56-11	9164-9165	,	_
56-12	9166-9172	caudal	_
56-13	9173-9176	and	_
56-14	9177-9184	rostral	_
56-15	9185-9188	MFG	_
56-16	9188-9189	,	_
56-17	9190-9193	and	_
56-18	9194-9197	IFG	_
56-19	9198-9199	(	_
56-20	9199-9202	i.e	_
56-21	9202-9203	.	_
56-22	9204-9208	pars	_
56-23	9209-9220	opercularis	_
56-24	9220-9221	,	_
56-25	9222-9226	pars	_
56-26	9227-9236	orbitalis	_
56-27	9236-9237	,	_
56-28	9238-9241	and	_
56-29	9242-9246	pars	_
56-30	9247-9251	pars	_
56-31	9252-9261	orbitalis	_
56-32	9261-9262	)	_
56-33	9263-9267	have	_
56-34	9268-9272	been	_
56-35	9273-9282	described	_
56-36	9283-9285	in	_
56-37	9286-9293	several	_
56-38	9294-9306	publications	_
56-39	9306-9307	.	_

#Text=Relative volumes were calculated by dividing volumes by the total intracranial volume of each subject as provided by the FreeSurfer output.
57-1	9308-9316	Relative	_
57-2	9317-9324	volumes	_
57-3	9325-9329	were	_
57-4	9330-9340	calculated	_
57-5	9341-9343	by	_
57-6	9344-9352	dividing	_
57-7	9353-9360	volumes	_
57-8	9361-9363	by	_
57-9	9364-9367	the	_
57-10	9368-9373	total	_
57-11	9374-9386	intracranial	_
57-12	9387-9393	volume	_
57-13	9394-9396	of	_
57-14	9397-9401	each	_
57-15	9402-9409	subject	_
57-16	9410-9412	as	_
57-17	9413-9421	provided	_
57-18	9422-9424	by	_
57-19	9425-9428	the	_
57-20	9429-9439	FreeSurfer	_
57-21	9440-9446	output	_
57-22	9446-9447	.	_

#Text=Statistical Analysis
#Text=One-way analysis of variance (ANOVA) was performed among FESZ, FEAFF, and HC groups for age, inter-scan interval, handedness, socioeconomic status (SES), parental SES, WAIS-R Information and Digit Span scaled scores with follow-up post hoc Tukey Honestly Significant Difference (HSD) tests.
58-1	9448-9459	Statistical	_
58-2	9460-9468	Analysis	_
58-3	9469-9476	One-way	_
58-4	9477-9485	analysis	_
58-5	9486-9488	of	_
58-6	9489-9497	variance	_
58-7	9498-9499	(	_
58-8	9499-9504	ANOVA	_
58-9	9504-9505	)	_
58-10	9506-9509	was	_
58-11	9510-9519	performed	_
58-12	9520-9525	among	_
58-13	9526-9530	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
58-14	9530-9531	,	_
58-15	9532-9537	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
58-16	9537-9538	,	_
58-17	9539-9542	and	_
58-18	9543-9545	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
58-19	9546-9552	groups	_
58-20	9553-9556	for	_
58-21	9557-9560	age	_
58-22	9560-9561	,	_
58-23	9562-9572	inter-scan	_
58-24	9573-9581	interval	_
58-25	9581-9582	,	_
58-26	9583-9593	handedness	_
58-27	9593-9594	,	_
58-28	9595-9608	socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[39]
58-29	9609-9615	status	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[39]
58-30	9616-9617	(	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[39]
58-31	9617-9620	SES	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[39]
58-32	9620-9621	)	_
58-33	9621-9622	,	_
58-34	9623-9631	parental	_
58-35	9632-9635	SES	_
58-36	9635-9636	,	_
58-37	9637-9643	WAIS-R	_
58-38	9644-9655	Information	_
58-39	9656-9659	and	_
58-40	9660-9665	Digit	_
58-41	9666-9670	Span	_
58-42	9671-9677	scaled	_
58-43	9678-9684	scores	_
58-44	9685-9689	with	_
58-45	9690-9699	follow-up	_
58-46	9700-9704	post	_
58-47	9705-9708	hoc	_
58-48	9709-9714	Tukey	_
58-49	9715-9723	Honestly	_
58-50	9724-9735	Significant	_
58-51	9736-9746	Difference	_
58-52	9747-9748	(	_
58-53	9748-9751	HSD	_
58-54	9751-9752	)	_
58-55	9753-9758	tests	_
58-56	9758-9759	.	_

#Text=In addition, t-tests were performed between FESZ and FEAFF groups for duration of illness, medication dosage [chlorpromazine equivalent antipsychotic dosage ], and BPRS scores.
59-1	9760-9762	In	_
59-2	9763-9771	addition	_
59-3	9771-9772	,	_
59-4	9773-9780	t-tests	_
59-5	9781-9785	were	_
59-6	9786-9795	performed	_
59-7	9796-9803	between	_
59-8	9804-9808	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
59-9	9809-9812	and	_
59-10	9813-9818	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
59-11	9819-9825	groups	_
59-12	9826-9829	for	_
59-13	9830-9838	duration	_
59-14	9839-9841	of	_
59-15	9842-9849	illness	_
59-16	9849-9850	,	_
59-17	9851-9861	medication	_
59-18	9862-9868	dosage	_
59-19	9869-9870	[	_
59-20	9870-9884	chlorpromazine	_
59-21	9885-9895	equivalent	_
59-22	9896-9909	antipsychotic	_
59-23	9910-9916	dosage	_
59-24	9917-9918	]	_
59-25	9918-9919	,	_
59-26	9920-9923	and	_
59-27	9924-9928	BPRS	_
59-28	9929-9935	scores	_
59-29	9935-9936	.	_

#Text=Group differences in PFC GMV at times 1 and 2 were first assessed using repeated measures ANOVA, with Group as the between-subjects factor and Hemisphere (left and right) and Region (FP, SFG, MFG, and IFG) as the within-subjects factors.
60-1	9937-9942	Group	_
60-2	9943-9954	differences	_
60-3	9955-9957	in	_
60-4	9958-9961	PFC	_
60-5	9962-9965	GMV	_
60-6	9966-9968	at	_
60-7	9969-9974	times	_
60-8	9975-9976	1	_
60-9	9977-9980	and	_
60-10	9981-9982	2	_
60-11	9983-9987	were	_
60-12	9988-9993	first	_
60-13	9994-10002	assessed	_
60-14	10003-10008	using	_
60-15	10009-10017	repeated	_
60-16	10018-10026	measures	_
60-17	10027-10032	ANOVA	_
60-18	10032-10033	,	_
60-19	10034-10038	with	_
60-20	10039-10044	Group	_
60-21	10045-10047	as	_
60-22	10048-10051	the	_
60-23	10052-10068	between-subjects	_
60-24	10069-10075	factor	_
60-25	10076-10079	and	_
60-26	10080-10090	Hemisphere	_
60-27	10091-10092	(	_
60-28	10092-10096	left	_
60-29	10097-10100	and	_
60-30	10101-10106	right	_
60-31	10106-10107	)	_
60-32	10108-10111	and	_
60-33	10112-10118	Region	_
60-34	10119-10120	(	_
60-35	10120-10122	FP	_
60-36	10122-10123	,	_
60-37	10124-10127	SFG	_
60-38	10127-10128	,	_
60-39	10129-10132	MFG	_
60-40	10132-10133	,	_
60-41	10134-10137	and	_
60-42	10138-10141	IFG	_
60-43	10141-10142	)	_
60-44	10143-10145	as	_
60-45	10146-10149	the	_
60-46	10150-10165	within-subjects	_
60-47	10166-10173	factors	_
60-48	10173-10174	.	_

#Text=Follow-up post hoc Tukey HSD tests were performed when a group difference was found.
61-1	10175-10184	Follow-up	_
61-2	10185-10189	post	_
61-3	10190-10193	hoc	_
61-4	10194-10199	Tukey	_
61-5	10200-10203	HSD	_
61-6	10204-10209	tests	_
61-7	10210-10214	were	_
61-8	10215-10224	performed	_
61-9	10225-10229	when	_
61-10	10230-10231	a	_
61-11	10232-10237	group	_
61-12	10238-10248	difference	_
61-13	10249-10252	was	_
61-14	10253-10258	found	_
61-15	10258-10259	.	_

#Text=Relative volume (given as a percentage and calculated as [Absolute volume/ICC] × 100) was used to control for individual head size in the cross-sectional analysis.
62-1	10260-10268	Relative	_
62-2	10269-10275	volume	_
62-3	10276-10277	(	_
62-4	10277-10282	given	_
62-5	10283-10285	as	_
62-6	10286-10287	a	_
62-7	10288-10298	percentage	_
62-8	10299-10302	and	_
62-9	10303-10313	calculated	_
62-10	10314-10316	as	_
62-11	10317-10318	[	_
62-12	10318-10326	Absolute	_
62-13	10327-10333	volume	_
62-14	10333-10334	/	_
62-15	10334-10337	ICC	_
62-16	10337-10338	]	_
62-17	10339-10340	×	_
62-18	10341-10344	100	_
62-19	10344-10345	)	_
62-20	10346-10349	was	_
62-21	10350-10354	used	_
62-22	10355-10357	to	_
62-23	10358-10365	control	_
62-24	10366-10369	for	_
62-25	10370-10380	individual	_
62-26	10381-10385	head	_
62-27	10386-10390	size	_
62-28	10391-10393	in	_
62-29	10394-10397	the	_
62-30	10398-10413	cross-sectional	_
62-31	10414-10422	analysis	_
62-32	10422-10423	.	_

#Text=Groups did not differ significantly in ICC at time 1 (F2,65 = 0.455, P = 0.636) or in their ICC volume changes between baseline and follow-up (t = 0.489, df = 67, P = 0.627).
63-1	10424-10430	Groups	_
63-2	10431-10434	did	_
63-3	10435-10438	not	_
63-4	10439-10445	differ	_
63-5	10446-10459	significantly	_
63-6	10460-10462	in	_
63-7	10463-10466	ICC	_
63-8	10467-10469	at	_
63-9	10470-10474	time	_
63-10	10475-10476	1	_
63-11	10477-10478	(	_
63-12	10478-10483	F2,65	_
63-13	10484-10485	=	_
63-14	10486-10491	0.455	_
63-15	10491-10492	,	_
63-16	10493-10494	P	_
63-17	10495-10496	=	_
63-18	10497-10502	0.636	_
63-19	10502-10503	)	_
63-20	10504-10506	or	_
63-21	10507-10509	in	_
63-22	10510-10515	their	_
63-23	10516-10519	ICC	_
63-24	10520-10526	volume	_
63-25	10527-10534	changes	_
63-26	10535-10542	between	_
63-27	10543-10551	baseline	_
63-28	10552-10555	and	_
63-29	10556-10565	follow-up	_
63-30	10566-10567	(	_
63-31	10567-10568	t	_
63-32	10569-10570	=	_
63-33	10571-10576	0.489	_
63-34	10576-10577	,	_
63-35	10578-10580	df	_
63-36	10581-10582	=	_
63-37	10583-10585	67	_
63-38	10585-10586	,	_
63-39	10587-10588	P	_
63-40	10589-10590	=	_
63-41	10591-10596	0.627	_
63-42	10596-10597	)	_
63-43	10597-10598	.	_

#Text=Of note, the statistical conclusions reported herein remained the same when we analyzed absolute volumes using ICC as a covariate, and when we included only FEAFF who were bipolar in a manic phase.
64-1	10599-10601	Of	_
64-2	10602-10606	note	_
64-3	10606-10607	,	_
64-4	10608-10611	the	_
64-5	10612-10623	statistical	_
64-6	10624-10635	conclusions	_
64-7	10636-10644	reported	_
64-8	10645-10651	herein	_
64-9	10652-10660	remained	_
64-10	10661-10664	the	_
64-11	10665-10669	same	_
64-12	10670-10674	when	_
64-13	10675-10677	we	_
64-14	10678-10686	analyzed	_
64-15	10687-10695	absolute	_
64-16	10696-10703	volumes	_
64-17	10704-10709	using	_
64-18	10710-10713	ICC	_
64-19	10714-10716	as	_
64-20	10717-10718	a	_
64-21	10719-10728	covariate	_
64-22	10728-10729	,	_
64-23	10730-10733	and	_
64-24	10734-10738	when	_
64-25	10739-10741	we	_
64-26	10742-10750	included	_
64-27	10751-10755	only	_
64-28	10756-10761	FEAFF	_
64-29	10762-10765	who	_
64-30	10766-10770	were	_
64-31	10771-10778	bipolar	_
64-32	10779-10781	in	_
64-33	10782-10783	a	_
64-34	10784-10789	manic	_
64-35	10790-10795	phase	_
64-36	10795-10796	.	_

#Text=For the longitudinal volume comparison, the percentage of volume change was calculated with the following formula: 100 × (Relative Volume at Second Scan–Relative Volume at Baseline Scan) / (Relative Volume at Baseline Scan) to control for any group difference in initial tissue volumes.
65-1	10797-10800	For	_
65-2	10801-10804	the	_
65-3	10805-10817	longitudinal	_
65-4	10818-10824	volume	_
65-5	10825-10835	comparison	_
65-6	10835-10836	,	_
65-7	10837-10840	the	_
65-8	10841-10851	percentage	_
65-9	10852-10854	of	_
65-10	10855-10861	volume	_
65-11	10862-10868	change	_
65-12	10869-10872	was	_
65-13	10873-10883	calculated	_
65-14	10884-10888	with	_
65-15	10889-10892	the	_
65-16	10893-10902	following	_
65-17	10903-10910	formula	_
65-18	10910-10911	:	_
65-19	10912-10915	100	_
65-20	10916-10917	×	_
65-21	10918-10919	(	_
65-22	10919-10927	Relative	_
65-23	10928-10934	Volume	_
65-24	10935-10937	at	_
65-25	10938-10944	Second	_
65-26	10945-10958	Scan–Relative	_
65-27	10959-10965	Volume	_
65-28	10966-10968	at	_
65-29	10969-10977	Baseline	_
65-30	10978-10982	Scan	_
65-31	10982-10983	)	_
65-32	10984-10985	/	_
65-33	10986-10987	(	_
65-34	10987-10995	Relative	_
65-35	10996-11002	Volume	_
65-36	11003-11005	at	_
65-37	11006-11014	Baseline	_
65-38	11015-11019	Scan	_
65-39	11019-11020	)	_
65-40	11021-11023	to	_
65-41	11024-11031	control	_
65-42	11032-11035	for	_
65-43	11036-11039	any	_
65-44	11040-11045	group	_
65-45	11046-11056	difference	_
65-46	11057-11059	in	_
65-47	11060-11067	initial	_
65-48	11068-11074	tissue	_
65-49	11075-11082	volumes	_
65-50	11082-11083	.	_

#Text=To evaluate which subregion showed differences between times 1 and 2 in GMV among groups, we examined the percentage of differences of relative volumes for each subregion using one-way ANOVA with follow-up post hoc Tukey HSD tests.
66-1	11084-11086	To	_
66-2	11087-11095	evaluate	_
66-3	11096-11101	which	_
66-4	11102-11111	subregion	_
66-5	11112-11118	showed	_
66-6	11119-11130	differences	_
66-7	11131-11138	between	_
66-8	11139-11144	times	_
66-9	11145-11146	1	_
66-10	11147-11150	and	_
66-11	11151-11152	2	_
66-12	11153-11155	in	_
66-13	11156-11159	GMV	_
66-14	11160-11165	among	_
66-15	11166-11172	groups	_
66-16	11172-11173	,	_
66-17	11174-11176	we	_
66-18	11177-11185	examined	_
66-19	11186-11189	the	_
66-20	11190-11200	percentage	_
66-21	11201-11203	of	_
66-22	11204-11215	differences	_
66-23	11216-11218	of	_
66-24	11219-11227	relative	_
66-25	11228-11235	volumes	_
66-26	11236-11239	for	_
66-27	11240-11244	each	_
66-28	11245-11254	subregion	_
66-29	11255-11260	using	_
66-30	11261-11268	one-way	_
66-31	11269-11274	ANOVA	_
66-32	11275-11279	with	_
66-33	11280-11289	follow-up	_
66-34	11290-11294	post	_
66-35	11295-11298	hoc	_
66-36	11299-11304	Tukey	_
66-37	11305-11308	HSD	_
66-38	11309-11314	tests	_
66-39	11314-11315	.	_

#Text=In the overall group comparison according to medication history, one-way ANOVA and post hoc Tukey HDS tests were performed.
67-1	11316-11318	In	_
67-2	11319-11322	the	_
67-3	11323-11330	overall	_
67-4	11331-11336	group	_
67-5	11337-11347	comparison	_
67-6	11348-11357	according	_
67-7	11358-11360	to	_
67-8	11361-11371	medication	_
67-9	11372-11379	history	_
67-10	11379-11380	,	_
67-11	11381-11388	one-way	_
67-12	11389-11394	ANOVA	_
67-13	11395-11398	and	_
67-14	11399-11403	post	_
67-15	11404-11407	hoc	_
67-16	11408-11413	Tukey	_
67-17	11414-11417	HDS	_
67-18	11418-11423	tests	_
67-19	11424-11428	were	_
67-20	11429-11438	performed	_
67-21	11438-11439	.	_

#Text=The correlations between the total scores of BPRS and medication dosage were analyzed at times 1 and 2 to evaluate any association between symptom severity and neuroleptic dosage.
68-1	11440-11443	The	_
68-2	11444-11456	correlations	_
68-3	11457-11464	between	_
68-4	11465-11468	the	_
68-5	11469-11474	total	_
68-6	11475-11481	scores	_
68-7	11482-11484	of	_
68-8	11485-11489	BPRS	_
68-9	11490-11493	and	_
68-10	11494-11504	medication	_
68-11	11505-11511	dosage	_
68-12	11512-11516	were	_
68-13	11517-11525	analyzed	_
68-14	11526-11528	at	_
68-15	11529-11534	times	_
68-16	11535-11536	1	_
68-17	11537-11540	and	_
68-18	11541-11542	2	_
68-19	11543-11545	to	_
68-20	11546-11554	evaluate	_
68-21	11555-11558	any	_
68-22	11559-11570	association	_
68-23	11571-11578	between	_
68-24	11579-11586	symptom	_
68-25	11587-11595	severity	_
68-26	11596-11599	and	_
68-27	11600-11611	neuroleptic	_
68-28	11612-11618	dosage	_
68-29	11618-11619	.	_

#Text=To eliminate any outlier and any non-normality effects, we used Spearman’s rho for these analyses.
69-1	11620-11622	To	_
69-2	11623-11632	eliminate	_
69-3	11633-11636	any	_
69-4	11637-11644	outlier	_
69-5	11645-11648	and	_
69-6	11649-11652	any	_
69-7	11653-11666	non-normality	_
69-8	11667-11674	effects	_
69-9	11674-11675	,	_
69-10	11676-11678	we	_
69-11	11679-11683	used	_
69-12	11684-11692	Spearman	_
69-13	11692-11693	’	_
69-14	11693-11694	s	_
69-15	11695-11698	rho	_
69-16	11699-11702	for	_
69-17	11703-11708	these	_
69-18	11709-11717	analyses	_
69-19	11717-11718	.	_

#Text=Hyunh-Feldt correction was used when sphericity could not be assumed in the ANOVA.
70-1	11719-11730	Hyunh-Feldt	_
70-2	11731-11741	correction	_
70-3	11742-11745	was	_
70-4	11746-11750	used	_
70-5	11751-11755	when	_
70-6	11756-11766	sphericity	_
70-7	11767-11772	could	_
70-8	11773-11776	not	_
70-9	11777-11779	be	_
70-10	11780-11787	assumed	_
70-11	11788-11790	in	_
70-12	11791-11794	the	_
70-13	11795-11800	ANOVA	_
70-14	11800-11801	.	_

#Text=To evaluate the magnitude of group differences, Cohen’s f2 is provided when group comparisons by ANOVA did not attain significance.
71-1	11802-11804	To	_
71-2	11805-11813	evaluate	_
71-3	11814-11817	the	_
71-4	11818-11827	magnitude	_
71-5	11828-11830	of	_
71-6	11831-11836	group	_
71-7	11837-11848	differences	_
71-8	11848-11849	,	_
71-9	11850-11855	Cohen	_
71-10	11855-11856	’	_
71-11	11856-11857	s	_
71-12	11858-11860	f2	_
71-13	11861-11863	is	_
71-14	11864-11872	provided	_
71-15	11873-11877	when	_
71-16	11878-11883	group	_
71-17	11884-11895	comparisons	_
71-18	11896-11898	by	_
71-19	11899-11904	ANOVA	_
71-20	11905-11908	did	_
71-21	11909-11912	not	_
71-22	11913-11919	attain	_
71-23	11920-11932	significance	_
71-24	11932-11933	.	_

#Text=Clinical outcome was evaluated as the percentage of change in factor scores in BPRS using the following equation: 100 × (Score at Second Scan–Score at Baseline Scan) / (Score at Baseline Scan).
72-1	11934-11942	Clinical	_
72-2	11943-11950	outcome	_
72-3	11951-11954	was	_
72-4	11955-11964	evaluated	_
72-5	11965-11967	as	_
72-6	11968-11971	the	_
72-7	11972-11982	percentage	_
72-8	11983-11985	of	_
72-9	11986-11992	change	_
72-10	11993-11995	in	_
72-11	11996-12002	factor	_
72-12	12003-12009	scores	_
72-13	12010-12012	in	_
72-14	12013-12017	BPRS	_
72-15	12018-12023	using	_
72-16	12024-12027	the	_
72-17	12028-12037	following	_
72-18	12038-12046	equation	_
72-19	12046-12047	:	_
72-20	12048-12051	100	_
72-21	12052-12053	×	_
72-22	12054-12055	(	_
72-23	12055-12060	Score	_
72-24	12061-12063	at	_
72-25	12064-12070	Second	_
72-26	12071-12081	Scan–Score	_
72-27	12082-12084	at	_
72-28	12085-12093	Baseline	_
72-29	12094-12098	Scan	_
72-30	12098-12099	)	_
72-31	12100-12101	/	_
72-32	12102-12103	(	_
72-33	12103-12108	Score	_
72-34	12109-12111	at	_
72-35	12112-12120	Baseline	_
72-36	12121-12125	Scan	_
72-37	12125-12126	)	_
72-38	12126-12127	.	_

#Text=We also used Spearman’s rho to compute associations between ROI volume change for those ROIs showing significant change and the following variables: 1) clinical symptom outcome (e.g., longitudinal changes in BPRS subscales, conceptual disorganization component, and total scores); and 2) interscan interval.
73-1	12128-12130	We	_
73-2	12131-12135	also	_
73-3	12136-12140	used	_
73-4	12141-12149	Spearman	_
73-5	12149-12150	’	_
73-6	12150-12151	s	_
73-7	12152-12155	rho	_
73-8	12156-12158	to	_
73-9	12159-12166	compute	_
73-10	12167-12179	associations	_
73-11	12180-12187	between	_
73-12	12188-12191	ROI	_
73-13	12192-12198	volume	_
73-14	12199-12205	change	_
73-15	12206-12209	for	_
73-16	12210-12215	those	_
73-17	12216-12220	ROIs	_
73-18	12221-12228	showing	_
73-19	12229-12240	significant	_
73-20	12241-12247	change	_
73-21	12248-12251	and	_
73-22	12252-12255	the	_
73-23	12256-12265	following	_
73-24	12266-12275	variables	_
73-25	12275-12276	:	_
73-26	12277-12278	1	_
73-27	12278-12279	)	_
73-28	12280-12288	clinical	_
73-29	12289-12296	symptom	_
73-30	12297-12304	outcome	_
73-31	12305-12306	(	_
73-32	12306-12309	e.g	_
73-33	12309-12310	.	_
73-34	12310-12311	,	_
73-35	12312-12324	longitudinal	_
73-36	12325-12332	changes	_
73-37	12333-12335	in	_
73-38	12336-12340	BPRS	_
73-39	12341-12350	subscales	_
73-40	12350-12351	,	_
73-41	12352-12362	conceptual	_
73-42	12363-12378	disorganization	_
73-43	12379-12388	component	_
73-44	12388-12389	,	_
73-45	12390-12393	and	_
73-46	12394-12399	total	_
73-47	12400-12406	scores	_
73-48	12406-12407	)	_
73-49	12407-12408	;	_
73-50	12409-12412	and	_
73-51	12413-12414	2	_
73-52	12414-12415	)	_
73-53	12416-12425	interscan	_
73-54	12426-12434	interval	_
73-55	12434-12435	.	_

#Text=Results
#Text=There were no significant group differences in age, sex, handedness, parental SES, or WAIS-R Information and Digit Span scales at baseline, while SES (P = 0.005) and years of education (P = 0.023) showed a group difference.
74-1	12436-12443	Results	_
74-2	12444-12449	There	_
74-3	12450-12454	were	_
74-4	12455-12457	no	_
74-5	12458-12469	significant	_
74-6	12470-12475	group	_
74-7	12476-12487	differences	_
74-8	12488-12490	in	_
74-9	12491-12494	age	_
74-10	12494-12495	,	_
74-11	12496-12499	sex	_
74-12	12499-12500	,	_
74-13	12501-12511	handedness	_
74-14	12511-12512	,	_
74-15	12513-12521	parental	_
74-16	12522-12525	SES	_
74-17	12525-12526	,	_
74-18	12527-12529	or	_
74-19	12530-12536	WAIS-R	_
74-20	12537-12548	Information	_
74-21	12549-12552	and	_
74-22	12553-12558	Digit	_
74-23	12559-12563	Span	_
74-24	12564-12570	scales	_
74-25	12571-12573	at	_
74-26	12574-12582	baseline	_
74-27	12582-12583	,	_
74-28	12584-12589	while	_
74-29	12590-12593	SES	_
74-30	12594-12595	(	_
74-31	12595-12596	P	_
74-32	12597-12598	=	_
74-33	12599-12604	0.005	_
74-34	12604-12605	)	_
74-35	12606-12609	and	_
74-36	12610-12615	years	_
74-37	12616-12618	of	_
74-38	12619-12628	education	_
74-39	12629-12630	(	_
74-40	12630-12631	P	_
74-41	12632-12633	=	_
74-42	12634-12639	0.023	_
74-43	12639-12640	)	_
74-44	12641-12647	showed	_
74-45	12648-12649	a	_
74-46	12650-12655	group	_
74-47	12656-12666	difference	_
74-48	12666-12667	.	_

#Text=The FESZ group had significantly fewer years of education (P = 0.022) and lower SES (P = 0.004) than the HC group by Tukey HSD tests (Table 1), consistent with reduced functioning due to the disorder.
75-1	12668-12671	The	_
75-2	12672-12676	FESZ	_
75-3	12677-12682	group	_
75-4	12683-12686	had	_
75-5	12687-12700	significantly	_
75-6	12701-12706	fewer	_
75-7	12707-12712	years	_
75-8	12713-12715	of	_
75-9	12716-12725	education	_
75-10	12726-12727	(	_
75-11	12727-12728	P	_
75-12	12729-12730	=	_
75-13	12731-12736	0.022	_
75-14	12736-12737	)	_
75-15	12738-12741	and	_
75-16	12742-12747	lower	_
75-17	12748-12751	SES	_
75-18	12752-12753	(	_
75-19	12753-12754	P	_
75-20	12755-12756	=	_
75-21	12757-12762	0.004	_
75-22	12762-12763	)	_
75-23	12764-12768	than	_
75-24	12769-12772	the	_
75-25	12773-12775	HC	_
75-26	12776-12781	group	_
75-27	12782-12784	by	_
75-28	12785-12790	Tukey	_
75-29	12791-12794	HSD	_
75-30	12795-12800	tests	_
75-31	12801-12802	(	_
75-32	12802-12807	Table	_
75-33	12808-12809	1	_
75-34	12809-12810	)	_
75-35	12810-12811	,	_
75-36	12812-12822	consistent	_
75-37	12823-12827	with	_
75-38	12828-12835	reduced	_
75-39	12836-12847	functioning	_
75-40	12848-12851	due	_
75-41	12852-12854	to	_
75-42	12855-12858	the	_
75-43	12859-12867	disorder	_
75-44	12867-12868	.	_

#Text=Initial Volumes (Cross-Sectional Study)
#Text=PFC volume measured by manual parcellation
#Text=Although a repeated measures ANOVA of PFC relative volume showed no group difference at time1 (F2,65 = 2.509, P = 0.089), with a relatively low effect size (partial eta squared = 0.072, Cohen’s d = 0.279), it showed a significant group difference at time 2 (F2,65 = 6.125, P = 0.004), with a medium effect size (partial eta squared = 0.159, Cohen’s d = 0.435).
76-1	12869-12876	Initial	_
76-2	12877-12884	Volumes	_
76-3	12885-12886	(	_
76-4	12886-12901	Cross-Sectional	_
76-5	12902-12907	Study	_
76-6	12907-12908	)	_
76-7	12909-12912	PFC	_
76-8	12913-12919	volume	_
76-9	12920-12928	measured	_
76-10	12929-12931	by	_
76-11	12932-12938	manual	_
76-12	12939-12951	parcellation	_
76-13	12952-12960	Although	_
76-14	12961-12962	a	_
76-15	12963-12971	repeated	_
76-16	12972-12980	measures	_
76-17	12981-12986	ANOVA	_
76-18	12987-12989	of	_
76-19	12990-12993	PFC	_
76-20	12994-13002	relative	_
76-21	13003-13009	volume	_
76-22	13010-13016	showed	_
76-23	13017-13019	no	_
76-24	13020-13025	group	_
76-25	13026-13036	difference	_
76-26	13037-13039	at	_
76-27	13040-13045	time1	_
76-28	13046-13047	(	_
76-29	13047-13052	F2,65	_
76-30	13053-13054	=	_
76-31	13055-13060	2.509	_
76-32	13060-13061	,	_
76-33	13062-13063	P	_
76-34	13064-13065	=	_
76-35	13066-13071	0.089	_
76-36	13071-13072	)	_
76-37	13072-13073	,	_
76-38	13074-13078	with	_
76-39	13079-13080	a	_
76-40	13081-13091	relatively	_
76-41	13092-13095	low	_
76-42	13096-13102	effect	_
76-43	13103-13107	size	_
76-44	13108-13109	(	_
76-45	13109-13116	partial	_
76-46	13117-13120	eta	_
76-47	13121-13128	squared	_
76-48	13129-13130	=	_
76-49	13131-13136	0.072	_
76-50	13136-13137	,	_
76-51	13138-13143	Cohen	_
76-52	13143-13144	’	_
76-53	13144-13145	s	_
76-54	13146-13147	d	_
76-55	13148-13149	=	_
76-56	13150-13155	0.279	_
76-57	13155-13156	)	_
76-58	13156-13157	,	_
76-59	13158-13160	it	_
76-60	13161-13167	showed	_
76-61	13168-13169	a	_
76-62	13170-13181	significant	_
76-63	13182-13187	group	_
76-64	13188-13198	difference	_
76-65	13199-13201	at	_
76-66	13202-13206	time	_
76-67	13207-13208	2	_
76-68	13209-13210	(	_
76-69	13210-13215	F2,65	_
76-70	13216-13217	=	_
76-71	13218-13223	6.125	_
76-72	13223-13224	,	_
76-73	13225-13226	P	_
76-74	13227-13228	=	_
76-75	13229-13234	0.004	_
76-76	13234-13235	)	_
76-77	13235-13236	,	_
76-78	13237-13241	with	_
76-79	13242-13243	a	_
76-80	13244-13250	medium	_
76-81	13251-13257	effect	_
76-82	13258-13262	size	_
76-83	13263-13264	(	_
76-84	13264-13271	partial	_
76-85	13272-13275	eta	_
76-86	13276-13283	squared	_
76-87	13284-13285	=	_
76-88	13286-13291	0.159	_
76-89	13291-13292	,	_
76-90	13293-13298	Cohen	_
76-91	13298-13299	’	_
76-92	13299-13300	s	_
76-93	13301-13302	d	_
76-94	13303-13304	=	_
76-95	13305-13310	0.435	_
76-96	13310-13311	)	_
76-97	13311-13312	.	_

#Text=Post hoc Tukey HSD tests indicated that the relative volume of the FESZ group was significantly smaller than that of the HC group (P = 0.003), although there was no significant difference with FEAFF (P = 0.337).
77-1	13313-13317	Post	_
77-2	13318-13321	hoc	_
77-3	13322-13327	Tukey	_
77-4	13328-13331	HSD	_
77-5	13332-13337	tests	_
77-6	13338-13347	indicated	_
77-7	13348-13352	that	_
77-8	13353-13356	the	_
77-9	13357-13365	relative	_
77-10	13366-13372	volume	_
77-11	13373-13375	of	_
77-12	13376-13379	the	_
77-13	13380-13384	FESZ	_
77-14	13385-13390	group	_
77-15	13391-13394	was	_
77-16	13395-13408	significantly	_
77-17	13409-13416	smaller	_
77-18	13417-13421	than	_
77-19	13422-13426	that	_
77-20	13427-13429	of	_
77-21	13430-13433	the	_
77-22	13434-13436	HC	_
77-23	13437-13442	group	_
77-24	13443-13444	(	_
77-25	13444-13445	P	_
77-26	13446-13447	=	_
77-27	13448-13453	0.003	_
77-28	13453-13454	)	_
77-29	13454-13455	,	_
77-30	13456-13464	although	_
77-31	13465-13470	there	_
77-32	13471-13474	was	_
77-33	13475-13477	no	_
77-34	13478-13489	significant	_
77-35	13490-13500	difference	_
77-36	13501-13505	with	_
77-37	13506-13511	FEAFF	_
77-38	13512-13513	(	_
77-39	13513-13514	P	_
77-40	13515-13516	=	_
77-41	13517-13522	0.337	_
77-42	13522-13523	)	_
77-43	13523-13524	.	_

#Text=PFC volume measured by FreeSurfer
#Text=A repeated measures ANOVA of PFC relative volume at time1 showed no group difference (F2,65 = 2.227, P = 0.116), with a low effect size (partial eta squared = 0.064 and Cohen’s d = 0.261); at time2, it showed no significant group difference (F2,65 = 2.220, P = 0.117), with a low effect size (partial eta squared = 0.064 and Cohen’s d = 0.261).
78-1	13525-13528	PFC	_
78-2	13529-13535	volume	_
78-3	13536-13544	measured	_
78-4	13545-13547	by	_
78-5	13548-13558	FreeSurfer	_
78-6	13559-13560	A	_
78-7	13561-13569	repeated	_
78-8	13570-13578	measures	_
78-9	13579-13584	ANOVA	_
78-10	13585-13587	of	_
78-11	13588-13591	PFC	_
78-12	13592-13600	relative	_
78-13	13601-13607	volume	_
78-14	13608-13610	at	_
78-15	13611-13616	time1	_
78-16	13617-13623	showed	_
78-17	13624-13626	no	_
78-18	13627-13632	group	_
78-19	13633-13643	difference	_
78-20	13644-13645	(	_
78-21	13645-13650	F2,65	_
78-22	13651-13652	=	_
78-23	13653-13658	2.227	_
78-24	13658-13659	,	_
78-25	13660-13661	P	_
78-26	13662-13663	=	_
78-27	13664-13669	0.116	_
78-28	13669-13670	)	_
78-29	13670-13671	,	_
78-30	13672-13676	with	_
78-31	13677-13678	a	_
78-32	13679-13682	low	_
78-33	13683-13689	effect	_
78-34	13690-13694	size	_
78-35	13695-13696	(	_
78-36	13696-13703	partial	_
78-37	13704-13707	eta	_
78-38	13708-13715	squared	_
78-39	13716-13717	=	_
78-40	13718-13723	0.064	_
78-41	13724-13727	and	_
78-42	13728-13733	Cohen	_
78-43	13733-13734	’	_
78-44	13734-13735	s	_
78-45	13736-13737	d	_
78-46	13738-13739	=	_
78-47	13740-13745	0.261	_
78-48	13745-13746	)	_
78-49	13746-13747	;	_
78-50	13748-13750	at	_
78-51	13751-13756	time2	_
78-52	13756-13757	,	_
78-53	13758-13760	it	_
78-54	13761-13767	showed	_
78-55	13768-13770	no	_
78-56	13771-13782	significant	_
78-57	13783-13788	group	_
78-58	13789-13799	difference	_
78-59	13800-13801	(	_
78-60	13801-13806	F2,65	_
78-61	13807-13808	=	_
78-62	13809-13814	2.220	_
78-63	13814-13815	,	_
78-64	13816-13817	P	_
78-65	13818-13819	=	_
78-66	13820-13825	0.117	_
78-67	13825-13826	)	_
78-68	13826-13827	,	_
78-69	13828-13832	with	_
78-70	13833-13834	a	_
78-71	13835-13838	low	_
78-72	13839-13845	effect	_
78-73	13846-13850	size	_
78-74	13851-13852	(	_
78-75	13852-13859	partial	_
78-76	13860-13863	eta	_
78-77	13864-13871	squared	_
78-78	13872-13873	=	_
78-79	13874-13879	0.064	_
78-80	13880-13883	and	_
78-81	13884-13889	Cohen	_
78-82	13889-13890	’	_
78-83	13890-13891	s	_
78-84	13892-13893	d	_
78-85	13894-13895	=	_
78-86	13896-13901	0.261	_
78-87	13901-13902	)	_
78-88	13902-13903	.	_

#Text=Correlations between symptom severity and neuroleptic dosage
#Text=There was no correlation between CPZ equivalent dosage and total BPRS scores at either time1 or 2 in our subjects.
79-1	13904-13916	Correlations	_
79-2	13917-13924	between	_
79-3	13925-13932	symptom	_
79-4	13933-13941	severity	_
79-5	13942-13945	and	_
79-6	13946-13957	neuroleptic	_
79-7	13958-13964	dosage	_
79-8	13965-13970	There	_
79-9	13971-13974	was	_
79-10	13975-13977	no	_
79-11	13978-13989	correlation	_
79-12	13990-13997	between	_
79-13	13998-14001	CPZ	_
79-14	14002-14012	equivalent	_
79-15	14013-14019	dosage	_
79-16	14020-14023	and	_
79-17	14024-14029	total	_
79-18	14030-14034	BPRS	_
79-19	14035-14041	scores	_
79-20	14042-14044	at	_
79-21	14045-14051	either	_
79-22	14052-14057	time1	_
79-23	14058-14060	or	_
79-24	14061-14062	2	_
79-25	14063-14065	in	_
79-26	14066-14069	our	_
79-27	14070-14078	subjects	_
79-28	14078-14079	.	_

#Text=Longitudinal Volume Changes
#Text=PFC volume changes over time
#Text=Repeated-measures ANOVA of volume difference (percentage of change) with Group as the between-subjects factor and Hemisphere and Region as the within-subjects factors revealed a significant main effect for Group (F2,65 = 50.102; P < 0.001) and Region (F2.882,187.354 = 10.596; P < 0.001).
80-1	14080-14092	Longitudinal	_
80-2	14093-14099	Volume	_
80-3	14100-14107	Changes	_
80-4	14108-14111	PFC	_
80-5	14112-14118	volume	_
80-6	14119-14126	changes	_
80-7	14127-14131	over	_
80-8	14132-14136	time	_
80-9	14137-14154	Repeated-measures	_
80-10	14155-14160	ANOVA	_
80-11	14161-14163	of	_
80-12	14164-14170	volume	_
80-13	14171-14181	difference	_
80-14	14182-14183	(	_
80-15	14183-14193	percentage	_
80-16	14194-14196	of	_
80-17	14197-14203	change	_
80-18	14203-14204	)	_
80-19	14205-14209	with	_
80-20	14210-14215	Group	_
80-21	14216-14218	as	_
80-22	14219-14222	the	_
80-23	14223-14239	between-subjects	_
80-24	14240-14246	factor	_
80-25	14247-14250	and	_
80-26	14251-14261	Hemisphere	_
80-27	14262-14265	and	_
80-28	14266-14272	Region	_
80-29	14273-14275	as	_
80-30	14276-14279	the	_
80-31	14280-14295	within-subjects	_
80-32	14296-14303	factors	_
80-33	14304-14312	revealed	_
80-34	14313-14314	a	_
80-35	14315-14326	significant	_
80-36	14327-14331	main	_
80-37	14332-14338	effect	_
80-38	14339-14342	for	_
80-39	14343-14348	Group	_
80-40	14349-14350	(	_
80-41	14350-14355	F2,65	_
80-42	14356-14357	=	_
80-43	14358-14364	50.102	_
80-44	14364-14365	;	_
80-45	14366-14367	P	_
80-46	14368-14369	<	_
80-47	14370-14375	0.001	_
80-48	14375-14376	)	_
80-49	14377-14380	and	_
80-50	14381-14387	Region	_
80-51	14388-14389	(	_
80-52	14389-14403	F2.882,187.354	_
80-53	14404-14405	=	_
80-54	14406-14412	10.596	_
80-55	14412-14413	;	_
80-56	14414-14415	P	_
80-57	14416-14417	<	_
80-58	14418-14423	0.001	_
80-59	14423-14424	)	_
80-60	14424-14425	.	_

#Text=The effect size for Group was high (partial eta squared = 0.607, Cohen’s d = 1.243).
81-1	14426-14429	The	_
81-2	14430-14436	effect	_
81-3	14437-14441	size	_
81-4	14442-14445	for	_
81-5	14446-14451	Group	_
81-6	14452-14455	was	_
81-7	14456-14460	high	_
81-8	14461-14462	(	_
81-9	14462-14469	partial	_
81-10	14470-14473	eta	_
81-11	14474-14481	squared	_
81-12	14482-14483	=	_
81-13	14484-14489	0.607	_
81-14	14489-14490	,	_
81-15	14491-14496	Cohen	_
81-16	14496-14497	’	_
81-17	14497-14498	s	_
81-18	14499-14500	d	_
81-19	14501-14502	=	_
81-20	14503-14508	1.243	_
81-21	14508-14509	)	_
81-22	14509-14510	.	_

#Text=There was no significant effect for Hemisphere (F1,65 = 0.632; P=0.430).
82-1	14511-14516	There	_
82-2	14517-14520	was	_
82-3	14521-14523	no	_
82-4	14524-14535	significant	_
82-5	14536-14542	effect	_
82-6	14543-14546	for	_
82-7	14547-14557	Hemisphere	_
82-8	14558-14559	(	_
82-9	14559-14564	F1,65	_
82-10	14565-14566	=	_
82-11	14567-14572	0.632	_
82-12	14572-14573	;	_
82-13	14574-14575	P	_
82-14	14575-14576	=	_
82-15	14576-14581	0.430	_
82-16	14581-14582	)	_
82-17	14582-14583	.	_

#Text=There was a significant interaction of Region × Group (F5.779,187.825 = 9.579; P < 0.001).
83-1	14584-14589	There	_
83-2	14590-14593	was	_
83-3	14594-14595	a	_
83-4	14596-14607	significant	_
83-5	14608-14619	interaction	_
83-6	14620-14622	of	_
83-7	14623-14629	Region	_
83-8	14630-14631	×	_
83-9	14632-14637	Group	_
83-10	14638-14639	(	_
83-11	14639-14653	F5.779,187.825	_
83-12	14654-14655	=	_
83-13	14656-14661	9.579	_
83-14	14661-14662	;	_
83-15	14663-14664	P	_
83-16	14665-14666	<	_
83-17	14667-14672	0.001	_
83-18	14672-14673	)	_
83-19	14673-14674	.	_

#Text=However, there were no significant interactions of Hemisphere × Group (F2,65 = 0.300; P = 0.742), Region × Hemisphere (F3,195 = 0.840; P = 0.473), or region × Hemisphere × Group (F6,195 = 1.535; P = 0.169) (Hyunh-Feldt ε: 0.963 with Region, 1.0 with Hemisphere, and 1.0 with Region-by-Hemisphere) (Table 2).
84-1	14675-14682	However	_
84-2	14682-14683	,	_
84-3	14684-14689	there	_
84-4	14690-14694	were	_
84-5	14695-14697	no	_
84-6	14698-14709	significant	_
84-7	14710-14722	interactions	_
84-8	14723-14725	of	_
84-9	14726-14736	Hemisphere	_
84-10	14737-14738	×	_
84-11	14739-14744	Group	_
84-12	14745-14746	(	_
84-13	14746-14751	F2,65	_
84-14	14752-14753	=	_
84-15	14754-14759	0.300	_
84-16	14759-14760	;	_
84-17	14761-14762	P	_
84-18	14763-14764	=	_
84-19	14765-14770	0.742	_
84-20	14770-14771	)	_
84-21	14771-14772	,	_
84-22	14773-14779	Region	_
84-23	14780-14781	×	_
84-24	14782-14792	Hemisphere	_
84-25	14793-14794	(	_
84-26	14794-14800	F3,195	_
84-27	14801-14802	=	_
84-28	14803-14808	0.840	_
84-29	14808-14809	;	_
84-30	14810-14811	P	_
84-31	14812-14813	=	_
84-32	14814-14819	0.473	_
84-33	14819-14820	)	_
84-34	14820-14821	,	_
84-35	14822-14824	or	_
84-36	14825-14831	region	_
84-37	14832-14833	×	_
84-38	14834-14844	Hemisphere	_
84-39	14845-14846	×	_
84-40	14847-14852	Group	_
84-41	14853-14854	(	_
84-42	14854-14860	F6,195	_
84-43	14861-14862	=	_
84-44	14863-14868	1.535	_
84-45	14868-14869	;	_
84-46	14870-14871	P	_
84-47	14872-14873	=	_
84-48	14874-14879	0.169	_
84-49	14879-14880	)	_
84-50	14881-14882	(	_
84-51	14882-14893	Hyunh-Feldt	_
84-52	14894-14895	ε	_
84-53	14895-14896	:	_
84-54	14897-14902	0.963	_
84-55	14903-14907	with	_
84-56	14908-14914	Region	_
84-57	14914-14915	,	_
84-58	14916-14919	1.0	_
84-59	14920-14924	with	_
84-60	14925-14935	Hemisphere	_
84-61	14935-14936	,	_
84-62	14937-14940	and	_
84-63	14941-14944	1.0	_
84-64	14945-14949	with	_
84-65	14950-14970	Region-by-Hemisphere	_
84-66	14970-14971	)	_
84-67	14972-14973	(	_
84-68	14973-14978	Table	_
84-69	14979-14980	2	_
84-70	14980-14981	)	_
84-71	14981-14982	.	_

#Text=Further analysis using one-way ANOVA comparisons revealed significant differences in left SFG (F2,65 = 17.444, P < 0.001), bilateral MFG (left: F2,65 = 30.132, P < 0.001; right: F2,65 = 23.607, P < 0.001), and bilateral IFG (left: F2,65 = 25.535, P < 0.001; right: F2,65 = 23.753, P < 0.001).
85-1	14983-14990	Further	_
85-2	14991-14999	analysis	_
85-3	15000-15005	using	_
85-4	15006-15013	one-way	_
85-5	15014-15019	ANOVA	_
85-6	15020-15031	comparisons	_
85-7	15032-15040	revealed	_
85-8	15041-15052	significant	_
85-9	15053-15064	differences	_
85-10	15065-15067	in	_
85-11	15068-15072	left	_
85-12	15073-15076	SFG	_
85-13	15077-15078	(	_
85-14	15078-15083	F2,65	_
85-15	15084-15085	=	_
85-16	15086-15092	17.444	_
85-17	15092-15093	,	_
85-18	15094-15095	P	_
85-19	15096-15097	<	_
85-20	15098-15103	0.001	_
85-21	15103-15104	)	_
85-22	15104-15105	,	_
85-23	15106-15115	bilateral	_
85-24	15116-15119	MFG	_
85-25	15120-15121	(	_
85-26	15121-15125	left	_
85-27	15125-15126	:	_
85-28	15127-15132	F2,65	_
85-29	15133-15134	=	_
85-30	15135-15141	30.132	_
85-31	15141-15142	,	_
85-32	15143-15144	P	_
85-33	15145-15146	<	_
85-34	15147-15152	0.001	_
85-35	15152-15153	;	_
85-36	15154-15159	right	_
85-37	15159-15160	:	_
85-38	15161-15166	F2,65	_
85-39	15167-15168	=	_
85-40	15169-15175	23.607	_
85-41	15175-15176	,	_
85-42	15177-15178	P	_
85-43	15179-15180	<	_
85-44	15181-15186	0.001	_
85-45	15186-15187	)	_
85-46	15187-15188	,	_
85-47	15189-15192	and	_
85-48	15193-15202	bilateral	_
85-49	15203-15206	IFG	_
85-50	15207-15208	(	_
85-51	15208-15212	left	_
85-52	15212-15213	:	_
85-53	15214-15219	F2,65	_
85-54	15220-15221	=	_
85-55	15222-15228	25.535	_
85-56	15228-15229	,	_
85-57	15230-15231	P	_
85-58	15232-15233	<	_
85-59	15234-15239	0.001	_
85-60	15239-15240	;	_
85-61	15241-15246	right	_
85-62	15246-15247	:	_
85-63	15248-15253	F2,65	_
85-64	15254-15255	=	_
85-65	15256-15262	23.753	_
85-66	15262-15263	,	_
85-67	15264-15265	P	_
85-68	15266-15267	<	_
85-69	15268-15273	0.001	_
85-70	15273-15274	)	_
85-71	15274-15275	.	_

#Text=Analyzing the volumetric data at times 1 and 2 using time as a within-subjects factor, instead of an analysis with percentage of change, did not change our conclusions of statistical significance.
86-1	15276-15285	Analyzing	_
86-2	15286-15289	the	_
86-3	15290-15300	volumetric	_
86-4	15301-15305	data	_
86-5	15306-15308	at	_
86-6	15309-15314	times	_
86-7	15315-15316	1	_
86-8	15317-15320	and	_
86-9	15321-15322	2	_
86-10	15323-15328	using	_
86-11	15329-15333	time	_
86-12	15334-15336	as	_
86-13	15337-15338	a	_
86-14	15339-15354	within-subjects	_
86-15	15355-15361	factor	_
86-16	15361-15362	,	_
86-17	15363-15370	instead	_
86-18	15371-15373	of	_
86-19	15374-15376	an	_
86-20	15377-15385	analysis	_
86-21	15386-15390	with	_
86-22	15391-15401	percentage	_
86-23	15402-15404	of	_
86-24	15405-15411	change	_
86-25	15411-15412	,	_
86-26	15413-15416	did	_
86-27	15417-15420	not	_
86-28	15421-15427	change	_
86-29	15428-15431	our	_
86-30	15432-15443	conclusions	_
86-31	15444-15446	of	_
86-32	15447-15458	statistical	_
86-33	15459-15471	significance	_
86-34	15471-15472	.	_

#Text=Follow-up post hoc Tukey HSD Two-Group Comparison tests showed that the percentages of relative volume change over time in the FESZ group were significantly bigger than those of the HC (P’s < 0.001) and FEAFF (P’s < 0.001) groups in left SFG, bilateral MFG, and bilateral IFG (Table 2, Fig. 2).
87-1	15473-15482	Follow-up	_
87-2	15483-15487	post	_
87-3	15488-15491	hoc	_
87-4	15492-15497	Tukey	_
87-5	15498-15501	HSD	_
87-6	15502-15511	Two-Group	_
87-7	15512-15522	Comparison	_
87-8	15523-15528	tests	_
87-9	15529-15535	showed	_
87-10	15536-15540	that	_
87-11	15541-15544	the	_
87-12	15545-15556	percentages	_
87-13	15557-15559	of	_
87-14	15560-15568	relative	_
87-15	15569-15575	volume	_
87-16	15576-15582	change	_
87-17	15583-15587	over	_
87-18	15588-15592	time	_
87-19	15593-15595	in	_
87-20	15596-15599	the	_
87-21	15600-15604	FESZ	_
87-22	15605-15610	group	_
87-23	15611-15615	were	_
87-24	15616-15629	significantly	_
87-25	15630-15636	bigger	_
87-26	15637-15641	than	_
87-27	15642-15647	those	_
87-28	15648-15650	of	_
87-29	15651-15654	the	_
87-30	15655-15657	HC	_
87-31	15658-15659	(	_
87-32	15659-15660	P	_
87-33	15660-15661	’	_
87-34	15661-15662	s	_
87-35	15663-15664	<	_
87-36	15665-15670	0.001	_
87-37	15670-15671	)	_
87-38	15672-15675	and	_
87-39	15676-15681	FEAFF	_
87-40	15682-15683	(	_
87-41	15683-15684	P	_
87-42	15684-15685	’	_
87-43	15685-15686	s	_
87-44	15687-15688	<	_
87-45	15689-15694	0.001	_
87-46	15694-15695	)	_
87-47	15696-15702	groups	_
87-48	15703-15705	in	_
87-49	15706-15710	left	_
87-50	15711-15714	SFG	_
87-51	15714-15715	,	_
87-52	15716-15725	bilateral	_
87-53	15726-15729	MFG	_
87-54	15729-15730	,	_
87-55	15731-15734	and	_
87-56	15735-15744	bilateral	_
87-57	15745-15748	IFG	_
87-58	15749-15750	(	_
87-59	15750-15755	Table	_
87-60	15756-15757	2	_
87-61	15757-15758	,	_
87-62	15759-15762	Fig	_
87-63	15762-15763	.	_
87-64	15764-15765	2	_
87-65	15765-15766	)	_
87-66	15766-15767	.	_

#Text=PFC volume changes over time measured by FreeSurfer
#Text=In the longitudinal volumetric comparisons, a repeated measures ANOVA of the relative volume (percentage change) with Group as the between-subject factor, and hemisphere (left and right) and PFC subregions (FP, SFG, MFG, and IFG) as the within-subject factors revealed that groups did not differ in percentage of volume change in prefrontal gray matter volume (F2,65 = 2.665, P = 0.077).
88-1	15768-15771	PFC	_
88-2	15772-15778	volume	_
88-3	15779-15786	changes	_
88-4	15787-15791	over	_
88-5	15792-15796	time	_
88-6	15797-15805	measured	_
88-7	15806-15808	by	_
88-8	15809-15819	FreeSurfer	_
88-9	15820-15822	In	_
88-10	15823-15826	the	_
88-11	15827-15839	longitudinal	_
88-12	15840-15850	volumetric	_
88-13	15851-15862	comparisons	_
88-14	15862-15863	,	_
88-15	15864-15865	a	_
88-16	15866-15874	repeated	_
88-17	15875-15883	measures	_
88-18	15884-15889	ANOVA	_
88-19	15890-15892	of	_
88-20	15893-15896	the	_
88-21	15897-15905	relative	_
88-22	15906-15912	volume	_
88-23	15913-15914	(	_
88-24	15914-15924	percentage	_
88-25	15925-15931	change	_
88-26	15931-15932	)	_
88-27	15933-15937	with	_
88-28	15938-15943	Group	_
88-29	15944-15946	as	_
88-30	15947-15950	the	_
88-31	15951-15966	between-subject	_
88-32	15967-15973	factor	_
88-33	15973-15974	,	_
88-34	15975-15978	and	_
88-35	15979-15989	hemisphere	_
88-36	15990-15991	(	_
88-37	15991-15995	left	_
88-38	15996-15999	and	_
88-39	16000-16005	right	_
88-40	16005-16006	)	_
88-41	16007-16010	and	_
88-42	16011-16014	PFC	_
88-43	16015-16025	subregions	_
88-44	16026-16027	(	_
88-45	16027-16029	FP	_
88-46	16029-16030	,	_
88-47	16031-16034	SFG	_
88-48	16034-16035	,	_
88-49	16036-16039	MFG	_
88-50	16039-16040	,	_
88-51	16041-16044	and	_
88-52	16045-16048	IFG	_
88-53	16048-16049	)	_
88-54	16050-16052	as	_
88-55	16053-16056	the	_
88-56	16057-16071	within-subject	_
88-57	16072-16079	factors	_
88-58	16080-16088	revealed	_
88-59	16089-16093	that	_
88-60	16094-16100	groups	_
88-61	16101-16104	did	_
88-62	16105-16108	not	_
88-63	16109-16115	differ	_
88-64	16116-16118	in	_
88-65	16119-16129	percentage	_
88-66	16130-16132	of	_
88-67	16133-16139	volume	_
88-68	16140-16146	change	_
88-69	16147-16149	in	_
88-70	16150-16160	prefrontal	_
88-71	16161-16165	gray	_
88-72	16166-16172	matter	_
88-73	16173-16179	volume	_
88-74	16180-16181	(	_
88-75	16181-16186	F2,65	_
88-76	16187-16188	=	_
88-77	16189-16194	2.665	_
88-78	16194-16195	,	_
88-79	16196-16197	P	_
88-80	16198-16199	=	_
88-81	16200-16205	0.077	_
88-82	16205-16206	)	_
88-83	16206-16207	.	_

#Text=FreeSurfer effect sizes were low for the 3 group comparisons on longitudinal volume measurements for prefrontal cortex (partial eta squared = 0.076, Cohen’s d = 0.286).
89-1	16208-16218	FreeSurfer	_
89-2	16219-16225	effect	_
89-3	16226-16231	sizes	_
89-4	16232-16236	were	_
89-5	16237-16240	low	_
89-6	16241-16244	for	_
89-7	16245-16248	the	_
89-8	16249-16250	3	_
89-9	16251-16256	group	_
89-10	16257-16268	comparisons	_
89-11	16269-16271	on	_
89-12	16272-16284	longitudinal	_
89-13	16285-16291	volume	_
89-14	16292-16304	measurements	_
89-15	16305-16308	for	_
89-16	16309-16319	prefrontal	_
89-17	16320-16326	cortex	_
89-18	16327-16328	(	_
89-19	16328-16335	partial	_
89-20	16336-16339	eta	_
89-21	16340-16347	squared	_
89-22	16348-16349	=	_
89-23	16350-16355	0.076	_
89-24	16355-16356	,	_
89-25	16357-16362	Cohen	_
89-26	16362-16363	’	_
89-27	16363-16364	s	_
89-28	16365-16366	d	_
89-29	16367-16368	=	_
89-30	16369-16374	0.286	_
89-31	16374-16375	)	_
89-32	16375-16376	.	_

#Text=For comparison, effect sizes of manual tracing were relatively high for prefrontal cortex (partial eta squared = 0.607, Cohen’s d = 1.243).
90-1	16377-16380	For	_
90-2	16381-16391	comparison	_
90-3	16391-16392	,	_
90-4	16393-16399	effect	_
90-5	16400-16405	sizes	_
90-6	16406-16408	of	_
90-7	16409-16415	manual	_
90-8	16416-16423	tracing	_
90-9	16424-16428	were	_
90-10	16429-16439	relatively	_
90-11	16440-16444	high	_
90-12	16445-16448	for	_
90-13	16449-16459	prefrontal	_
90-14	16460-16466	cortex	_
90-15	16467-16468	(	_
90-16	16468-16475	partial	_
90-17	16476-16479	eta	_
90-18	16480-16487	squared	_
90-19	16488-16489	=	_
90-20	16490-16495	0.607	_
90-21	16495-16496	,	_
90-22	16497-16502	Cohen	_
90-23	16502-16503	’	_
90-24	16503-16504	s	_
90-25	16505-16506	d	_
90-26	16507-16508	=	_
90-27	16509-16514	1.243	_
90-28	16514-16515	)	_
90-29	16515-16516	.	_

#Text=Correlations between percentage of change of PFC relative volumes and interscan intervals
#Text=Interscan interval did not differ among groups, and there was no significant association between percentage of change of any PFC subregion relative volume and interscan interval in FESZ (rho values range 0.001–0.265, P values range 0.246–0.996), FEAFF, (rho values range 0.031–0.316, P values range 0.133–0.885) and HC (rho values range 0.025–0.237, P values range 0.276–0.911) groups.
91-1	16517-16529	Correlations	_
91-2	16530-16537	between	_
91-3	16538-16548	percentage	_
91-4	16549-16551	of	_
91-5	16552-16558	change	_
91-6	16559-16561	of	_
91-7	16562-16565	PFC	_
91-8	16566-16574	relative	_
91-9	16575-16582	volumes	_
91-10	16583-16586	and	_
91-11	16587-16596	interscan	_
91-12	16597-16606	intervals	_
91-13	16607-16616	Interscan	_
91-14	16617-16625	interval	_
91-15	16626-16629	did	_
91-16	16630-16633	not	_
91-17	16634-16640	differ	_
91-18	16641-16646	among	_
91-19	16647-16653	groups	_
91-20	16653-16654	,	_
91-21	16655-16658	and	_
91-22	16659-16664	there	_
91-23	16665-16668	was	_
91-24	16669-16671	no	_
91-25	16672-16683	significant	_
91-26	16684-16695	association	_
91-27	16696-16703	between	_
91-28	16704-16714	percentage	_
91-29	16715-16717	of	_
91-30	16718-16724	change	_
91-31	16725-16727	of	_
91-32	16728-16731	any	_
91-33	16732-16735	PFC	_
91-34	16736-16745	subregion	_
91-35	16746-16754	relative	_
91-36	16755-16761	volume	_
91-37	16762-16765	and	_
91-38	16766-16775	interscan	_
91-39	16776-16784	interval	_
91-40	16785-16787	in	_
91-41	16788-16792	FESZ	_
91-42	16793-16794	(	_
91-43	16794-16797	rho	_
91-44	16798-16804	values	_
91-45	16805-16810	range	_
91-46	16811-16816	0.001	_
91-47	16816-16817	–	_
91-48	16817-16822	0.265	_
91-49	16822-16823	,	_
91-50	16824-16825	P	_
91-51	16826-16832	values	_
91-52	16833-16838	range	_
91-53	16839-16844	0.246	_
91-54	16844-16845	–	_
91-55	16845-16850	0.996	_
91-56	16850-16851	)	_
91-57	16851-16852	,	_
91-58	16853-16858	FEAFF	_
91-59	16858-16859	,	_
91-60	16860-16861	(	_
91-61	16861-16864	rho	_
91-62	16865-16871	values	_
91-63	16872-16877	range	_
91-64	16878-16883	0.031	_
91-65	16883-16884	–	_
91-66	16884-16889	0.316	_
91-67	16889-16890	,	_
91-68	16891-16892	P	_
91-69	16893-16899	values	_
91-70	16900-16905	range	_
91-71	16906-16911	0.133	_
91-72	16911-16912	–	_
91-73	16912-16917	0.885	_
91-74	16917-16918	)	_
91-75	16919-16922	and	_
91-76	16923-16925	HC	_
91-77	16926-16927	(	_
91-78	16927-16930	rho	_
91-79	16931-16937	values	_
91-80	16938-16943	range	_
91-81	16944-16949	0.025	_
91-82	16949-16950	–	_
91-83	16950-16955	0.237	_
91-84	16955-16956	,	_
91-85	16957-16958	P	_
91-86	16959-16965	values	_
91-87	16966-16971	range	_
91-88	16972-16977	0.276	_
91-89	16977-16978	–	_
91-90	16978-16983	0.911	_
91-91	16983-16984	)	_
91-92	16985-16991	groups	_
91-93	16991-16992	.	_

#Text=Comparison of percentage of change of volumes among patient subgroups by medication history
#Text=An overall group comparison of percentage of volume changes (1-Factor ANOVA by Group) showed a difference in left SFG (F5,65 = 9.683, P < 0.001), bilateral MFG (left: F5,65 = 15.695, P < 0.001; right: F5,65 = 13.583, P < 0.001) and bilateral IFG (left: F5,65 = 10.677, P < 0.001; right: F5,65 = 8.919, P < 0.001).
92-1	16993-17003	Comparison	_
92-2	17004-17006	of	_
92-3	17007-17017	percentage	_
92-4	17018-17020	of	_
92-5	17021-17027	change	_
92-6	17028-17030	of	_
92-7	17031-17038	volumes	_
92-8	17039-17044	among	_
92-9	17045-17052	patient	_
92-10	17053-17062	subgroups	_
92-11	17063-17065	by	_
92-12	17066-17076	medication	_
92-13	17077-17084	history	_
92-14	17085-17087	An	_
92-15	17088-17095	overall	_
92-16	17096-17101	group	_
92-17	17102-17112	comparison	_
92-18	17113-17115	of	_
92-19	17116-17126	percentage	_
92-20	17127-17129	of	_
92-21	17130-17136	volume	_
92-22	17137-17144	changes	_
92-23	17145-17146	(	_
92-24	17146-17147	1	_
92-25	17147-17148	-	_
92-26	17148-17154	Factor	_
92-27	17155-17160	ANOVA	_
92-28	17161-17163	by	_
92-29	17164-17169	Group	_
92-30	17169-17170	)	_
92-31	17171-17177	showed	_
92-32	17178-17179	a	_
92-33	17180-17190	difference	_
92-34	17191-17193	in	_
92-35	17194-17198	left	_
92-36	17199-17202	SFG	_
92-37	17203-17204	(	_
92-38	17204-17209	F5,65	_
92-39	17210-17211	=	_
92-40	17212-17217	9.683	_
92-41	17217-17218	,	_
92-42	17219-17220	P	_
92-43	17221-17222	<	_
92-44	17223-17228	0.001	_
92-45	17228-17229	)	_
92-46	17229-17230	,	_
92-47	17231-17240	bilateral	_
92-48	17241-17244	MFG	_
92-49	17245-17246	(	_
92-50	17246-17250	left	_
92-51	17250-17251	:	_
92-52	17252-17257	F5,65	_
92-53	17258-17259	=	_
92-54	17260-17266	15.695	_
92-55	17266-17267	,	_
92-56	17268-17269	P	_
92-57	17270-17271	<	_
92-58	17272-17277	0.001	_
92-59	17277-17278	;	_
92-60	17279-17284	right	_
92-61	17284-17285	:	_
92-62	17286-17291	F5,65	_
92-63	17292-17293	=	_
92-64	17294-17300	13.583	_
92-65	17300-17301	,	_
92-66	17302-17303	P	_
92-67	17304-17305	<	_
92-68	17306-17311	0.001	_
92-69	17311-17312	)	_
92-70	17313-17316	and	_
92-71	17317-17326	bilateral	_
92-72	17327-17330	IFG	_
92-73	17331-17332	(	_
92-74	17332-17336	left	_
92-75	17336-17337	:	_
92-76	17338-17343	F5,65	_
92-77	17344-17345	=	_
92-78	17346-17352	10.677	_
92-79	17352-17353	,	_
92-80	17354-17355	P	_
92-81	17356-17357	<	_
92-82	17358-17363	0.001	_
92-83	17363-17364	;	_
92-84	17365-17370	right	_
92-85	17370-17371	:	_
92-86	17372-17377	F5,65	_
92-87	17378-17379	=	_
92-88	17380-17385	8.919	_
92-89	17385-17386	,	_
92-90	17387-17388	P	_
92-91	17389-17390	<	_
92-92	17391-17396	0.001	_
92-93	17396-17397	)	_
92-94	17397-17398	.	_

#Text=No significant effect of medication (typical, atypical antipsychotics, and presence or absence of mood stabilizers) on the PFC subregion volumes in the FESZ or FEAFF group was found in the follow-up post hoc Tukey’s HDS tests (Table 3).
93-1	17399-17401	No	_
93-2	17402-17413	significant	_
93-3	17414-17420	effect	_
93-4	17421-17423	of	_
93-5	17424-17434	medication	_
93-6	17435-17436	(	_
93-7	17436-17443	typical	_
93-8	17443-17444	,	_
93-9	17445-17453	atypical	_
93-10	17454-17468	antipsychotics	_
93-11	17468-17469	,	_
93-12	17470-17473	and	_
93-13	17474-17482	presence	_
93-14	17483-17485	or	_
93-15	17486-17493	absence	_
93-16	17494-17496	of	_
93-17	17497-17501	mood	_
93-18	17502-17513	stabilizers	_
93-19	17513-17514	)	_
93-20	17515-17517	on	_
93-21	17518-17521	the	_
93-22	17522-17525	PFC	_
93-23	17526-17535	subregion	_
93-24	17536-17543	volumes	_
93-25	17544-17546	in	_
93-26	17547-17550	the	_
93-27	17551-17555	FESZ	_
93-28	17556-17558	or	_
93-29	17559-17564	FEAFF	_
93-30	17565-17570	group	_
93-31	17571-17574	was	_
93-32	17575-17580	found	_
93-33	17581-17583	in	_
93-34	17584-17587	the	_
93-35	17588-17597	follow-up	_
93-36	17598-17602	post	_
93-37	17603-17606	hoc	_
93-38	17607-17612	Tukey	_
93-39	17612-17613	’	_
93-40	17613-17614	s	_
93-41	17615-17618	HDS	_
93-42	17619-17624	tests	_
93-43	17625-17626	(	_
93-44	17626-17631	Table	_
93-45	17632-17633	3	_
93-46	17633-17634	)	_
93-47	17634-17635	.	_

#Text=Clinical correlations of symptom change with volume change over time (Fig. 3)
#Text=In the FESZ group, left MFG relative volume percentage of change was significantly correlated with the percentage of change in total BPRS score (rho = −0.725, P < 0.001, n = 21) and BPRS subscale score of withdrawal-retardation (rho = −0.555, P = 0.009, n = 21).
94-1	17636-17644	Clinical	_
94-2	17645-17657	correlations	_
94-3	17658-17660	of	_
94-4	17661-17668	symptom	_
94-5	17669-17675	change	_
94-6	17676-17680	with	_
94-7	17681-17687	volume	_
94-8	17688-17694	change	_
94-9	17695-17699	over	_
94-10	17700-17704	time	_
94-11	17705-17706	(	_
94-12	17706-17709	Fig	_
94-13	17709-17710	.	_
94-14	17711-17712	3	_
94-15	17712-17713	)	_
94-16	17714-17716	In	_
94-17	17717-17720	the	_
94-18	17721-17725	FESZ	_
94-19	17726-17731	group	_
94-20	17731-17732	,	_
94-21	17733-17737	left	_
94-22	17738-17741	MFG	_
94-23	17742-17750	relative	_
94-24	17751-17757	volume	_
94-25	17758-17768	percentage	_
94-26	17769-17771	of	_
94-27	17772-17778	change	_
94-28	17779-17782	was	_
94-29	17783-17796	significantly	_
94-30	17797-17807	correlated	_
94-31	17808-17812	with	_
94-32	17813-17816	the	_
94-33	17817-17827	percentage	_
94-34	17828-17830	of	_
94-35	17831-17837	change	_
94-36	17838-17840	in	_
94-37	17841-17846	total	_
94-38	17847-17851	BPRS	_
94-39	17852-17857	score	_
94-40	17858-17859	(	_
94-41	17859-17862	rho	_
94-42	17863-17864	=	_
94-43	17865-17866	−	_
94-44	17866-17871	0.725	_
94-45	17871-17872	,	_
94-46	17873-17874	P	_
94-47	17875-17876	<	_
94-48	17877-17882	0.001	_
94-49	17882-17883	,	_
94-50	17884-17885	n	_
94-51	17886-17887	=	_
94-52	17888-17890	21	_
94-53	17890-17891	)	_
94-54	17892-17895	and	_
94-55	17896-17900	BPRS	_
94-56	17901-17909	subscale	_
94-57	17910-17915	score	_
94-58	17916-17918	of	_
94-59	17919-17941	withdrawal-retardation	_
94-60	17942-17943	(	_
94-61	17943-17946	rho	_
94-62	17947-17948	=	_
94-63	17949-17950	−	_
94-64	17950-17955	0.555	_
94-65	17955-17956	,	_
94-66	17957-17958	P	_
94-67	17959-17960	=	_
94-68	17961-17966	0.009	_
94-69	17966-17967	,	_
94-70	17968-17969	n	_
94-71	17970-17971	=	_
94-72	17972-17974	21	_
94-73	17974-17975	)	_
94-74	17975-17976	.	_

#Text=Moreover, the left IFG relative volume percentage of change was also correlated with the percentage of change in total BPRS score (rho = −0.617, P = 0.003, n = 21).
95-1	17977-17985	Moreover	_
95-2	17985-17986	,	_
95-3	17987-17990	the	_
95-4	17991-17995	left	_
95-5	17996-17999	IFG	_
95-6	18000-18008	relative	_
95-7	18009-18015	volume	_
95-8	18016-18026	percentage	_
95-9	18027-18029	of	_
95-10	18030-18036	change	_
95-11	18037-18040	was	_
95-12	18041-18045	also	_
95-13	18046-18056	correlated	_
95-14	18057-18061	with	_
95-15	18062-18065	the	_
95-16	18066-18076	percentage	_
95-17	18077-18079	of	_
95-18	18080-18086	change	_
95-19	18087-18089	in	_
95-20	18090-18095	total	_
95-21	18096-18100	BPRS	_
95-22	18101-18106	score	_
95-23	18107-18108	(	_
95-24	18108-18111	rho	_
95-25	18112-18113	=	_
95-26	18114-18115	−	_
95-27	18115-18120	0.617	_
95-28	18120-18121	,	_
95-29	18122-18123	P	_
95-30	18124-18125	=	_
95-31	18126-18131	0.003	_
95-32	18131-18132	,	_
95-33	18133-18134	n	_
95-34	18135-18136	=	_
95-35	18137-18139	21	_
95-36	18139-18140	)	_
95-37	18140-18141	.	_

#Text=Although the associations were relatively weak, there were associations between percentage of change in left MFG volume and BPRS subscale score of anxious-depression and conceptual disorganization as well as an association between percentage of change in left IFG volume and BPRS subscale score of withdrawal-retardation and conceptual disorganization (rho values range −0.467–0.534, P values range 0.015–0.038) (see supplementary Fig.
96-1	18142-18150	Although	_
96-2	18151-18154	the	_
96-3	18155-18167	associations	_
96-4	18168-18172	were	_
96-5	18173-18183	relatively	_
96-6	18184-18188	weak	_
96-7	18188-18189	,	_
96-8	18190-18195	there	_
96-9	18196-18200	were	_
96-10	18201-18213	associations	_
96-11	18214-18221	between	_
96-12	18222-18232	percentage	_
96-13	18233-18235	of	_
96-14	18236-18242	change	_
96-15	18243-18245	in	_
96-16	18246-18250	left	_
96-17	18251-18254	MFG	_
96-18	18255-18261	volume	_
96-19	18262-18265	and	_
96-20	18266-18270	BPRS	_
96-21	18271-18279	subscale	_
96-22	18280-18285	score	_
96-23	18286-18288	of	_
96-24	18289-18307	anxious-depression	_
96-25	18308-18311	and	_
96-26	18312-18322	conceptual	_
96-27	18323-18338	disorganization	_
96-28	18339-18341	as	_
96-29	18342-18346	well	_
96-30	18347-18349	as	_
96-31	18350-18352	an	_
96-32	18353-18364	association	_
96-33	18365-18372	between	_
96-34	18373-18383	percentage	_
96-35	18384-18386	of	_
96-36	18387-18393	change	_
96-37	18394-18396	in	_
96-38	18397-18401	left	_
96-39	18402-18405	IFG	_
96-40	18406-18412	volume	_
96-41	18413-18416	and	_
96-42	18417-18421	BPRS	_
96-43	18422-18430	subscale	_
96-44	18431-18436	score	_
96-45	18437-18439	of	_
96-46	18440-18462	withdrawal-retardation	_
96-47	18463-18466	and	_
96-48	18467-18477	conceptual	_
96-49	18478-18493	disorganization	_
96-50	18494-18495	(	_
96-51	18495-18498	rho	_
96-52	18499-18505	values	_
96-53	18506-18511	range	_
96-54	18512-18513	−	_
96-55	18513-18518	0.467	_
96-56	18518-18519	–	_
96-57	18519-18524	0.534	_
96-58	18524-18525	,	_
96-59	18526-18527	P	_
96-60	18528-18534	values	_
96-61	18535-18540	range	_
96-62	18541-18546	0.015	_
96-63	18546-18547	–	_
96-64	18547-18552	0.038	_
96-65	18552-18553	)	_
96-66	18554-18555	(	_
96-67	18555-18558	see	_
96-68	18559-18572	supplementary	_
96-69	18573-18576	Fig	_
96-70	18576-18577	.	_

#Text=S2).
97-1	18578-18580	S2	_
97-2	18580-18581	)	_
97-3	18581-18582	.	_

#Text=Discussion
#Text=Using manual parcellation of ROIs, the present study showed a longitudinal progression of GMV loss in FESZ, but not in FEAFF.
98-1	18583-18593	Discussion	_
98-2	18594-18599	Using	_
98-3	18600-18606	manual	_
98-4	18607-18619	parcellation	_
98-5	18620-18622	of	_
98-6	18623-18627	ROIs	_
98-7	18627-18628	,	_
98-8	18629-18632	the	_
98-9	18633-18640	present	_
98-10	18641-18646	study	_
98-11	18647-18653	showed	_
98-12	18654-18655	a	_
98-13	18656-18668	longitudinal	_
98-14	18669-18680	progression	_
98-15	18681-18683	of	_
98-16	18684-18687	GMV	_
98-17	18688-18692	loss	_
98-18	18693-18695	in	_
98-19	18696-18700	FESZ	_
98-20	18700-18701	,	_
98-21	18702-18705	but	_
98-22	18706-18709	not	_
98-23	18710-18712	in	_
98-24	18713-18718	FEAFF	_
98-25	18718-18719	.	_

#Text=Moreover, the specific association with BPRS withdrawal-retardation implies that left MFG and IFG progressive GMV loss may be an important factor in negative symptom development as well as overall psychotic symptom severity as indexed by the BPRS.
99-1	18720-18728	Moreover	_
99-2	18728-18729	,	_
99-3	18730-18733	the	_
99-4	18734-18742	specific	_
99-5	18743-18754	association	_
99-6	18755-18759	with	_
99-7	18760-18764	BPRS	_
99-8	18765-18787	withdrawal-retardation	_
99-9	18788-18795	implies	_
99-10	18796-18800	that	_
99-11	18801-18805	left	_
99-12	18806-18809	MFG	_
99-13	18810-18813	and	_
99-14	18814-18817	IFG	_
99-15	18818-18829	progressive	_
99-16	18830-18833	GMV	_
99-17	18834-18838	loss	_
99-18	18839-18842	may	_
99-19	18843-18845	be	_
99-20	18846-18848	an	_
99-21	18849-18858	important	_
99-22	18859-18865	factor	_
99-23	18866-18868	in	_
99-24	18869-18877	negative	_
99-25	18878-18885	symptom	_
99-26	18886-18897	development	_
99-27	18898-18900	as	_
99-28	18901-18905	well	_
99-29	18906-18908	as	_
99-30	18909-18916	overall	_
99-31	18917-18926	psychotic	_
99-32	18927-18934	symptom	_
99-33	18935-18943	severity	_
99-34	18944-18946	as	_
99-35	18947-18954	indexed	_
99-36	18955-18957	by	_
99-37	18958-18961	the	_
99-38	18962-18966	BPRS	_
99-39	18966-18967	.	_

#Text=However, these findings were not observed using the automated brain segmentation provided by FreeSurfer.
100-1	18968-18975	However	_
100-2	18975-18976	,	_
100-3	18977-18982	these	_
100-4	18983-18991	findings	_
100-5	18992-18996	were	_
100-6	18997-19000	not	_
100-7	19001-19009	observed	_
100-8	19010-19015	using	_
100-9	19016-19019	the	_
100-10	19020-19029	automated	_
100-11	19030-19035	brain	_
100-12	19036-19048	segmentation	_
100-13	19049-19057	provided	_
100-14	19058-19060	by	_
100-15	19061-19071	FreeSurfer	_
100-16	19071-19072	.	_

#Text=Findings in the present longitudinal study with regard to FESZ were consistent with, but also more gyrally specific than, the longitudinal VBM study that showed progressive volume reduction between baseline and 1.5-year follow-up scan in the voxels in the superior temporal gyrus (STG) and in the neocortical regions of frontal, parietal, and limbic regions in FESZ group compared with HC group.
101-1	19073-19081	Findings	_
101-2	19082-19084	in	_
101-3	19085-19088	the	_
101-4	19089-19096	present	_
101-5	19097-19109	longitudinal	_
101-6	19110-19115	study	_
101-7	19116-19120	with	_
101-8	19121-19127	regard	_
101-9	19128-19130	to	_
101-10	19131-19135	FESZ	_
101-11	19136-19140	were	_
101-12	19141-19151	consistent	_
101-13	19152-19156	with	_
101-14	19156-19157	,	_
101-15	19158-19161	but	_
101-16	19162-19166	also	_
101-17	19167-19171	more	_
101-18	19172-19179	gyrally	_
101-19	19180-19188	specific	_
101-20	19189-19193	than	_
101-21	19193-19194	,	_
101-22	19195-19198	the	_
101-23	19199-19211	longitudinal	_
101-24	19212-19215	VBM	_
101-25	19216-19221	study	_
101-26	19222-19226	that	_
101-27	19227-19233	showed	_
101-28	19234-19245	progressive	_
101-29	19246-19252	volume	_
101-30	19253-19262	reduction	_
101-31	19263-19270	between	_
101-32	19271-19279	baseline	_
101-33	19280-19283	and	_
101-34	19284-19287	1.5	_
101-35	19287-19288	-	_
101-36	19288-19292	year	_
101-37	19293-19302	follow-up	_
101-38	19303-19307	scan	_
101-39	19308-19310	in	_
101-40	19311-19314	the	_
101-41	19315-19321	voxels	_
101-42	19322-19324	in	_
101-43	19325-19328	the	_
101-44	19329-19337	superior	_
101-45	19338-19346	temporal	_
101-46	19347-19352	gyrus	_
101-47	19353-19354	(	_
101-48	19354-19357	STG	_
101-49	19357-19358	)	_
101-50	19359-19362	and	_
101-51	19363-19365	in	_
101-52	19366-19369	the	_
101-53	19370-19381	neocortical	_
101-54	19382-19389	regions	_
101-55	19390-19392	of	_
101-56	19393-19400	frontal	_
101-57	19400-19401	,	_
101-58	19402-19410	parietal	_
101-59	19410-19411	,	_
101-60	19412-19415	and	_
101-61	19416-19422	limbic	_
101-62	19423-19430	regions	_
101-63	19431-19433	in	_
101-64	19434-19438	FESZ	_
101-65	19439-19444	group	_
101-66	19445-19453	compared	_
101-67	19454-19458	with	_
101-68	19459-19461	HC	_
101-69	19462-19467	group	_
101-70	19467-19468	.	_

#Text=The present study results were also consistent with another longitudinal study using semiautomated segmentation of the brain based on the Talairach proportional grid system in showing progressive volume reduction between baseline and 2-year follow-up scan in frontal lobe GMV in the FESZ group compared with HC group.
102-1	19469-19472	The	_
102-2	19473-19480	present	_
102-3	19481-19486	study	_
102-4	19487-19494	results	_
102-5	19495-19499	were	_
102-6	19500-19504	also	_
102-7	19505-19515	consistent	_
102-8	19516-19520	with	_
102-9	19521-19528	another	_
102-10	19529-19541	longitudinal	_
102-11	19542-19547	study	_
102-12	19548-19553	using	_
102-13	19554-19567	semiautomated	_
102-14	19568-19580	segmentation	_
102-15	19581-19583	of	_
102-16	19584-19587	the	_
102-17	19588-19593	brain	_
102-18	19594-19599	based	_
102-19	19600-19602	on	_
102-20	19603-19606	the	_
102-21	19607-19616	Talairach	_
102-22	19617-19629	proportional	_
102-23	19630-19634	grid	_
102-24	19635-19641	system	_
102-25	19642-19644	in	_
102-26	19645-19652	showing	_
102-27	19653-19664	progressive	_
102-28	19665-19671	volume	_
102-29	19672-19681	reduction	_
102-30	19682-19689	between	_
102-31	19690-19698	baseline	_
102-32	19699-19702	and	_
102-33	19703-19704	2	_
102-34	19704-19705	-	_
102-35	19705-19709	year	_
102-36	19710-19719	follow-up	_
102-37	19720-19724	scan	_
102-38	19725-19727	in	_
102-39	19728-19735	frontal	_
102-40	19736-19740	lobe	_
102-41	19741-19744	GMV	_
102-42	19745-19747	in	_
102-43	19748-19751	the	_
102-44	19752-19756	FESZ	_
102-45	19757-19762	group	_
102-46	19763-19771	compared	_
102-47	19772-19776	with	_
102-48	19777-19779	HC	_
102-49	19780-19785	group	_
102-50	19785-19786	.	_

#Text=Hence, the present study revealed the important finding that the first 1.5 years after onset are associated with major GMV decrease in schizophrenia but not FEAFF.
103-1	19787-19792	Hence	_
103-2	19792-19793	,	_
103-3	19794-19797	the	_
103-4	19798-19805	present	_
103-5	19806-19811	study	_
103-6	19812-19820	revealed	_
103-7	19821-19824	the	_
103-8	19825-19834	important	_
103-9	19835-19842	finding	_
103-10	19843-19847	that	_
103-11	19848-19851	the	_
103-12	19852-19857	first	_
103-13	19858-19861	1.5	_
103-14	19862-19867	years	_
103-15	19868-19873	after	_
103-16	19874-19879	onset	_
103-17	19880-19883	are	_
103-18	19884-19894	associated	_
103-19	19895-19899	with	_
103-20	19900-19905	major	_
103-21	19906-19909	GMV	_
103-22	19910-19918	decrease	_
103-23	19919-19921	in	_
103-24	19922-19935	schizophrenia	_
103-25	19936-19939	but	_
103-26	19940-19943	not	_
103-27	19944-19949	FEAFF	_
103-28	19949-19950	.	_

#Text=Medication effects
#Text=The present results revealed no significant effect of antipsychotics on the PFC ROIs.
104-1	19951-19961	Medication	_
104-2	19962-19969	effects	_
104-3	19970-19973	The	_
104-4	19974-19981	present	_
104-5	19982-19989	results	_
104-6	19990-19998	revealed	_
104-7	19999-20001	no	_
104-8	20002-20013	significant	_
104-9	20014-20020	effect	_
104-10	20021-20023	of	_
104-11	20024-20038	antipsychotics	_
104-12	20039-20041	on	_
104-13	20042-20045	the	_
104-14	20046-20049	PFC	_
104-15	20050-20054	ROIs	_
104-16	20054-20055	.	_

#Text=We note that our previous study suggested a protective effect of antipsychotics on GMV reduction.
105-1	20056-20058	We	_
105-2	20059-20063	note	_
105-3	20064-20068	that	_
105-4	20069-20072	our	_
105-5	20073-20081	previous	_
105-6	20082-20087	study	_
105-7	20088-20097	suggested	_
105-8	20098-20099	a	_
105-9	20100-20110	protective	_
105-10	20111-20117	effect	_
105-11	20118-20120	of	_
105-12	20121-20135	antipsychotics	_
105-13	20136-20138	on	_
105-14	20139-20142	GMV	_
105-15	20143-20152	reduction	_
105-16	20152-20153	.	_

#Text=These findings are consistent with a review concluding that antipsychotic medication is either not associated with brain volume reduction in SZ or attenuates it (Hulshoff Pol and Lahn 2008).
106-1	20154-20159	These	_
106-2	20160-20168	findings	_
106-3	20169-20172	are	_
106-4	20173-20183	consistent	_
106-5	20184-20188	with	_
106-6	20189-20190	a	_
106-7	20191-20197	review	_
106-8	20198-20208	concluding	_
106-9	20209-20213	that	_
106-10	20214-20227	antipsychotic	_
106-11	20228-20238	medication	_
106-12	20239-20241	is	_
106-13	20242-20248	either	_
106-14	20249-20252	not	_
106-15	20253-20263	associated	_
106-16	20264-20268	with	_
106-17	20269-20274	brain	_
106-18	20275-20281	volume	_
106-19	20282-20291	reduction	_
106-20	20292-20294	in	_
106-21	20295-20297	SZ	_
106-22	20298-20300	or	_
106-23	20301-20311	attenuates	_
106-24	20312-20314	it	_
106-25	20315-20316	(	_
106-26	20316-20324	Hulshoff	_
106-27	20325-20328	Pol	_
106-28	20329-20332	and	_
106-29	20333-20337	Lahn	_
106-30	20338-20342	2008	_
106-31	20342-20343	)	_
106-32	20343-20344	.	_

#Text=In contrast, a study over longer time intervals showed measureable antipsychotic effects in increasing brain tissue loss in SZ.
107-1	20345-20347	In	_
107-2	20348-20356	contrast	_
107-3	20356-20357	,	_
107-4	20358-20359	a	_
107-5	20360-20365	study	_
107-6	20366-20370	over	_
107-7	20371-20377	longer	_
107-8	20378-20382	time	_
107-9	20383-20392	intervals	_
107-10	20393-20399	showed	_
107-11	20400-20411	measureable	_
107-12	20412-20425	antipsychotic	_
107-13	20426-20433	effects	_
107-14	20434-20436	in	_
107-15	20437-20447	increasing	_
107-16	20448-20453	brain	_
107-17	20454-20460	tissue	_
107-18	20461-20465	loss	_
107-19	20466-20468	in	_
107-20	20469-20471	SZ	_
107-21	20471-20472	.	_

#Text=In this study, it is possible that greater symptom severity led to more neuroleptic exposure and hence, more association with brain changes and it is difficult to rule out this possibility.
108-1	20473-20475	In	_
108-2	20476-20480	this	_
108-3	20481-20486	study	_
108-4	20486-20487	,	_
108-5	20488-20490	it	_
108-6	20491-20493	is	_
108-7	20494-20502	possible	_
108-8	20503-20507	that	_
108-9	20508-20515	greater	_
108-10	20516-20523	symptom	_
108-11	20524-20532	severity	_
108-12	20533-20536	led	_
108-13	20537-20539	to	_
108-14	20540-20544	more	_
108-15	20545-20556	neuroleptic	_
108-16	20557-20565	exposure	_
108-17	20566-20569	and	_
108-18	20570-20575	hence	_
108-19	20575-20576	,	_
108-20	20577-20581	more	_
108-21	20582-20593	association	_
108-22	20594-20598	with	_
108-23	20599-20604	brain	_
108-24	20605-20612	changes	_
108-25	20613-20616	and	_
108-26	20617-20619	it	_
108-27	20620-20622	is	_
108-28	20623-20632	difficult	_
108-29	20633-20635	to	_
108-30	20636-20640	rule	_
108-31	20641-20644	out	_
108-32	20645-20649	this	_
108-33	20650-20661	possibility	_
108-34	20661-20662	.	_

#Text=In terms of the effect of the type of antipsychotic medication, two studies suggest that volumetric changes, if present, are more evident with typical than with atypical antipsychotic usage.
109-1	20663-20665	In	_
109-2	20666-20671	terms	_
109-3	20672-20674	of	_
109-4	20675-20678	the	_
109-5	20679-20685	effect	_
109-6	20686-20688	of	_
109-7	20689-20692	the	_
109-8	20693-20697	type	_
109-9	20698-20700	of	_
109-10	20701-20714	antipsychotic	_
109-11	20715-20725	medication	_
109-12	20725-20726	,	_
109-13	20727-20730	two	_
109-14	20731-20738	studies	_
109-15	20739-20746	suggest	_
109-16	20747-20751	that	_
109-17	20752-20762	volumetric	_
109-18	20763-20770	changes	_
109-19	20770-20771	,	_
109-20	20772-20774	if	_
109-21	20775-20782	present	_
109-22	20782-20783	,	_
109-23	20784-20787	are	_
109-24	20788-20792	more	_
109-25	20793-20800	evident	_
109-26	20801-20805	with	_
109-27	20806-20813	typical	_
109-28	20814-20818	than	_
109-29	20819-20823	with	_
109-30	20824-20832	atypical	_
109-31	20833-20846	antipsychotic	_
109-32	20847-20852	usage	_
109-33	20852-20853	.	_

#Text=In the present study, no correlations between CPZ equivalents and total BPRS scores at either Time 1 or 2 were found.
110-1	20854-20856	In	_
110-2	20857-20860	the	_
110-3	20861-20868	present	_
110-4	20869-20874	study	_
110-5	20874-20875	,	_
110-6	20876-20878	no	_
110-7	20879-20891	correlations	_
110-8	20892-20899	between	_
110-9	20900-20903	CPZ	_
110-10	20904-20915	equivalents	_
110-11	20916-20919	and	_
110-12	20920-20925	total	_
110-13	20926-20930	BPRS	_
110-14	20931-20937	scores	_
110-15	20938-20940	at	_
110-16	20941-20947	either	_
110-17	20948-20952	Time	_
110-18	20953-20954	1	_
110-19	20955-20957	or	_
110-20	20958-20959	2	_
110-21	20960-20964	were	_
110-22	20965-20970	found	_
110-23	20970-20971	.	_

#Text=In summary, the present results and previous studies from our laboratory showed ongoing progressive volume reduction associated with function impairment in the schizophrenia patients’ brain during the initial years after diagnosis despite ongoing antipsychotic medication.
111-1	20972-20974	In	_
111-2	20975-20982	summary	_
111-3	20982-20983	,	_
111-4	20984-20987	the	_
111-5	20988-20995	present	_
111-6	20996-21003	results	_
111-7	21004-21007	and	_
111-8	21008-21016	previous	_
111-9	21017-21024	studies	_
111-10	21025-21029	from	_
111-11	21030-21033	our	_
111-12	21034-21044	laboratory	_
111-13	21045-21051	showed	_
111-14	21052-21059	ongoing	_
111-15	21060-21071	progressive	_
111-16	21072-21078	volume	_
111-17	21079-21088	reduction	_
111-18	21089-21099	associated	_
111-19	21100-21104	with	_
111-20	21105-21113	function	_
111-21	21114-21124	impairment	_
111-22	21125-21127	in	_
111-23	21128-21131	the	_
111-24	21132-21145	schizophrenia	_
111-25	21146-21154	patients	_
111-26	21154-21155	’	_
111-27	21156-21161	brain	_
111-28	21162-21168	during	_
111-29	21169-21172	the	_
111-30	21173-21180	initial	_
111-31	21181-21186	years	_
111-32	21187-21192	after	_
111-33	21193-21202	diagnosis	_
111-34	21203-21210	despite	_
111-35	21211-21218	ongoing	_
111-36	21219-21232	antipsychotic	_
111-37	21233-21243	medication	_
111-38	21243-21244	.	_

#Text=With respect to the FEAFF data, a meta-analysis showed an overlap of brain abnormalities in affective and non-affective psychotic disorders at the onset of the disease.
112-1	21245-21249	With	_
112-2	21250-21257	respect	_
112-3	21258-21260	to	_
112-4	21261-21264	the	_
112-5	21265-21270	FEAFF	_
112-6	21271-21275	data	_
112-7	21275-21276	,	_
112-8	21277-21278	a	_
112-9	21279-21292	meta-analysis	_
112-10	21293-21299	showed	_
112-11	21300-21302	an	_
112-12	21303-21310	overlap	_
112-13	21311-21313	of	_
112-14	21314-21319	brain	_
112-15	21320-21333	abnormalities	_
112-16	21334-21336	in	_
112-17	21337-21346	affective	_
112-18	21347-21350	and	_
112-19	21351-21364	non-affective	_
112-20	21365-21374	psychotic	_
112-21	21375-21384	disorders	_
112-22	21385-21387	at	_
112-23	21388-21391	the	_
112-24	21392-21397	onset	_
112-25	21398-21400	of	_
112-26	21401-21404	the	_
112-27	21405-21412	disease	_
112-28	21412-21413	.	_

#Text=In the longitudinal analysis, the present data are consistent with a two year longitudinal VBM study showing no progressive volume change comparing older BD patients and HCs.
113-1	21414-21416	In	_
113-2	21417-21420	the	_
113-3	21421-21433	longitudinal	_
113-4	21434-21442	analysis	_
113-5	21442-21443	,	_
113-6	21444-21447	the	_
113-7	21448-21455	present	_
113-8	21456-21460	data	_
113-9	21461-21464	are	_
113-10	21465-21475	consistent	_
113-11	21476-21480	with	_
113-12	21481-21482	a	_
113-13	21483-21486	two	_
113-14	21487-21491	year	_
113-15	21492-21504	longitudinal	_
113-16	21505-21508	VBM	_
113-17	21509-21514	study	_
113-18	21515-21522	showing	_
113-19	21523-21525	no	_
113-20	21526-21537	progressive	_
113-21	21538-21544	volume	_
113-22	21545-21551	change	_
113-23	21552-21561	comparing	_
113-24	21562-21567	older	_
113-25	21568-21570	BD	_
113-26	21571-21579	patients	_
113-27	21580-21583	and	_
113-28	21584-21587	HCs	_
113-29	21587-21588	.	_

#Text=In terms of the effect of medication, mood stabilizer usage has been suggested to increase GMV in BD patients.
114-1	21589-21591	In	_
114-2	21592-21597	terms	_
114-3	21598-21600	of	_
114-4	21601-21604	the	_
114-5	21605-21611	effect	_
114-6	21612-21614	of	_
114-7	21615-21625	medication	_
114-8	21625-21626	,	_
114-9	21627-21631	mood	_
114-10	21632-21642	stabilizer	_
114-11	21643-21648	usage	_
114-12	21649-21652	has	_
114-13	21653-21657	been	_
114-14	21658-21667	suggested	_
114-15	21668-21670	to	_
114-16	21671-21679	increase	_
114-17	21680-21683	GMV	_
114-18	21684-21686	in	_
114-19	21687-21689	BD	_
114-20	21690-21698	patients	_
114-21	21698-21699	.	_

#Text=In the present study, the small subject number (N = 4) of FEAFF not given mood stabilizers, renders a comparison with mood stabilizer treatment inconclusive, although we found no difference between these groups (Table 3).
115-1	21700-21702	In	_
115-2	21703-21706	the	_
115-3	21707-21714	present	_
115-4	21715-21720	study	_
115-5	21720-21721	,	_
115-6	21722-21725	the	_
115-7	21726-21731	small	_
115-8	21732-21739	subject	_
115-9	21740-21746	number	_
115-10	21747-21748	(	_
115-11	21748-21749	N	_
115-12	21750-21751	=	_
115-13	21752-21753	4	_
115-14	21753-21754	)	_
115-15	21755-21757	of	_
115-16	21758-21763	FEAFF	_
115-17	21764-21767	not	_
115-18	21768-21773	given	_
115-19	21774-21778	mood	_
115-20	21779-21790	stabilizers	_
115-21	21790-21791	,	_
115-22	21792-21799	renders	_
115-23	21800-21801	a	_
115-24	21802-21812	comparison	_
115-25	21813-21817	with	_
115-26	21818-21822	mood	_
115-27	21823-21833	stabilizer	_
115-28	21834-21843	treatment	_
115-29	21844-21856	inconclusive	_
115-30	21856-21857	,	_
115-31	21858-21866	although	_
115-32	21867-21869	we	_
115-33	21870-21875	found	_
115-34	21876-21878	no	_
115-35	21879-21889	difference	_
115-36	21890-21897	between	_
115-37	21898-21903	these	_
115-38	21904-21910	groups	_
115-39	21911-21912	(	_
115-40	21912-21917	Table	_
115-41	21918-21919	3	_
115-42	21919-21920	)	_
115-43	21920-21921	.	_

#Text=The MFG and IFG were associated with poor change score in the total BPRS, and progressive GMV reduction in the MFG was associated with poor change in the withdrawal-retardation subscale of BPRS.
116-1	21922-21925	The	_
116-2	21926-21929	MFG	_
116-3	21930-21933	and	_
116-4	21934-21937	IFG	_
116-5	21938-21942	were	_
116-6	21943-21953	associated	_
116-7	21954-21958	with	_
116-8	21959-21963	poor	_
116-9	21964-21970	change	_
116-10	21971-21976	score	_
116-11	21977-21979	in	_
116-12	21980-21983	the	_
116-13	21984-21989	total	_
116-14	21990-21994	BPRS	_
116-15	21994-21995	,	_
116-16	21996-21999	and	_
116-17	22000-22011	progressive	_
116-18	22012-22015	GMV	_
116-19	22016-22025	reduction	_
116-20	22026-22028	in	_
116-21	22029-22032	the	_
116-22	22033-22036	MFG	_
116-23	22037-22040	was	_
116-24	22041-22051	associated	_
116-25	22052-22056	with	_
116-26	22057-22061	poor	_
116-27	22062-22068	change	_
116-28	22069-22071	in	_
116-29	22072-22075	the	_
116-30	22076-22098	withdrawal-retardation	_
116-31	22099-22107	subscale	_
116-32	22108-22110	of	_
116-33	22111-22115	BPRS	_
116-34	22115-22116	.	_

#Text=A VBM study from our laboratory showed significant associations between bilateral IFG progressive volume reduction in schizophrenia and worse withdrawal-retardation subscale scores in BPRS.
117-1	22117-22118	A	_
117-2	22119-22122	VBM	_
117-3	22123-22128	study	_
117-4	22129-22133	from	_
117-5	22134-22137	our	_
117-6	22138-22148	laboratory	_
117-7	22149-22155	showed	_
117-8	22156-22167	significant	_
117-9	22168-22180	associations	_
117-10	22181-22188	between	_
117-11	22189-22198	bilateral	_
117-12	22199-22202	IFG	_
117-13	22203-22214	progressive	_
117-14	22215-22221	volume	_
117-15	22222-22231	reduction	_
117-16	22232-22234	in	_
117-17	22235-22248	schizophrenia	_
117-18	22249-22252	and	_
117-19	22253-22258	worse	_
117-20	22259-22281	withdrawal-retardation	_
117-21	22282-22290	subscale	_
117-22	22291-22297	scores	_
117-23	22298-22300	in	_
117-24	22301-22305	BPRS	_
117-25	22305-22306	.	_

#Text=Although the present gyral IFG ROI partially differed from the VBM localization, the common link to the IFG strengthens the present report of an IFG and withdrawal-retardation subscale association.
118-1	22307-22315	Although	_
118-2	22316-22319	the	_
118-3	22320-22327	present	_
118-4	22328-22333	gyral	_
118-5	22334-22337	IFG	_
118-6	22338-22341	ROI	_
118-7	22342-22351	partially	_
118-8	22352-22360	differed	_
118-9	22361-22365	from	_
118-10	22366-22369	the	_
118-11	22370-22373	VBM	_
118-12	22374-22386	localization	_
118-13	22386-22387	,	_
118-14	22388-22391	the	_
118-15	22392-22398	common	_
118-16	22399-22403	link	_
118-17	22404-22406	to	_
118-18	22407-22410	the	_
118-19	22411-22414	IFG	_
118-20	22415-22426	strengthens	_
118-21	22427-22430	the	_
118-22	22431-22438	present	_
118-23	22439-22445	report	_
118-24	22446-22448	of	_
118-25	22449-22451	an	_
118-26	22452-22455	IFG	_
118-27	22456-22459	and	_
118-28	22460-22482	withdrawal-retardation	_
118-29	22483-22491	subscale	_
118-30	22492-22503	association	_
118-31	22503-22504	.	_

#Text=No study, to our knowledge, has reported the association between progressive volume reduction in specific PFC subregions and a worse BPRS total score.
119-1	22505-22507	No	_
119-2	22508-22513	study	_
119-3	22513-22514	,	_
119-4	22515-22517	to	_
119-5	22518-22521	our	_
119-6	22522-22531	knowledge	_
119-7	22531-22532	,	_
119-8	22533-22536	has	_
119-9	22537-22545	reported	_
119-10	22546-22549	the	_
119-11	22550-22561	association	_
119-12	22562-22569	between	_
119-13	22570-22581	progressive	_
119-14	22582-22588	volume	_
119-15	22589-22598	reduction	_
119-16	22599-22601	in	_
119-17	22602-22610	specific	_
119-18	22611-22614	PFC	_
119-19	22615-22625	subregions	_
119-20	22626-22629	and	_
119-21	22630-22631	a	_
119-22	22632-22637	worse	_
119-23	22638-22642	BPRS	_
119-24	22643-22648	total	_
119-25	22649-22654	score	_
119-26	22654-22655	.	_

#Text=We note that the observed associations between progressive volume reductions and exacerbation in BPRS total scores in FESZ are consistent with a previous review suggesting that progressive brain changes in patients with schizophrenia were associated with poor outcome.
120-1	22656-22658	We	_
120-2	22659-22663	note	_
120-3	22664-22668	that	_
120-4	22669-22672	the	_
120-5	22673-22681	observed	_
120-6	22682-22694	associations	_
120-7	22695-22702	between	_
120-8	22703-22714	progressive	_
120-9	22715-22721	volume	_
120-10	22722-22732	reductions	_
120-11	22733-22736	and	_
120-12	22737-22749	exacerbation	_
120-13	22750-22752	in	_
120-14	22753-22757	BPRS	_
120-15	22758-22763	total	_
120-16	22764-22770	scores	_
120-17	22771-22773	in	_
120-18	22774-22778	FESZ	_
120-19	22779-22782	are	_
120-20	22783-22793	consistent	_
120-21	22794-22798	with	_
120-22	22799-22800	a	_
120-23	22801-22809	previous	_
120-24	22810-22816	review	_
120-25	22817-22827	suggesting	_
120-26	22828-22832	that	_
120-27	22833-22844	progressive	_
120-28	22845-22850	brain	_
120-29	22851-22858	changes	_
120-30	22859-22861	in	_
120-31	22862-22870	patients	_
120-32	22871-22875	with	_
120-33	22876-22889	schizophrenia	_
120-34	22890-22894	were	_
120-35	22895-22905	associated	_
120-36	22906-22910	with	_
120-37	22911-22915	poor	_
120-38	22916-22923	outcome	_
120-39	22923-22924	.	_

#Text=GMV reduction over time in the left MFG or IFG was associated either with an exacerbation or a failure to improve on specific BPRS subscale scores including anxious-depression (MFG), and withdrawal-retardation (IFG) (see Supplemental Fig.
121-1	22925-22928	GMV	_
121-2	22929-22938	reduction	_
121-3	22939-22943	over	_
121-4	22944-22948	time	_
121-5	22949-22951	in	_
121-6	22952-22955	the	_
121-7	22956-22960	left	_
121-8	22961-22964	MFG	_
121-9	22965-22967	or	_
121-10	22968-22971	IFG	_
121-11	22972-22975	was	_
121-12	22976-22986	associated	_
121-13	22987-22993	either	_
121-14	22994-22998	with	_
121-15	22999-23001	an	_
121-16	23002-23014	exacerbation	_
121-17	23015-23017	or	_
121-18	23018-23019	a	_
121-19	23020-23027	failure	_
121-20	23028-23030	to	_
121-21	23031-23038	improve	_
121-22	23039-23041	on	_
121-23	23042-23050	specific	_
121-24	23051-23055	BPRS	_
121-25	23056-23064	subscale	_
121-26	23065-23071	scores	_
121-27	23072-23081	including	_
121-28	23082-23100	anxious-depression	_
121-29	23101-23102	(	_
121-30	23102-23105	MFG	_
121-31	23105-23106	)	_
121-32	23106-23107	,	_
121-33	23108-23111	and	_
121-34	23112-23134	withdrawal-retardation	_
121-35	23135-23136	(	_
121-36	23136-23139	IFG	_
121-37	23139-23140	)	_
121-38	23141-23142	(	_
121-39	23142-23145	see	_
121-40	23146-23158	Supplemental	_
121-41	23159-23162	Fig	_
121-42	23162-23163	.	_

#Text=S2).
122-1	23164-23166	S2	_
122-2	23166-23167	)	_
122-3	23167-23168	.	_

#Text=No other study, to our knowledge, examined the relationship between progressive PFC gyral GMV reduction and worse outcome of anxious-depression subscale in schizophrenia.
123-1	23169-23171	No	_
123-2	23172-23177	other	_
123-3	23178-23183	study	_
123-4	23183-23184	,	_
123-5	23185-23187	to	_
123-6	23188-23191	our	_
123-7	23192-23201	knowledge	_
123-8	23201-23202	,	_
123-9	23203-23211	examined	_
123-10	23212-23215	the	_
123-11	23216-23228	relationship	_
123-12	23229-23236	between	_
123-13	23237-23248	progressive	_
123-14	23249-23252	PFC	_
123-15	23253-23258	gyral	_
123-16	23259-23262	GMV	_
123-17	23263-23272	reduction	_
123-18	23273-23276	and	_
123-19	23277-23282	worse	_
123-20	23283-23290	outcome	_
123-21	23291-23293	of	_
123-22	23294-23312	anxious-depression	_
123-23	23313-23321	subscale	_
123-24	23322-23324	in	_
123-25	23325-23338	schizophrenia	_
123-26	23338-23339	.	_

#Text=Consistent with our anxious-depression association, an MRS study reported that right frontal metabolic abnormalities were associated with anxious-depression BPRS factor severity in schizophrenia.
124-1	23340-23350	Consistent	_
124-2	23351-23355	with	_
124-3	23356-23359	our	_
124-4	23360-23378	anxious-depression	_
124-5	23379-23390	association	_
124-6	23390-23391	,	_
124-7	23392-23394	an	_
124-8	23395-23398	MRS	_
124-9	23399-23404	study	_
124-10	23405-23413	reported	_
124-11	23414-23418	that	_
124-12	23419-23424	right	_
124-13	23425-23432	frontal	_
124-14	23433-23442	metabolic	_
124-15	23443-23456	abnormalities	_
124-16	23457-23461	were	_
124-17	23462-23472	associated	_
124-18	23473-23477	with	_
124-19	23478-23496	anxious-depression	_
124-20	23497-23501	BPRS	_
124-21	23502-23508	factor	_
124-22	23509-23517	severity	_
124-23	23518-23520	in	_
124-24	23521-23534	schizophrenia	_
124-25	23534-23535	.	_

#Text=Clinically, post-psychotic depression often appears after the acute psychotic state in schizophrenia, and thus we speculate that post-acute depressive symptoms may have been reflected in our anxious-depression findings.
125-1	23536-23546	Clinically	_
125-2	23546-23547	,	_
125-3	23548-23562	post-psychotic	_
125-4	23563-23573	depression	_
125-5	23574-23579	often	_
125-6	23580-23587	appears	_
125-7	23588-23593	after	_
125-8	23594-23597	the	_
125-9	23598-23603	acute	_
125-10	23604-23613	psychotic	_
125-11	23614-23619	state	_
125-12	23620-23622	in	_
125-13	23623-23636	schizophrenia	_
125-14	23636-23637	,	_
125-15	23638-23641	and	_
125-16	23642-23646	thus	_
125-17	23647-23649	we	_
125-18	23650-23659	speculate	_
125-19	23660-23664	that	_
125-20	23665-23675	post-acute	_
125-21	23676-23686	depressive	_
125-22	23687-23695	symptoms	_
125-23	23696-23699	may	_
125-24	23700-23704	have	_
125-25	23705-23709	been	_
125-26	23710-23719	reflected	_
125-27	23720-23722	in	_
125-28	23723-23726	our	_
125-29	23727-23745	anxious-depression	_
125-30	23746-23754	findings	_
125-31	23754-23755	.	_

#Text=Our findings regarding conceptual disorganization appear to be congruent with previous studies, and add an important longitudinal dimension.
126-1	23756-23759	Our	_
126-2	23760-23768	findings	_
126-3	23769-23778	regarding	_
126-4	23779-23789	conceptual	_
126-5	23790-23805	disorganization	_
126-6	23806-23812	appear	_
126-7	23813-23815	to	_
126-8	23816-23818	be	_
126-9	23819-23828	congruent	_
126-10	23829-23833	with	_
126-11	23834-23842	previous	_
126-12	23843-23850	studies	_
126-13	23850-23851	,	_
126-14	23852-23855	and	_
126-15	23856-23859	add	_
126-16	23860-23862	an	_
126-17	23863-23872	important	_
126-18	23873-23885	longitudinal	_
126-19	23886-23895	dimension	_
126-20	23895-23896	.	_

#Text=Dorsolateral PFC volume reduction and MFG dysfunction have been related to disorganization symptoms in schizophrenia.
127-1	23897-23909	Dorsolateral	_
127-2	23910-23913	PFC	_
127-3	23914-23920	volume	_
127-4	23921-23930	reduction	_
127-5	23931-23934	and	_
127-6	23935-23938	MFG	_
127-7	23939-23950	dysfunction	_
127-8	23951-23955	have	_
127-9	23956-23960	been	_
127-10	23961-23968	related	_
127-11	23969-23971	to	_
127-12	23972-23987	disorganization	_
127-13	23988-23996	symptoms	_
127-14	23997-23999	in	_
127-15	24000-24013	schizophrenia	_
127-16	24013-24014	.	_

#Text=Furthermore, left hypofrontality in schizophrenia was associated with more severe conceptual disorganization suggesting a possibility of functional deficits in Broca’s area of the IFG.
128-1	24015-24026	Furthermore	_
128-2	24026-24027	,	_
128-3	24028-24032	left	_
128-4	24033-24047	hypofrontality	_
128-5	24048-24050	in	_
128-6	24051-24064	schizophrenia	_
128-7	24065-24068	was	_
128-8	24069-24079	associated	_
128-9	24080-24084	with	_
128-10	24085-24089	more	_
128-11	24090-24096	severe	_
128-12	24097-24107	conceptual	_
128-13	24108-24123	disorganization	_
128-14	24124-24134	suggesting	_
128-15	24135-24136	a	_
128-16	24137-24148	possibility	_
128-17	24149-24151	of	_
128-18	24152-24162	functional	_
128-19	24163-24171	deficits	_
128-20	24172-24174	in	_
128-21	24175-24180	Broca	_
128-22	24180-24181	’	_
128-23	24181-24182	s	_
128-24	24183-24187	area	_
128-25	24188-24190	of	_
128-26	24191-24194	the	_
128-27	24195-24198	IFG	_
128-28	24198-24199	.	_

#Text=Why do FESZ show progressive GMV reduction?
129-1	24200-24203	Why	_
129-2	24204-24206	do	_
129-3	24207-24211	FESZ	_
129-4	24212-24216	show	_
129-5	24217-24228	progressive	_
129-6	24229-24232	GMV	_
129-7	24233-24242	reduction	_
129-8	24242-24243	?	_

#Text=have speculated that this may be related to excitotoxicity in schizophrenia, due to excitatory amino acid neurotransmission dysregulation.
130-1	24245-24249	have	_
130-2	24250-24260	speculated	_
130-3	24261-24265	that	_
130-4	24266-24270	this	_
130-5	24271-24274	may	_
130-6	24275-24277	be	_
130-7	24278-24285	related	_
130-8	24286-24288	to	_
130-9	24289-24303	excitotoxicity	_
130-10	24304-24306	in	_
130-11	24307-24320	schizophrenia	_
130-12	24320-24321	,	_
130-13	24322-24325	due	_
130-14	24326-24328	to	_
130-15	24329-24339	excitatory	_
130-16	24340-24345	amino	_
130-17	24346-24350	acid	_
130-18	24351-24368	neurotransmission	_
130-19	24369-24382	dysregulation	_
130-20	24382-24383	.	_

#Text=We have elsewhere reviewed evidence in accord with a GABA-Glutamate imbalance that would be associated with developmental abnormalities just prior to, and after the onset of SZ, with excitotoxic reduction in dendritic spines and synapses leading to a progressive MRI GMV reduction.
131-1	24384-24386	We	_
131-2	24387-24391	have	_
131-3	24392-24401	elsewhere	_
131-4	24402-24410	reviewed	_
131-5	24411-24419	evidence	_
131-6	24420-24422	in	_
131-7	24423-24429	accord	_
131-8	24430-24434	with	_
131-9	24435-24436	a	_
131-10	24437-24451	GABA-Glutamate	_
131-11	24452-24461	imbalance	_
131-12	24462-24466	that	_
131-13	24467-24472	would	_
131-14	24473-24475	be	_
131-15	24476-24486	associated	_
131-16	24487-24491	with	_
131-17	24492-24505	developmental	_
131-18	24506-24519	abnormalities	_
131-19	24520-24524	just	_
131-20	24525-24530	prior	_
131-21	24531-24533	to	_
131-22	24533-24534	,	_
131-23	24535-24538	and	_
131-24	24539-24544	after	_
131-25	24545-24548	the	_
131-26	24549-24554	onset	_
131-27	24555-24557	of	_
131-28	24558-24560	SZ	_
131-29	24560-24561	,	_
131-30	24562-24566	with	_
131-31	24567-24578	excitotoxic	_
131-32	24579-24588	reduction	_
131-33	24589-24591	in	_
131-34	24592-24601	dendritic	_
131-35	24602-24608	spines	_
131-36	24609-24612	and	_
131-37	24613-24621	synapses	_
131-38	24622-24629	leading	_
131-39	24630-24632	to	_
131-40	24633-24634	a	_
131-41	24635-24646	progressive	_
131-42	24647-24650	MRI	_
131-43	24651-24654	GMV	_
131-44	24655-24664	reduction	_
131-45	24664-24665	.	_

#Text=There is some current evidence that patients in the early stage of schizophrenia show increased glutamatergic metabolites consistent with glutamate-related excitotoxicity.
132-1	24666-24671	There	_
132-2	24672-24674	is	_
132-3	24675-24679	some	_
132-4	24680-24687	current	_
132-5	24688-24696	evidence	_
132-6	24697-24701	that	_
132-7	24702-24710	patients	_
132-8	24711-24713	in	_
132-9	24714-24717	the	_
132-10	24718-24723	early	_
132-11	24724-24729	stage	_
132-12	24730-24732	of	_
132-13	24733-24746	schizophrenia	_
132-14	24747-24751	show	_
132-15	24752-24761	increased	_
132-16	24762-24775	glutamatergic	_
132-17	24776-24787	metabolites	_
132-18	24788-24798	consistent	_
132-19	24799-24803	with	_
132-20	24804-24821	glutamate-related	_
132-21	24822-24836	excitotoxicity	_
132-22	24836-24837	.	_

#Text=However, to evaluate this hypothesis, conjoint longitudinal evaluation of MRI GMV, magnetic resonance spectroscopy GABA, glutamate levels in many ROIs in prodromal, and first onset schizophrenic subjects will be needed.
133-1	24838-24845	However	_
133-2	24845-24846	,	_
133-3	24847-24849	to	_
133-4	24850-24858	evaluate	_
133-5	24859-24863	this	_
133-6	24864-24874	hypothesis	_
133-7	24874-24875	,	_
133-8	24876-24884	conjoint	_
133-9	24885-24897	longitudinal	_
133-10	24898-24908	evaluation	_
133-11	24909-24911	of	_
133-12	24912-24915	MRI	_
133-13	24916-24919	GMV	_
133-14	24919-24920	,	_
133-15	24921-24929	magnetic	_
133-16	24930-24939	resonance	_
133-17	24940-24952	spectroscopy	_
133-18	24953-24957	GABA	_
133-19	24957-24958	,	_
133-20	24959-24968	glutamate	_
133-21	24969-24975	levels	_
133-22	24976-24978	in	_
133-23	24979-24983	many	_
133-24	24984-24988	ROIs	_
133-25	24989-24991	in	_
133-26	24992-25001	prodromal	_
133-27	25001-25002	,	_
133-28	25003-25006	and	_
133-29	25007-25012	first	_
133-30	25013-25018	onset	_
133-31	25019-25032	schizophrenic	_
133-32	25033-25041	subjects	_
133-33	25042-25046	will	_
133-34	25047-25049	be	_
133-35	25050-25056	needed	_
133-36	25056-25057	.	_

#Text=This excitotoxic mechanism may be present in early FESZ but there is no supporting evidence we are aware of for this in early stage FEAFF.
134-1	25058-25062	This	_
134-2	25063-25074	excitotoxic	_
134-3	25075-25084	mechanism	_
134-4	25085-25088	may	_
134-5	25089-25091	be	_
134-6	25092-25099	present	_
134-7	25100-25102	in	_
134-8	25103-25108	early	_
134-9	25109-25113	FESZ	_
134-10	25114-25117	but	_
134-11	25118-25123	there	_
134-12	25124-25126	is	_
134-13	25127-25129	no	_
134-14	25130-25140	supporting	_
134-15	25141-25149	evidence	_
134-16	25150-25152	we	_
134-17	25153-25156	are	_
134-18	25157-25162	aware	_
134-19	25163-25165	of	_
134-20	25166-25169	for	_
134-21	25170-25174	this	_
134-22	25175-25177	in	_
134-23	25178-25183	early	_
134-24	25184-25189	stage	_
134-25	25190-25195	FEAFF	_
134-26	25195-25196	.	_

#Text=Comparison between manual parcellation and FreeSurfer parcellation
#Text=In recent volumetric studies, FreeSurfer parcellation has been replacing manual parcellation, still considered the gold standard of volume measurement.
135-1	25197-25207	Comparison	_
135-2	25208-25215	between	_
135-3	25216-25222	manual	_
135-4	25223-25235	parcellation	_
135-5	25236-25239	and	_
135-6	25240-25250	FreeSurfer	_
135-7	25251-25263	parcellation	_
135-8	25264-25266	In	_
135-9	25267-25273	recent	_
135-10	25274-25284	volumetric	_
135-11	25285-25292	studies	_
135-12	25292-25293	,	_
135-13	25294-25304	FreeSurfer	_
135-14	25305-25317	parcellation	_
135-15	25318-25321	has	_
135-16	25322-25326	been	_
135-17	25327-25336	replacing	_
135-18	25337-25343	manual	_
135-19	25344-25356	parcellation	_
135-20	25356-25357	,	_
135-21	25358-25363	still	_
135-22	25364-25374	considered	_
135-23	25375-25378	the	_
135-24	25379-25383	gold	_
135-25	25384-25392	standard	_
135-26	25393-25395	of	_
135-27	25396-25402	volume	_
135-28	25403-25414	measurement	_
135-29	25414-25415	.	_

#Text=FreeSurfer can significantly reduce the time spent parcellating the brain.
136-1	25416-25426	FreeSurfer	_
136-2	25427-25430	can	_
136-3	25431-25444	significantly	_
136-4	25445-25451	reduce	_
136-5	25452-25455	the	_
136-6	25456-25460	time	_
136-7	25461-25466	spent	_
136-8	25467-25479	parcellating	_
136-9	25480-25483	the	_
136-10	25484-25489	brain	_
136-11	25489-25490	.	_

#Text=Nonetheless, in the current study FreeSurfer could not replicate the results obtained by careful manual parcellation.
137-1	25491-25502	Nonetheless	_
137-2	25502-25503	,	_
137-3	25504-25506	in	_
137-4	25507-25510	the	_
137-5	25511-25518	current	_
137-6	25519-25524	study	_
137-7	25525-25535	FreeSurfer	_
137-8	25536-25541	could	_
137-9	25542-25545	not	_
137-10	25546-25555	replicate	_
137-11	25556-25559	the	_
137-12	25560-25567	results	_
137-13	25568-25576	obtained	_
137-14	25577-25579	by	_
137-15	25580-25587	careful	_
137-16	25588-25594	manual	_
137-17	25595-25607	parcellation	_
137-18	25607-25608	.	_

#Text=FreeSurfer tends to be more inclusive and produce larger volumes than manual parcellation as has been reported in other publications, and requires a higher number of subjects in order to achieve enough power to detect group differences of several cortical and subcortical brain regions compared to the number of subjects needed to achieve the same power by using manual parcellation.
138-1	25609-25619	FreeSurfer	_
138-2	25620-25625	tends	_
138-3	25626-25628	to	_
138-4	25629-25631	be	_
138-5	25632-25636	more	_
138-6	25637-25646	inclusive	_
138-7	25647-25650	and	_
138-8	25651-25658	produce	_
138-9	25659-25665	larger	_
138-10	25666-25673	volumes	_
138-11	25674-25678	than	_
138-12	25679-25685	manual	_
138-13	25686-25698	parcellation	_
138-14	25699-25701	as	_
138-15	25702-25705	has	_
138-16	25706-25710	been	_
138-17	25711-25719	reported	_
138-18	25720-25722	in	_
138-19	25723-25728	other	_
138-20	25729-25741	publications	_
138-21	25741-25742	,	_
138-22	25743-25746	and	_
138-23	25747-25755	requires	_
138-24	25756-25757	a	_
138-25	25758-25764	higher	_
138-26	25765-25771	number	_
138-27	25772-25774	of	_
138-28	25775-25783	subjects	_
138-29	25784-25786	in	_
138-30	25787-25792	order	_
138-31	25793-25795	to	_
138-32	25796-25803	achieve	_
138-33	25804-25810	enough	_
138-34	25811-25816	power	_
138-35	25817-25819	to	_
138-36	25820-25826	detect	_
138-37	25827-25832	group	_
138-38	25833-25844	differences	_
138-39	25845-25847	of	_
138-40	25848-25855	several	_
138-41	25856-25864	cortical	_
138-42	25865-25868	and	_
138-43	25869-25880	subcortical	_
138-44	25881-25886	brain	_
138-45	25887-25894	regions	_
138-46	25895-25903	compared	_
138-47	25904-25906	to	_
138-48	25907-25910	the	_
138-49	25911-25917	number	_
138-50	25918-25920	of	_
138-51	25921-25929	subjects	_
138-52	25930-25936	needed	_
138-53	25937-25939	to	_
138-54	25940-25947	achieve	_
138-55	25948-25951	the	_
138-56	25952-25956	same	_
138-57	25957-25962	power	_
138-58	25963-25965	by	_
138-59	25966-25971	using	_
138-60	25972-25978	manual	_
138-61	25979-25991	parcellation	_
138-62	25991-25992	.	_

#Text=Brain areas such as the temporal and the frontal lobe might be especially sensitive to the necessity of a larger sample.
139-1	25993-25998	Brain	_
139-2	25999-26004	areas	_
139-3	26005-26009	such	_
139-4	26010-26012	as	_
139-5	26013-26016	the	_
139-6	26017-26025	temporal	_
139-7	26026-26029	and	_
139-8	26030-26033	the	_
139-9	26034-26041	frontal	_
139-10	26042-26046	lobe	_
139-11	26047-26052	might	_
139-12	26053-26055	be	_
139-13	26056-26066	especially	_
139-14	26067-26076	sensitive	_
139-15	26077-26079	to	_
139-16	26080-26083	the	_
139-17	26084-26093	necessity	_
139-18	26094-26096	of	_
139-19	26097-26098	a	_
139-20	26099-26105	larger	_
139-21	26106-26112	sample	_
139-22	26112-26113	.	_

#Text=While, FreeSurfer parcellation offers an undisputable advantage by deploying an automated methodology that permits examination of several brain structures or of the entire brain, it may fail to find subtle volumetric abnormalities in specific brain regions such as those in this study.
140-1	26114-26119	While	_
140-2	26119-26120	,	_
140-3	26121-26131	FreeSurfer	_
140-4	26132-26144	parcellation	_
140-5	26145-26151	offers	_
140-6	26152-26154	an	_
140-7	26155-26167	undisputable	_
140-8	26168-26177	advantage	_
140-9	26178-26180	by	_
140-10	26181-26190	deploying	_
140-11	26191-26193	an	_
140-12	26194-26203	automated	_
140-13	26204-26215	methodology	_
140-14	26216-26220	that	_
140-15	26221-26228	permits	_
140-16	26229-26240	examination	_
140-17	26241-26243	of	_
140-18	26244-26251	several	_
140-19	26252-26257	brain	_
140-20	26258-26268	structures	_
140-21	26269-26271	or	_
140-22	26272-26274	of	_
140-23	26275-26278	the	_
140-24	26279-26285	entire	_
140-25	26286-26291	brain	_
140-26	26291-26292	,	_
140-27	26293-26295	it	_
140-28	26296-26299	may	_
140-29	26300-26304	fail	_
140-30	26305-26307	to	_
140-31	26308-26312	find	_
140-32	26313-26319	subtle	_
140-33	26320-26330	volumetric	_
140-34	26331-26344	abnormalities	_
140-35	26345-26347	in	_
140-36	26348-26356	specific	_
140-37	26357-26362	brain	_
140-38	26363-26370	regions	_
140-39	26371-26375	such	_
140-40	26376-26378	as	_
140-41	26379-26384	those	_
140-42	26385-26387	in	_
140-43	26388-26392	this	_
140-44	26393-26398	study	_
140-45	26398-26399	.	_

#Text=This might be an especially important issue when studying illnesses such as schizophrenia where volumetric brain differences with healthy controls albeit important might be very small.
141-1	26400-26404	This	_
141-2	26405-26410	might	_
141-3	26411-26413	be	_
141-4	26414-26416	an	_
141-5	26417-26427	especially	_
141-6	26428-26437	important	_
141-7	26438-26443	issue	_
141-8	26444-26448	when	_
141-9	26449-26457	studying	_
141-10	26458-26467	illnesses	_
141-11	26468-26472	such	_
141-12	26473-26475	as	_
141-13	26476-26489	schizophrenia	_
141-14	26490-26495	where	_
141-15	26496-26506	volumetric	_
141-16	26507-26512	brain	_
141-17	26513-26524	differences	_
141-18	26525-26529	with	_
141-19	26530-26537	healthy	_
141-20	26538-26546	controls	_
141-21	26547-26553	albeit	_
141-22	26554-26563	important	_
141-23	26564-26569	might	_
141-24	26570-26572	be	_
141-25	26573-26577	very	_
141-26	26578-26583	small	_
141-27	26583-26584	.	_

#Text=Comparison between the present results and our group’s previous studies of FESZ, FEAFF, and HC
#Text=A review of our group’s previous studies of FESZ, FEAFF, and HC has been presented elsewhere.
142-1	26585-26595	Comparison	_
142-2	26596-26603	between	_
142-3	26604-26607	the	_
142-4	26608-26615	present	_
142-5	26616-26623	results	_
142-6	26624-26627	and	_
142-7	26628-26631	our	_
142-8	26632-26637	group	_
142-9	26637-26638	’	_
142-10	26638-26639	s	_
142-11	26640-26648	previous	_
142-12	26649-26656	studies	_
142-13	26657-26659	of	_
142-14	26660-26664	FESZ	_
142-15	26664-26665	,	_
142-16	26666-26671	FEAFF	_
142-17	26671-26672	,	_
142-18	26673-26676	and	_
142-19	26677-26679	HC	_
142-20	26680-26681	A	_
142-21	26682-26688	review	_
142-22	26689-26691	of	_
142-23	26692-26695	our	_
142-24	26696-26701	group	_
142-25	26701-26702	’	_
142-26	26702-26703	s	_
142-27	26704-26712	previous	_
142-28	26713-26720	studies	_
142-29	26721-26723	of	_
142-30	26724-26728	FESZ	_
142-31	26728-26729	,	_
142-32	26730-26735	FEAFF	_
142-33	26735-26736	,	_
142-34	26737-26740	and	_
142-35	26741-26743	HC	_
142-36	26744-26747	has	_
142-37	26748-26752	been	_
142-38	26753-26762	presented	_
142-39	26763-26772	elsewhere	_
142-40	26772-26773	.	_

#Text=The present results are consistent with our previous studies in showing that longitudinal progressive volume loss in the early stage of illness is a feature of FESZ but not of FEAFF.
143-1	26774-26777	The	_
143-2	26778-26785	present	_
143-3	26786-26793	results	_
143-4	26794-26797	are	_
143-5	26798-26808	consistent	_
143-6	26809-26813	with	_
143-7	26814-26817	our	_
143-8	26818-26826	previous	_
143-9	26827-26834	studies	_
143-10	26835-26837	in	_
143-11	26838-26845	showing	_
143-12	26846-26850	that	_
143-13	26851-26863	longitudinal	_
143-14	26864-26875	progressive	_
143-15	26876-26882	volume	_
143-16	26883-26887	loss	_
143-17	26888-26890	in	_
143-18	26891-26894	the	_
143-19	26895-26900	early	_
143-20	26901-26906	stage	_
143-21	26907-26909	of	_
143-22	26910-26917	illness	_
143-23	26918-26920	is	_
143-24	26921-26922	a	_
143-25	26923-26930	feature	_
143-26	26931-26933	of	_
143-27	26934-26938	FESZ	_
143-28	26939-26942	but	_
143-29	26943-26946	not	_
143-30	26947-26949	of	_
143-31	26950-26955	FEAFF	_
143-32	26955-26956	.	_

#Text=Furthermore, the observed associations between progressive volume loss in MFG / IFG regions and exacerbation in symptoms’ severity in FESZ might add to the strength of our previous studies in providing the evidence that region-specific progressive volume loss can bring an exacerbation of symptoms in the early stage of FESZ.
144-1	26957-26968	Furthermore	_
144-2	26968-26969	,	_
144-3	26970-26973	the	_
144-4	26974-26982	observed	_
144-5	26983-26995	associations	_
144-6	26996-27003	between	_
144-7	27004-27015	progressive	_
144-8	27016-27022	volume	_
144-9	27023-27027	loss	_
144-10	27028-27030	in	_
144-11	27031-27034	MFG	_
144-12	27035-27036	/	_
144-13	27037-27040	IFG	_
144-14	27041-27048	regions	_
144-15	27049-27052	and	_
144-16	27053-27065	exacerbation	_
144-17	27066-27068	in	_
144-18	27069-27077	symptoms	_
144-19	27077-27078	’	_
144-20	27079-27087	severity	_
144-21	27088-27090	in	_
144-22	27091-27095	FESZ	_
144-23	27096-27101	might	_
144-24	27102-27105	add	_
144-25	27106-27108	to	_
144-26	27109-27112	the	_
144-27	27113-27121	strength	_
144-28	27122-27124	of	_
144-29	27125-27128	our	_
144-30	27129-27137	previous	_
144-31	27138-27145	studies	_
144-32	27146-27148	in	_
144-33	27149-27158	providing	_
144-34	27159-27162	the	_
144-35	27163-27171	evidence	_
144-36	27172-27176	that	_
144-37	27177-27192	region-specific	_
144-38	27193-27204	progressive	_
144-39	27205-27211	volume	_
144-40	27212-27216	loss	_
144-41	27217-27220	can	_
144-42	27221-27226	bring	_
144-43	27227-27229	an	_
144-44	27230-27242	exacerbation	_
144-45	27243-27245	of	_
144-46	27246-27254	symptoms	_
144-47	27255-27257	in	_
144-48	27258-27261	the	_
144-49	27262-27267	early	_
144-50	27268-27273	stage	_
144-51	27274-27276	of	_
144-52	27277-27281	FESZ	_
144-53	27281-27282	.	_

#Text=Limitations
#Text=Several issues should be considered in the interpretation of the present results.
145-1	27283-27294	Limitations	_
145-2	27295-27302	Several	_
145-3	27303-27309	issues	_
145-4	27310-27316	should	_
145-5	27317-27319	be	_
145-6	27320-27330	considered	_
145-7	27331-27333	in	_
145-8	27334-27337	the	_
145-9	27338-27352	interpretation	_
145-10	27353-27355	of	_
145-11	27356-27359	the	_
145-12	27360-27367	present	_
145-13	27368-27375	results	_
145-14	27375-27376	.	_

#Text=First, the sample size of 21 FESZ, 24 FEAFF, 23 HC, while not small for manual ROI longitudinal studies, may have contributed to the reduced statistical power to detect group differences using automated techniques.
146-1	27377-27382	First	_
146-2	27382-27383	,	_
146-3	27384-27387	the	_
146-4	27388-27394	sample	_
146-5	27395-27399	size	_
146-6	27400-27402	of	_
146-7	27403-27405	21	_
146-8	27406-27410	FESZ	_
146-9	27410-27411	,	_
146-10	27412-27414	24	_
146-11	27415-27420	FEAFF	_
146-12	27420-27421	,	_
146-13	27422-27424	23	_
146-14	27425-27427	HC	_
146-15	27427-27428	,	_
146-16	27429-27434	while	_
146-17	27435-27438	not	_
146-18	27439-27444	small	_
146-19	27445-27448	for	_
146-20	27449-27455	manual	_
146-21	27456-27459	ROI	_
146-22	27460-27472	longitudinal	_
146-23	27473-27480	studies	_
146-24	27480-27481	,	_
146-25	27482-27485	may	_
146-26	27486-27490	have	_
146-27	27491-27502	contributed	_
146-28	27503-27505	to	_
146-29	27506-27509	the	_
146-30	27510-27517	reduced	_
146-31	27518-27529	statistical	_
146-32	27530-27535	power	_
146-33	27536-27538	to	_
146-34	27539-27545	detect	_
146-35	27546-27551	group	_
146-36	27552-27563	differences	_
146-37	27564-27569	using	_
146-38	27570-27579	automated	_
146-39	27580-27590	techniques	_
146-40	27590-27591	.	_

#Text=Second, the follow up interval of this study was relatively short, and it is possible that FEAFF group may experience similar progressive changes but at a much slower rate and perhaps only in a subset of frontal cortical subregions affected by SCZ.
147-1	27592-27598	Second	_
147-2	27598-27599	,	_
147-3	27600-27603	the	_
147-4	27604-27610	follow	_
147-5	27611-27613	up	_
147-6	27614-27622	interval	_
147-7	27623-27625	of	_
147-8	27626-27630	this	_
147-9	27631-27636	study	_
147-10	27637-27640	was	_
147-11	27641-27651	relatively	_
147-12	27652-27657	short	_
147-13	27657-27658	,	_
147-14	27659-27662	and	_
147-15	27663-27665	it	_
147-16	27666-27668	is	_
147-17	27669-27677	possible	_
147-18	27678-27682	that	_
147-19	27683-27688	FEAFF	_
147-20	27689-27694	group	_
147-21	27695-27698	may	_
147-22	27699-27709	experience	_
147-23	27710-27717	similar	_
147-24	27718-27729	progressive	_
147-25	27730-27737	changes	_
147-26	27738-27741	but	_
147-27	27742-27744	at	_
147-28	27745-27746	a	_
147-29	27747-27751	much	_
147-30	27752-27758	slower	_
147-31	27759-27763	rate	_
147-32	27764-27767	and	_
147-33	27768-27775	perhaps	_
147-34	27776-27780	only	_
147-35	27781-27783	in	_
147-36	27784-27785	a	_
147-37	27786-27792	subset	_
147-38	27793-27795	of	_
147-39	27796-27803	frontal	_
147-40	27804-27812	cortical	_
147-41	27813-27823	subregions	_
147-42	27824-27832	affected	_
147-43	27833-27835	by	_
147-44	27836-27839	SCZ	_
147-45	27839-27840	.	_

#Text=Thus, further follow up studies where scan intervals are longer might reveal the progressive changes in FEAFF group.
148-1	27841-27845	Thus	_
148-2	27845-27846	,	_
148-3	27847-27854	further	_
148-4	27855-27861	follow	_
148-5	27862-27864	up	_
148-6	27865-27872	studies	_
148-7	27873-27878	where	_
148-8	27879-27883	scan	_
148-9	27884-27893	intervals	_
148-10	27894-27897	are	_
148-11	27898-27904	longer	_
148-12	27905-27910	might	_
148-13	27911-27917	reveal	_
148-14	27918-27921	the	_
148-15	27922-27933	progressive	_
148-16	27934-27941	changes	_
148-17	27942-27944	in	_
148-18	27945-27950	FEAFF	_
148-19	27951-27956	group	_
148-20	27956-27957	.	_

#Text=Third, we did not specifically assess the effect of cannabis usage, but the literature, although complex, suggests the limited usage permitted by our exclusion criteria would have minimal effects on GMV.
149-1	27958-27963	Third	_
149-2	27963-27964	,	_
149-3	27965-27967	we	_
149-4	27968-27971	did	_
149-5	27972-27975	not	_
149-6	27976-27988	specifically	_
149-7	27989-27995	assess	_
149-8	27996-27999	the	_
149-9	28000-28006	effect	_
149-10	28007-28009	of	_
149-11	28010-28018	cannabis	_
149-12	28019-28024	usage	_
149-13	28024-28025	,	_
149-14	28026-28029	but	_
149-15	28030-28033	the	_
149-16	28034-28044	literature	_
149-17	28044-28045	,	_
149-18	28046-28054	although	_
149-19	28055-28062	complex	_
149-20	28062-28063	,	_
149-21	28064-28072	suggests	_
149-22	28073-28076	the	_
149-23	28077-28084	limited	_
149-24	28085-28090	usage	_
149-25	28091-28100	permitted	_
149-26	28101-28103	by	_
149-27	28104-28107	our	_
149-28	28108-28117	exclusion	_
149-29	28118-28126	criteria	_
149-30	28127-28132	would	_
149-31	28133-28137	have	_
149-32	28138-28145	minimal	_
149-33	28146-28153	effects	_
149-34	28154-28156	on	_
149-35	28157-28160	GMV	_
149-36	28160-28161	.	_

#Text=Fourth, medication effect, as an explanation for GMV loss, cannot be decisively ruled out since most of the longitudinally evaluated first-episode patients were medicated.
150-1	28162-28168	Fourth	_
150-2	28168-28169	,	_
150-3	28170-28180	medication	_
150-4	28181-28187	effect	_
150-5	28187-28188	,	_
150-6	28189-28191	as	_
150-7	28192-28194	an	_
150-8	28195-28206	explanation	_
150-9	28207-28210	for	_
150-10	28211-28214	GMV	_
150-11	28215-28219	loss	_
150-12	28219-28220	,	_
150-13	28221-28227	cannot	_
150-14	28228-28230	be	_
150-15	28231-28241	decisively	_
150-16	28242-28247	ruled	_
150-17	28248-28251	out	_
150-18	28252-28257	since	_
150-19	28258-28262	most	_
150-20	28263-28265	of	_
150-21	28266-28269	the	_
150-22	28270-28284	longitudinally	_
150-23	28285-28294	evaluated	_
150-24	28295-28308	first-episode	_
150-25	28309-28317	patients	_
150-26	28318-28322	were	_
150-27	28323-28332	medicated	_
150-28	28332-28333	.	_

#Text=Typical and atypical antipsychotics have divergent effects on cortical thickness during the first episode of psychosis that are independent from changes due to illness.
151-1	28334-28341	Typical	_
151-2	28342-28345	and	_
151-3	28346-28354	atypical	_
151-4	28355-28369	antipsychotics	_
151-5	28370-28374	have	_
151-6	28375-28384	divergent	_
151-7	28385-28392	effects	_
151-8	28393-28395	on	_
151-9	28396-28404	cortical	_
151-10	28405-28414	thickness	_
151-11	28415-28421	during	_
151-12	28422-28425	the	_
151-13	28426-28431	first	_
151-14	28432-28439	episode	_
151-15	28440-28442	of	_
151-16	28443-28452	psychosis	_
151-17	28453-28457	that	_
151-18	28458-28461	are	_
151-19	28462-28473	independent	_
151-20	28474-28478	from	_
151-21	28479-28486	changes	_
151-22	28487-28490	due	_
151-23	28491-28493	to	_
151-24	28494-28501	illness	_
151-25	28501-28502	.	_

#Text=However, in the present results, the dosage and the type of antipsychotics were not associated with GMV changes in the PFC ROI as assessed cross-sectionally at time 1 and time 2.
152-1	28503-28510	However	_
152-2	28510-28511	,	_
152-3	28512-28514	in	_
152-4	28515-28518	the	_
152-5	28519-28526	present	_
152-6	28527-28534	results	_
152-7	28534-28535	,	_
152-8	28536-28539	the	_
152-9	28540-28546	dosage	_
152-10	28547-28550	and	_
152-11	28551-28554	the	_
152-12	28555-28559	type	_
152-13	28560-28562	of	_
152-14	28563-28577	antipsychotics	_
152-15	28578-28582	were	_
152-16	28583-28586	not	_
152-17	28587-28597	associated	_
152-18	28598-28602	with	_
152-19	28603-28606	GMV	_
152-20	28607-28614	changes	_
152-21	28615-28617	in	_
152-22	28618-28621	the	_
152-23	28622-28625	PFC	_
152-24	28626-28629	ROI	_
152-25	28630-28632	as	_
152-26	28633-28641	assessed	_
152-27	28642-28659	cross-sectionally	_
152-28	28660-28662	at	_
152-29	28663-28667	time	_
152-30	28668-28669	1	_
152-31	28670-28673	and	_
152-32	28674-28678	time	_
152-33	28679-28680	2	_
152-34	28680-28681	.	_

#Text=Nonetheless, suggested longitudinal effects of antipsychotic medication and such effects may also exist in the present results.
153-1	28682-28693	Nonetheless	_
153-2	28693-28694	,	_
153-3	28695-28704	suggested	_
153-4	28705-28717	longitudinal	_
153-5	28718-28725	effects	_
153-6	28726-28728	of	_
153-7	28729-28742	antipsychotic	_
153-8	28743-28753	medication	_
153-9	28754-28757	and	_
153-10	28758-28762	such	_
153-11	28763-28770	effects	_
153-12	28771-28774	may	_
153-13	28775-28779	also	_
153-14	28780-28785	exist	_
153-15	28786-28788	in	_
153-16	28789-28792	the	_
153-17	28793-28800	present	_
153-18	28801-28808	results	_
153-19	28808-28809	.	_

#Text=Studies in which subjects are treated with only typical or atypical antipsychotics within the same study design might reveal the longitudinal effects of the medication.
154-1	28810-28817	Studies	_
154-2	28818-28820	in	_
154-3	28821-28826	which	_
154-4	28827-28835	subjects	_
154-5	28836-28839	are	_
154-6	28840-28847	treated	_
154-7	28848-28852	with	_
154-8	28853-28857	only	_
154-9	28858-28865	typical	_
154-10	28866-28868	or	_
154-11	28869-28877	atypical	_
154-12	28878-28892	antipsychotics	_
154-13	28893-28899	within	_
154-14	28900-28903	the	_
154-15	28904-28908	same	_
154-16	28909-28914	study	_
154-17	28915-28921	design	_
154-18	28922-28927	might	_
154-19	28928-28934	reveal	_
154-20	28935-28938	the	_
154-21	28939-28951	longitudinal	_
154-22	28952-28959	effects	_
154-23	28960-28962	of	_
154-24	28963-28966	the	_
154-25	28967-28977	medication	_
154-26	28977-28978	.	_

#Text=Finally, we did not apply correction for the number of correlations tested in our ROI-clinical associations, since the hypothesis-driven correlation analysis was performed only in the regions showing volume reduction – reducing the number of correlations.
155-1	28979-28986	Finally	_
155-2	28986-28987	,	_
155-3	28988-28990	we	_
155-4	28991-28994	did	_
155-5	28995-28998	not	_
155-6	28999-29004	apply	_
155-7	29005-29015	correction	_
155-8	29016-29019	for	_
155-9	29020-29023	the	_
155-10	29024-29030	number	_
155-11	29031-29033	of	_
155-12	29034-29046	correlations	_
155-13	29047-29053	tested	_
155-14	29054-29056	in	_
155-15	29057-29060	our	_
155-16	29061-29073	ROI-clinical	_
155-17	29074-29086	associations	_
155-18	29086-29087	,	_
155-19	29088-29093	since	_
155-20	29094-29097	the	_
155-21	29098-29115	hypothesis-driven	_
155-22	29116-29127	correlation	_
155-23	29128-29136	analysis	_
155-24	29137-29140	was	_
155-25	29141-29150	performed	_
155-26	29151-29155	only	_
155-27	29156-29158	in	_
155-28	29159-29162	the	_
155-29	29163-29170	regions	_
155-30	29171-29178	showing	_
155-31	29179-29185	volume	_
155-32	29186-29195	reduction	_
155-33	29196-29197	–	_
155-34	29198-29206	reducing	_
155-35	29207-29210	the	_
155-36	29211-29217	number	_
155-37	29218-29220	of	_
155-38	29221-29233	correlations	_
155-39	29233-29234	.	_

#Text=However, even if Bonferroni corrections for all possible clinical correlations were applied to the results involving volume-reduced regions, the correlation between left MFG volume change and BPRS total score change would remain significant.
156-1	29235-29242	However	_
156-2	29242-29243	,	_
156-3	29244-29248	even	_
156-4	29249-29251	if	_
156-5	29252-29262	Bonferroni	_
156-6	29263-29274	corrections	_
156-7	29275-29278	for	_
156-8	29279-29282	all	_
156-9	29283-29291	possible	_
156-10	29292-29300	clinical	_
156-11	29301-29313	correlations	_
156-12	29314-29318	were	_
156-13	29319-29326	applied	_
156-14	29327-29329	to	_
156-15	29330-29333	the	_
156-16	29334-29341	results	_
156-17	29342-29351	involving	_
156-18	29352-29366	volume-reduced	_
156-19	29367-29374	regions	_
156-20	29374-29375	,	_
156-21	29376-29379	the	_
156-22	29380-29391	correlation	_
156-23	29392-29399	between	_
156-24	29400-29404	left	_
156-25	29405-29408	MFG	_
156-26	29409-29415	volume	_
156-27	29416-29422	change	_
156-28	29423-29426	and	_
156-29	29427-29431	BPRS	_
156-30	29432-29437	total	_
156-31	29438-29443	score	_
156-32	29444-29450	change	_
156-33	29451-29456	would	_
156-34	29457-29463	remain	_
156-35	29464-29475	significant	_
156-36	29475-29476	.	_

#Text=Conclusion
#Text=This study is, to our knowledge, the first demonstration of progression of PFC GMV volume deficits in FESZ using manually parcellated gyral ROI, as well as the demonstration of the associations between MFG and/or IFG progressive GMV reduction and a worse symptom outcome.
157-1	29477-29487	Conclusion	_
157-2	29488-29492	This	_
157-3	29493-29498	study	_
157-4	29499-29501	is	_
157-5	29501-29502	,	_
157-6	29503-29505	to	_
157-7	29506-29509	our	_
157-8	29510-29519	knowledge	_
157-9	29519-29520	,	_
157-10	29521-29524	the	_
157-11	29525-29530	first	_
157-12	29531-29544	demonstration	_
157-13	29545-29547	of	_
157-14	29548-29559	progression	_
157-15	29560-29562	of	_
157-16	29563-29566	PFC	_
157-17	29567-29570	GMV	_
157-18	29571-29577	volume	_
157-19	29578-29586	deficits	_
157-20	29587-29589	in	_
157-21	29590-29594	FESZ	_
157-22	29595-29600	using	_
157-23	29601-29609	manually	_
157-24	29610-29621	parcellated	_
157-25	29622-29627	gyral	_
157-26	29628-29631	ROI	_
157-27	29631-29632	,	_
157-28	29633-29635	as	_
157-29	29636-29640	well	_
157-30	29641-29643	as	_
157-31	29644-29647	the	_
157-32	29648-29661	demonstration	_
157-33	29662-29664	of	_
157-34	29665-29668	the	_
157-35	29669-29681	associations	_
157-36	29682-29689	between	_
157-37	29690-29693	MFG	_
157-38	29694-29697	and	_
157-39	29697-29698	/	_
157-40	29698-29700	or	_
157-41	29701-29704	IFG	_
157-42	29705-29716	progressive	_
157-43	29717-29720	GMV	_
157-44	29721-29730	reduction	_
157-45	29731-29734	and	_
157-46	29735-29736	a	_
157-47	29737-29742	worse	_
157-48	29743-29750	symptom	_
157-49	29751-29758	outcome	_
157-50	29758-29759	.	_

#Text=Furthermore, the GMV reduction in the early stage of FESZ might be associated with an exacerbation in negative symptoms.
158-1	29760-29771	Furthermore	_
158-2	29771-29772	,	_
158-3	29773-29776	the	_
158-4	29777-29780	GMV	_
158-5	29781-29790	reduction	_
158-6	29791-29793	in	_
158-7	29794-29797	the	_
158-8	29798-29803	early	_
158-9	29804-29809	stage	_
158-10	29810-29812	of	_
158-11	29813-29817	FESZ	_
158-12	29818-29823	might	_
158-13	29824-29826	be	_
158-14	29827-29837	associated	_
158-15	29838-29842	with	_
158-16	29843-29845	an	_
158-17	29846-29858	exacerbation	_
158-18	29859-29861	in	_
158-19	29862-29870	negative	_
158-20	29871-29879	symptoms	_
158-21	29879-29880	.	_

#Text=The use of a FEAFF group has enabled us to show that the GMV reduction progression was specific to FESZ, and not present in FEAFF.
159-1	29881-29884	The	_
159-2	29885-29888	use	_
159-3	29889-29891	of	_
159-4	29892-29893	a	_
159-5	29894-29899	FEAFF	_
159-6	29900-29905	group	_
159-7	29906-29909	has	_
159-8	29910-29917	enabled	_
159-9	29918-29920	us	_
159-10	29921-29923	to	_
159-11	29924-29928	show	_
159-12	29929-29933	that	_
159-13	29934-29937	the	_
159-14	29938-29941	GMV	_
159-15	29942-29951	reduction	_
159-16	29952-29963	progression	_
159-17	29964-29967	was	_
159-18	29968-29976	specific	_
159-19	29977-29979	to	_
159-20	29980-29984	FESZ	_
159-21	29984-29985	,	_
159-22	29986-29989	and	_
159-23	29990-29993	not	_
159-24	29994-30001	present	_
159-25	30002-30004	in	_
159-26	30005-30010	FEAFF	_
159-27	30010-30011	.	_

#Text=These noteworthy findings could not be observed using FreeSurfer parcellation.
160-1	30012-30017	These	_
160-2	30018-30028	noteworthy	_
160-3	30029-30037	findings	_
160-4	30038-30043	could	_
160-5	30044-30047	not	_
160-6	30048-30050	be	_
160-7	30051-30059	observed	_
160-8	30060-30065	using	_
160-9	30066-30076	FreeSurfer	_
160-10	30077-30089	parcellation	_
160-11	30089-30090	.	_

#Text=Although manual parcellation requires much effort, approximately 50 hours per subject, it afforded us a more precise analysis and yielded results that could not be detected with automated methodology.
161-1	30091-30099	Although	_
161-2	30100-30106	manual	_
161-3	30107-30119	parcellation	_
161-4	30120-30128	requires	_
161-5	30129-30133	much	_
161-6	30134-30140	effort	_
161-7	30140-30141	,	_
161-8	30142-30155	approximately	_
161-9	30156-30158	50	_
161-10	30159-30164	hours	_
161-11	30165-30168	per	_
161-12	30169-30176	subject	_
161-13	30176-30177	,	_
161-14	30178-30180	it	_
161-15	30181-30189	afforded	_
161-16	30190-30192	us	_
161-17	30193-30194	a	_
161-18	30195-30199	more	_
161-19	30200-30207	precise	_
161-20	30208-30216	analysis	_
161-21	30217-30220	and	_
161-22	30221-30228	yielded	_
161-23	30229-30236	results	_
161-24	30237-30241	that	_
161-25	30242-30247	could	_
161-26	30248-30251	not	_
161-27	30252-30254	be	_
161-28	30255-30263	detected	_
161-29	30264-30268	with	_
161-30	30269-30278	automated	_
161-31	30279-30290	methodology	_
161-32	30290-30291	.	_

#Text=Supplementary Material
#Text=           Conflict of interest
#Text=Authors have no actual or potential conflicts of interest.
162-1	30292-30305	Supplementary	_
162-2	30306-30314	Material	_
162-3	30326-30334	Conflict	_
162-4	30335-30337	of	_
162-5	30338-30346	interest	_
162-6	30356-30363	Authors	_
162-7	30364-30368	have	_
162-8	30369-30371	no	_
162-9	30372-30378	actual	_
162-10	30379-30381	or	_
162-11	30382-30391	potential	_
162-12	30392-30401	conflicts	_
162-13	30402-30404	of	_
162-14	30405-30413	interest	_
162-15	30413-30414	.	_

#Text=Electronic supplementary material
#Text=The online version of this article contains supplementary material, which is available to authorized users.
163-1	30426-30436	Electronic	_
163-2	30437-30450	supplementary	_
163-3	30451-30459	material	_
163-4	30469-30472	The	_
163-5	30473-30479	online	_
163-6	30480-30487	version	_
163-7	30488-30490	of	_
163-8	30491-30495	this	_
163-9	30496-30503	article	_
163-10	30504-30512	contains	_
163-11	30513-30526	supplementary	_
163-12	30527-30535	material	_
163-13	30535-30536	,	_
163-14	30537-30542	which	_
163-15	30543-30545	is	_
163-16	30546-30555	available	_
163-17	30556-30558	to	_
163-18	30559-30569	authorized	_
163-19	30570-30575	users	_
163-20	30575-30576	.	_

#Text=Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia
#Text=Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis
#Text=Progressive brain changes in children and adolescents with first-episode psychosis
#Text=Longitudinal loss of gray matter volume in patients with first-episode schizophrenia: DARTEL automated analysis and ROI validation
#Text=Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine
#Text=1H-MRS at 4 tesla in minimally treated early schizophrenia
#Text=In vivo hippocampal measurement and memory: a comparison of manual tracing and automated segmentation in a large community-based sample
#Text=Post-psychotic depression in schizophrenia
#Text=
#Text=Cortical surface-based analysis.
164-1	30577-30588	Progressive	_
164-2	30589-30594	Brain	_
164-3	30595-30601	Change	_
164-4	30602-30604	in	_
164-5	30605-30618	Schizophrenia	_
164-6	30618-30619	:	_
164-7	30620-30621	A	_
164-8	30622-30633	Prospective	_
164-9	30634-30646	Longitudinal	_
164-10	30647-30652	Study	_
164-11	30653-30655	of	_
164-12	30656-30669	First-Episode	_
164-13	30670-30683	Schizophrenia	_
164-14	30684-30693	Divergent	_
164-15	30694-30701	effects	_
164-16	30702-30704	of	_
164-17	30705-30721	first-generation	_
164-18	30722-30725	and	_
164-19	30726-30743	second-generation	_
164-20	30744-30758	antipsychotics	_
164-21	30759-30761	on	_
164-22	30762-30770	cortical	_
164-23	30771-30780	thickness	_
164-24	30781-30783	in	_
164-25	30784-30797	first-episode	_
164-26	30798-30807	psychosis	_
164-27	30808-30819	Progressive	_
164-28	30820-30825	brain	_
164-29	30826-30833	changes	_
164-30	30834-30836	in	_
164-31	30837-30845	children	_
164-32	30846-30849	and	_
164-33	30850-30861	adolescents	_
164-34	30862-30866	with	_
164-35	30867-30880	first-episode	_
164-36	30881-30890	psychosis	_
164-37	30891-30903	Longitudinal	_
164-38	30904-30908	loss	_
164-39	30909-30911	of	_
164-40	30912-30916	gray	_
164-41	30917-30923	matter	_
164-42	30924-30930	volume	_
164-43	30931-30933	in	_
164-44	30934-30942	patients	_
164-45	30943-30947	with	_
164-46	30948-30961	first-episode	_
164-47	30962-30975	schizophrenia	_
164-48	30975-30976	:	_
164-49	30977-30983	DARTEL	_
164-50	30984-30993	automated	_
164-51	30994-31002	analysis	_
164-52	31003-31006	and	_
164-53	31007-31010	ROI	_
164-54	31011-31021	validation	_
164-55	31022-31031	Cingulate	_
164-56	31032-31037	gyrus	_
164-57	31038-31047	volumetry	_
164-58	31048-31050	in	_
164-59	31051-31055	drug	_
164-60	31056-31060	free	_
164-61	31061-31068	bipolar	_
164-62	31069-31077	patients	_
164-63	31078-31081	and	_
164-64	31082-31090	patients	_
164-65	31091-31098	treated	_
164-66	31099-31103	with	_
164-67	31104-31113	valproate	_
164-68	31114-31116	or	_
164-69	31117-31126	valproate	_
164-70	31127-31130	and	_
164-71	31131-31141	quetiapine	_
164-72	31142-31148	1H-MRS	_
164-73	31149-31151	at	_
164-74	31152-31153	4	_
164-75	31154-31159	tesla	_
164-76	31160-31162	in	_
164-77	31163-31172	minimally	_
164-78	31173-31180	treated	_
164-79	31181-31186	early	_
164-80	31187-31200	schizophrenia	_
164-81	31201-31203	In	_
164-82	31204-31208	vivo	_
164-83	31209-31220	hippocampal	_
164-84	31221-31232	measurement	_
164-85	31233-31236	and	_
164-86	31237-31243	memory	_
164-87	31243-31244	:	_
164-88	31245-31246	a	_
164-89	31247-31257	comparison	_
164-90	31258-31260	of	_
164-91	31261-31267	manual	_
164-92	31268-31275	tracing	_
164-93	31276-31279	and	_
164-94	31280-31289	automated	_
164-95	31290-31302	segmentation	_
164-96	31303-31305	in	_
164-97	31306-31307	a	_
164-98	31308-31313	large	_
164-99	31314-31329	community-based	_
164-100	31330-31336	sample	_
164-101	31337-31351	Post-psychotic	_
164-102	31352-31362	depression	_
164-103	31363-31365	in	_
164-104	31366-31379	schizophrenia	_
164-105	31381-31389	Cortical	_
164-106	31390-31403	surface-based	_
164-107	31404-31412	analysis	_
164-108	31412-31413	.	_

#Text=I.
165-1	31414-31415	I	_
165-2	31415-31416	.	_

#Text=Segmentation and surface reconstruction
#Text=Longitudinal changes in brain structure following the first episode of psychosis
#Text=31phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia
#Text=Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies
#Text=Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder
#Text=Manic episodes are associated with grey matter volume reduction - a voxel-based morphometry brain analysis
#Text=
#Text=Cortical surface-based analysis.
166-1	31417-31429	Segmentation	_
166-2	31430-31433	and	_
166-3	31434-31441	surface	_
166-4	31442-31456	reconstruction	_
166-5	31457-31469	Longitudinal	_
166-6	31470-31477	changes	_
166-7	31478-31480	in	_
166-8	31481-31486	brain	_
166-9	31487-31496	structure	_
166-10	31497-31506	following	_
166-11	31507-31510	the	_
166-12	31511-31516	first	_
166-13	31517-31524	episode	_
166-14	31525-31527	of	_
166-15	31528-31537	psychosis	_
166-16	31538-31550	31phosphorus	_
166-17	31551-31559	magnetic	_
166-18	31560-31569	resonance	_
166-19	31570-31582	spectroscopy	_
166-20	31583-31585	of	_
166-21	31586-31589	the	_
166-22	31590-31597	frontal	_
166-23	31598-31601	and	_
166-24	31602-31610	parietal	_
166-25	31611-31616	lobes	_
166-26	31617-31619	in	_
166-27	31620-31627	chronic	_
166-28	31628-31641	schizophrenia	_
166-29	31642-31647	Brain	_
166-30	31648-31658	structural	_
166-31	31659-31672	abnormalities	_
166-32	31673-31675	at	_
166-33	31676-31679	the	_
166-34	31680-31685	onset	_
166-35	31686-31688	of	_
166-36	31689-31702	schizophrenia	_
166-37	31703-31706	and	_
166-38	31707-31714	bipolar	_
166-39	31715-31723	disorder	_
166-40	31723-31724	:	_
166-41	31725-31726	a	_
166-42	31727-31740	meta-analysis	_
166-43	31741-31743	of	_
166-44	31744-31754	controlled	_
166-45	31755-31763	magnetic	_
166-46	31764-31773	resonance	_
166-47	31774-31781	imaging	_
166-48	31782-31789	studies	_
166-49	31790-31802	Longitudinal	_
166-50	31803-31811	analysis	_
166-51	31812-31814	of	_
166-52	31815-31824	cognitive	_
166-53	31825-31837	performances	_
166-54	31838-31841	and	_
166-55	31842-31852	structural	_
166-56	31853-31858	brain	_
166-57	31859-31866	changes	_
166-58	31867-31869	in	_
166-59	31870-31879	late-life	_
166-60	31880-31887	bipolar	_
166-61	31888-31896	disorder	_
166-62	31897-31902	Manic	_
166-63	31903-31911	episodes	_
166-64	31912-31915	are	_
166-65	31916-31926	associated	_
166-66	31927-31931	with	_
166-67	31932-31936	grey	_
166-68	31937-31943	matter	_
166-69	31944-31950	volume	_
166-70	31951-31960	reduction	_
166-71	31961-31962	-	_
166-72	31963-31964	a	_
166-73	31965-31976	voxel-based	_
166-74	31977-31988	morphometry	_
166-75	31989-31994	brain	_
166-76	31995-32003	analysis	_
166-77	32005-32013	Cortical	_
166-78	32014-32027	surface-based	_
166-79	32028-32036	analysis	_
166-80	32036-32037	.	_

#Text=II: Inflation, flattening, and a surface-based coordinate system
#Text=Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain
#Text=Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies
#Text=Progressive brain changes in schizophrenia related to antipsychotic treatment?
167-1	32038-32040	II	_
167-2	32040-32041	:	_
167-3	32042-32051	Inflation	_
167-4	32051-32052	,	_
167-5	32053-32063	flattening	_
167-6	32063-32064	,	_
167-7	32065-32068	and	_
167-8	32069-32070	a	_
167-9	32071-32084	surface-based	_
167-10	32085-32095	coordinate	_
167-11	32096-32102	system	_
167-12	32103-32108	Whole	_
167-13	32109-32114	brain	_
167-14	32115-32127	segmentation	_
167-15	32127-32128	:	_
167-16	32129-32138	automated	_
167-17	32139-32147	labeling	_
167-18	32148-32150	of	_
167-19	32151-32166	neuroanatomical	_
167-20	32167-32177	structures	_
167-21	32178-32180	in	_
167-22	32181-32184	the	_
167-23	32185-32190	human	_
167-24	32191-32196	brain	_
167-25	32197-32204	Mapping	_
167-26	32205-32209	grey	_
167-27	32210-32216	matter	_
167-28	32217-32227	reductions	_
167-29	32228-32230	in	_
167-30	32231-32244	schizophrenia	_
167-31	32244-32245	:	_
167-32	32246-32248	an	_
167-33	32249-32259	anatomical	_
167-34	32260-32270	likelihood	_
167-35	32271-32281	estimation	_
167-36	32282-32290	analysis	_
167-37	32291-32293	of	_
167-38	32294-32305	voxel-based	_
167-39	32306-32317	morphometry	_
167-40	32318-32325	studies	_
167-41	32326-32337	Progressive	_
167-42	32338-32343	brain	_
167-43	32344-32351	changes	_
167-44	32352-32354	in	_
167-45	32355-32368	schizophrenia	_
167-46	32369-32376	related	_
167-47	32377-32379	to	_
167-48	32380-32393	antipsychotic	_
167-49	32394-32403	treatment	_
167-50	32403-32404	?	_

#Text=A meta-analysis of longitudinal MRI studies
#Text=Neuroanatomical abnormalities as risk factors for bipolar disorder
#Text=Structural abnormalities in gyri of the prefrontal cortex in individuals with schizophrenia and their unaffected siblings
#Text=Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia
#Text=Preliminary evidence for progressive prefrontal abnormalities in adolescents and young adults with bipolar disorder
#Text=Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in schizophrenia: A longitudinal study of first-episode patients
#Text=Initial and Progressive Gray Matter Abnormalities in Insular Gyrus and Temporal Pole in First-Episode Schizophrenia Contrasted with First-Episode Affective Psychosis
#Text=Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
#Text=Reliability and statistical power analysis of cortical and subcortical FreeSurfer metrics in a large sample of healthy elderly
#Text=Automated ROI-based brain parcellation analysis of frontal and temporal brain volumes in schizophrenia
#Text=Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis
#Text=A comparison of FreeSurfer-generated data with and without manual intervention
#Text=Functional neuroanatomy of auditory working memory in schizophrenia: relation to positive and negative symptoms
#Text=Neocortical Gray Matter Volume in First-Episode Schizophrenia and First-Episode Affective Psychosis: A Cross-Sectional and Longitudinal MRI Study
#Text=Increases in regional subarachnoid CSF without apparent cortical gray matter deficits in schizophrenia: modulating effects of sex and age
#Text=Do antipsychotic drugs affect brain structure?
168-1	32405-32406	A	_
168-2	32407-32420	meta-analysis	_
168-3	32421-32423	of	_
168-4	32424-32436	longitudinal	_
168-5	32437-32440	MRI	_
168-6	32441-32448	studies	_
168-7	32449-32464	Neuroanatomical	_
168-8	32465-32478	abnormalities	_
168-9	32479-32481	as	_
168-10	32482-32486	risk	_
168-11	32487-32494	factors	_
168-12	32495-32498	for	_
168-13	32499-32506	bipolar	_
168-14	32507-32515	disorder	_
168-15	32516-32526	Structural	_
168-16	32527-32540	abnormalities	_
168-17	32541-32543	in	_
168-18	32544-32548	gyri	_
168-19	32549-32551	of	_
168-20	32552-32555	the	_
168-21	32556-32566	prefrontal	_
168-22	32567-32573	cortex	_
168-23	32574-32576	in	_
168-24	32577-32588	individuals	_
168-25	32589-32593	with	_
168-26	32594-32607	schizophrenia	_
168-27	32608-32611	and	_
168-28	32612-32617	their	_
168-29	32618-32628	unaffected	_
168-30	32629-32637	siblings	_
168-31	32638-32649	Cannabinoid	_
168-32	32650-32658	receptor	_
168-33	32659-32660	1	_
168-34	32661-32665	gene	_
168-35	32666-32679	polymorphisms	_
168-36	32680-32683	and	_
168-37	32684-32693	marijuana	_
168-38	32694-32700	misuse	_
168-39	32701-32713	interactions	_
168-40	32714-32716	on	_
168-41	32717-32722	white	_
168-42	32723-32729	matter	_
168-43	32730-32733	and	_
168-44	32734-32743	cognitive	_
168-45	32744-32752	deficits	_
168-46	32753-32755	in	_
168-47	32756-32769	schizophrenia	_
168-48	32770-32781	Preliminary	_
168-49	32782-32790	evidence	_
168-50	32791-32794	for	_
168-51	32795-32806	progressive	_
168-52	32807-32817	prefrontal	_
168-53	32818-32831	abnormalities	_
168-54	32832-32834	in	_
168-55	32835-32846	adolescents	_
168-56	32847-32850	and	_
168-57	32851-32856	young	_
168-58	32857-32863	adults	_
168-59	32864-32868	with	_
168-60	32869-32876	bipolar	_
168-61	32877-32885	disorder	_
168-62	32886-32897	Progressive	_
168-63	32898-32906	decrease	_
168-64	32907-32909	of	_
168-65	32910-32914	left	_
168-66	32915-32921	Heschl	_
168-67	32922-32927	gyrus	_
168-68	32928-32931	and	_
168-69	32932-32938	planum	_
168-70	32939-32948	temporale	_
168-71	32949-32953	gray	_
168-72	32954-32960	matter	_
168-73	32961-32967	volume	_
168-74	32968-32970	in	_
168-75	32971-32984	schizophrenia	_
168-76	32984-32985	:	_
168-77	32986-32987	A	_
168-78	32988-33000	longitudinal	_
168-79	33001-33006	study	_
168-80	33007-33009	of	_
168-81	33010-33023	first-episode	_
168-82	33024-33032	patients	_
168-83	33033-33040	Initial	_
168-84	33041-33044	and	_
168-85	33045-33056	Progressive	_
168-86	33057-33061	Gray	_
168-87	33062-33068	Matter	_
168-88	33069-33082	Abnormalities	_
168-89	33083-33085	in	_
168-90	33086-33093	Insular	_
168-91	33094-33099	Gyrus	_
168-92	33100-33103	and	_
168-93	33104-33112	Temporal	_
168-94	33113-33117	Pole	_
168-95	33118-33120	in	_
168-96	33121-33134	First-Episode	_
168-97	33135-33148	Schizophrenia	_
168-98	33149-33159	Contrasted	_
168-99	33160-33164	with	_
168-100	33165-33178	First-Episode	_
168-101	33179-33188	Affective	_
168-102	33189-33198	Psychosis	_
168-103	33199-33212	Effectiveness	_
168-104	33213-33215	of	_
168-105	33216-33229	antipsychotic	_
168-106	33230-33235	drugs	_
168-107	33236-33238	in	_
168-108	33239-33247	patients	_
168-109	33248-33252	with	_
168-110	33253-33260	chronic	_
168-111	33261-33274	schizophrenia	_
168-112	33275-33286	Reliability	_
168-113	33287-33290	and	_
168-114	33291-33302	statistical	_
168-115	33303-33308	power	_
168-116	33309-33317	analysis	_
168-117	33318-33320	of	_
168-118	33321-33329	cortical	_
168-119	33330-33333	and	_
168-120	33334-33345	subcortical	_
168-121	33346-33356	FreeSurfer	_
168-122	33357-33364	metrics	_
168-123	33365-33367	in	_
168-124	33368-33369	a	_
168-125	33370-33375	large	_
168-126	33376-33382	sample	_
168-127	33383-33385	of	_
168-128	33386-33393	healthy	_
168-129	33394-33401	elderly	_
168-130	33402-33411	Automated	_
168-131	33412-33421	ROI-based	_
168-132	33422-33427	brain	_
168-133	33428-33440	parcellation	_
168-134	33441-33449	analysis	_
168-135	33450-33452	of	_
168-136	33453-33460	frontal	_
168-137	33461-33464	and	_
168-138	33465-33473	temporal	_
168-139	33474-33479	brain	_
168-140	33480-33487	volumes	_
168-141	33488-33490	in	_
168-142	33491-33504	schizophrenia	_
168-143	33505-33516	Specificity	_
168-144	33517-33519	of	_
168-145	33520-33530	prefrontal	_
168-146	33531-33542	dysfunction	_
168-147	33543-33546	and	_
168-148	33547-33554	context	_
168-149	33555-33565	processing	_
168-150	33566-33574	deficits	_
168-151	33575-33577	to	_
168-152	33578-33591	schizophrenia	_
168-153	33592-33594	in	_
168-154	33595-33610	never-medicated	_
168-155	33611-33619	patients	_
168-156	33620-33624	with	_
168-157	33625-33638	first-episode	_
168-158	33639-33648	psychosis	_
168-159	33649-33650	A	_
168-160	33651-33661	comparison	_
168-161	33662-33664	of	_
168-162	33665-33685	FreeSurfer-generated	_
168-163	33686-33690	data	_
168-164	33691-33695	with	_
168-165	33696-33699	and	_
168-166	33700-33707	without	_
168-167	33708-33714	manual	_
168-168	33715-33727	intervention	_
168-169	33728-33738	Functional	_
168-170	33739-33751	neuroanatomy	_
168-171	33752-33754	of	_
168-172	33755-33763	auditory	_
168-173	33764-33771	working	_
168-174	33772-33778	memory	_
168-175	33779-33781	in	_
168-176	33782-33795	schizophrenia	_
168-177	33795-33796	:	_
168-178	33797-33805	relation	_
168-179	33806-33808	to	_
168-180	33809-33817	positive	_
168-181	33818-33821	and	_
168-182	33822-33830	negative	_
168-183	33831-33839	symptoms	_
168-184	33840-33851	Neocortical	_
168-185	33852-33856	Gray	_
168-186	33857-33863	Matter	_
168-187	33864-33870	Volume	_
168-188	33871-33873	in	_
168-189	33874-33887	First-Episode	_
168-190	33888-33901	Schizophrenia	_
168-191	33902-33905	and	_
168-192	33906-33919	First-Episode	_
168-193	33920-33929	Affective	_
168-194	33930-33939	Psychosis	_
168-195	33939-33940	:	_
168-196	33941-33942	A	_
168-197	33943-33958	Cross-Sectional	_
168-198	33959-33962	and	_
168-199	33963-33975	Longitudinal	_
168-200	33976-33979	MRI	_
168-201	33980-33985	Study	_
168-202	33986-33995	Increases	_
168-203	33996-33998	in	_
168-204	33999-34007	regional	_
168-205	34008-34020	subarachnoid	_
168-206	34021-34024	CSF	_
168-207	34025-34032	without	_
168-208	34033-34041	apparent	_
168-209	34042-34050	cortical	_
168-210	34051-34055	gray	_
168-211	34056-34062	matter	_
168-212	34063-34071	deficits	_
168-213	34072-34074	in	_
168-214	34075-34088	schizophrenia	_
168-215	34088-34089	:	_
168-216	34090-34100	modulating	_
168-217	34101-34108	effects	_
168-218	34109-34111	of	_
168-219	34112-34115	sex	_
168-220	34116-34119	and	_
168-221	34120-34123	age	_
168-222	34124-34126	Do	_
168-223	34127-34140	antipsychotic	_
168-224	34141-34146	drugs	_
168-225	34147-34153	affect	_
168-226	34154-34159	brain	_
168-227	34160-34169	structure	_
168-228	34169-34170	?	_

#Text=A systematic and critical review of MRI findings
#Text=The assessment and analysis of handedness: the Edinburgh inventory
#Text=Glutamate receptor dysfunction and schizophrenia
#Text=The Brief Psychiatric Rating Scale
#Text=Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient
#Text=Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents
#Text=
#Text=
#Text=Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study
#Text=Delta EEG band as a marker of left hypofrontality for language in schizophrenia patients
#Text=Differential contributions of prefrontal and temporolimbic pathology to mechanisms of psychosis
#Text=Changes in cortical thickness during the course of illness in schizophrenia
#Text=
#Text=Comparing manual and automatic segmentation of hippocampal volumes: reliability and validity issues in younger and older brains
#Text=Gamma oscillation deficits and the onset and early progression of schizophrenia
#Text=Chlorpromazine equivalent doses for the newer atypical antipsychotics
#Text=Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study
#Text=Anatomical regions of interest. a) 3D model of PFC subregions. b) Coronal slice of PFC subregions.
169-1	34171-34172	A	_
169-2	34173-34183	systematic	_
169-3	34184-34187	and	_
169-4	34188-34196	critical	_
169-5	34197-34203	review	_
169-6	34204-34206	of	_
169-7	34207-34210	MRI	_
169-8	34211-34219	findings	_
169-9	34220-34223	The	_
169-10	34224-34234	assessment	_
169-11	34235-34238	and	_
169-12	34239-34247	analysis	_
169-13	34248-34250	of	_
169-14	34251-34261	handedness	_
169-15	34261-34262	:	_
169-16	34263-34266	the	_
169-17	34267-34276	Edinburgh	_
169-18	34277-34286	inventory	_
169-19	34287-34296	Glutamate	_
169-20	34297-34305	receptor	_
169-21	34306-34317	dysfunction	_
169-22	34318-34321	and	_
169-23	34322-34335	schizophrenia	_
169-24	34336-34339	The	_
169-25	34340-34345	Brief	_
169-26	34346-34357	Psychiatric	_
169-27	34358-34364	Rating	_
169-28	34365-34370	Scale	_
169-29	34371-34376	Brain	_
169-30	34377-34383	volume	_
169-31	34384-34394	reductions	_
169-32	34395-34397	in	_
169-33	34398-34414	medication-naive	_
169-34	34415-34423	patients	_
169-35	34424-34428	with	_
169-36	34429-34442	schizophrenia	_
169-37	34443-34445	in	_
169-38	34446-34454	relation	_
169-39	34455-34457	to	_
169-40	34458-34470	intelligence	_
169-41	34471-34479	quotient	_
169-42	34480-34490	Depression	_
169-43	34491-34493	in	_
169-44	34494-34507	schizophrenia	_
169-45	34507-34508	:	_
169-46	34509-34520	perspective	_
169-47	34521-34523	in	_
169-48	34524-34527	the	_
169-49	34528-34531	era	_
169-50	34532-34534	of	_
169-51	34535-34536	“	_
169-52	34536-34544	Atypical	_
169-53	34544-34545	”	_
169-54	34546-34559	antipsychotic	_
169-55	34560-34566	agents	_
169-56	34569-34574	Brain	_
169-57	34575-34582	surface	_
169-58	34583-34594	contraction	_
169-59	34595-34601	mapped	_
169-60	34602-34604	in	_
169-61	34605-34618	first-episode	_
169-62	34619-34632	schizophrenia	_
169-63	34632-34633	:	_
169-64	34634-34635	a	_
169-65	34636-34648	longitudinal	_
169-66	34649-34657	magnetic	_
169-67	34658-34667	resonance	_
169-68	34668-34675	imaging	_
169-69	34676-34681	study	_
169-70	34682-34687	Delta	_
169-71	34688-34691	EEG	_
169-72	34692-34696	band	_
169-73	34697-34699	as	_
169-74	34700-34701	a	_
169-75	34702-34708	marker	_
169-76	34709-34711	of	_
169-77	34712-34716	left	_
169-78	34717-34731	hypofrontality	_
169-79	34732-34735	for	_
169-80	34736-34744	language	_
169-81	34745-34747	in	_
169-82	34748-34761	schizophrenia	_
169-83	34762-34770	patients	_
169-84	34771-34783	Differential	_
169-85	34784-34797	contributions	_
169-86	34798-34800	of	_
169-87	34801-34811	prefrontal	_
169-88	34812-34815	and	_
169-89	34816-34829	temporolimbic	_
169-90	34830-34839	pathology	_
169-91	34840-34842	to	_
169-92	34843-34853	mechanisms	_
169-93	34854-34856	of	_
169-94	34857-34866	psychosis	_
169-95	34867-34874	Changes	_
169-96	34875-34877	in	_
169-97	34878-34886	cortical	_
169-98	34887-34896	thickness	_
169-99	34897-34903	during	_
169-100	34904-34907	the	_
169-101	34908-34914	course	_
169-102	34915-34917	of	_
169-103	34918-34925	illness	_
169-104	34926-34928	in	_
169-105	34929-34942	schizophrenia	_
169-106	34944-34953	Comparing	_
169-107	34954-34960	manual	_
169-108	34961-34964	and	_
169-109	34965-34974	automatic	_
169-110	34975-34987	segmentation	_
169-111	34988-34990	of	_
169-112	34991-35002	hippocampal	_
169-113	35003-35010	volumes	_
169-114	35010-35011	:	_
169-115	35012-35023	reliability	_
169-116	35024-35027	and	_
169-117	35028-35036	validity	_
169-118	35037-35043	issues	_
169-119	35044-35046	in	_
169-120	35047-35054	younger	_
169-121	35055-35058	and	_
169-122	35059-35064	older	_
169-123	35065-35071	brains	_
169-124	35072-35077	Gamma	_
169-125	35078-35089	oscillation	_
169-126	35090-35098	deficits	_
169-127	35099-35102	and	_
169-128	35103-35106	the	_
169-129	35107-35112	onset	_
169-130	35113-35116	and	_
169-131	35117-35122	early	_
169-132	35123-35134	progression	_
169-133	35135-35137	of	_
169-134	35138-35151	schizophrenia	_
169-135	35152-35166	Chlorpromazine	_
169-136	35167-35177	equivalent	_
169-137	35178-35183	doses	_
169-138	35184-35187	for	_
169-139	35188-35191	the	_
169-140	35192-35197	newer	_
169-141	35198-35206	atypical	_
169-142	35207-35221	antipsychotics	_
169-143	35222-35231	Localized	_
169-144	35232-35238	volume	_
169-145	35239-35248	reduction	_
169-146	35249-35251	in	_
169-147	35252-35262	prefrontal	_
169-148	35262-35263	,	_
169-149	35264-35277	temporolimbic	_
169-150	35277-35278	,	_
169-151	35279-35282	and	_
169-152	35283-35293	paralimbic	_
169-153	35294-35301	regions	_
169-154	35302-35304	in	_
169-155	35305-35318	schizophrenia	_
169-156	35318-35319	:	_
169-157	35320-35322	an	_
169-158	35323-35326	MRI	_
169-159	35327-35339	parcellation	_
169-160	35340-35345	study	_
169-161	35346-35356	Anatomical	_
169-162	35357-35364	regions	_
169-163	35365-35367	of	_
169-164	35368-35376	interest	_
169-165	35376-35377	.	_
169-166	35378-35379	a	_
169-167	35379-35380	)	_
169-168	35381-35383	3D	_
169-169	35384-35389	model	_
169-170	35390-35392	of	_
169-171	35393-35396	PFC	_
169-172	35397-35407	subregions	_
169-173	35407-35408	.	_
169-174	35409-35410	b	_
169-175	35410-35411	)	_
169-176	35412-35419	Coronal	_
169-177	35420-35425	slice	_
169-178	35426-35428	of	_
169-179	35429-35432	PFC	_
169-180	35433-35443	subregions	_
169-181	35443-35444	.	_

#Text=PFC: prefrontal cortex, FP: frontal pole, SFG: superior frontal gyrus, MFG: middle frontal gyrus, IFG: inferior frontal gyrus.
170-1	35445-35448	PFC	_
170-2	35448-35449	:	_
170-3	35450-35460	prefrontal	_
170-4	35461-35467	cortex	_
170-5	35467-35468	,	_
170-6	35469-35471	FP	_
170-7	35471-35472	:	_
170-8	35473-35480	frontal	_
170-9	35481-35485	pole	_
170-10	35485-35486	,	_
170-11	35487-35490	SFG	_
170-12	35490-35491	:	_
170-13	35492-35500	superior	_
170-14	35501-35508	frontal	_
170-15	35509-35514	gyrus	_
170-16	35514-35515	,	_
170-17	35516-35519	MFG	_
170-18	35519-35520	:	_
170-19	35521-35527	middle	_
170-20	35528-35535	frontal	_
170-21	35536-35541	gyrus	_
170-22	35541-35542	,	_
170-23	35543-35546	IFG	_
170-24	35546-35547	:	_
170-25	35548-35556	inferior	_
170-26	35557-35564	frontal	_
170-27	35565-35570	gyrus	_
170-28	35570-35571	.	_

#Text=Longitudinal volume changes in left and right prefrontal regions of interest in first-episode schizophrenia (FESZ, red) (n = 21), first-episode affective psychosis (FEAFF, dark blue) (n = 24) and healthy control (HC, green) (n = 23) subjects.
171-1	35572-35584	Longitudinal	_
171-2	35585-35591	volume	_
171-3	35592-35599	changes	_
171-4	35600-35602	in	_
171-5	35603-35607	left	_
171-6	35608-35611	and	_
171-7	35612-35617	right	_
171-8	35618-35628	prefrontal	_
171-9	35629-35636	regions	_
171-10	35637-35639	of	_
171-11	35640-35648	interest	_
171-12	35649-35651	in	_
171-13	35652-35665	first-episode	_
171-14	35666-35679	schizophrenia	_
171-15	35680-35681	(	_
171-16	35681-35685	FESZ	_
171-17	35685-35686	,	_
171-18	35687-35690	red	_
171-19	35690-35691	)	_
171-20	35692-35693	(	_
171-21	35693-35694	n	_
171-22	35695-35696	=	_
171-23	35697-35699	21	_
171-24	35699-35700	)	_
171-25	35700-35701	,	_
171-26	35702-35715	first-episode	_
171-27	35716-35725	affective	_
171-28	35726-35735	psychosis	_
171-29	35736-35737	(	_
171-30	35737-35742	FEAFF	_
171-31	35742-35743	,	_
171-32	35744-35748	dark	_
171-33	35749-35753	blue	_
171-34	35753-35754	)	_
171-35	35755-35756	(	_
171-36	35756-35757	n	_
171-37	35758-35759	=	_
171-38	35760-35762	24	_
171-39	35762-35763	)	_
171-40	35764-35767	and	_
171-41	35768-35775	healthy	_
171-42	35776-35783	control	_
171-43	35784-35785	(	_
171-44	35785-35787	HC	_
171-45	35787-35788	,	_
171-46	35789-35794	green	_
171-47	35794-35795	)	_
171-48	35796-35797	(	_
171-49	35797-35798	n	_
171-50	35799-35800	=	_
171-51	35801-35803	23	_
171-52	35803-35804	)	_
171-53	35805-35813	subjects	_
171-54	35813-35814	.	_

#Text=Each volume for each scan is expressed as relative volume, given as a percentage and calculated as (Absolute volume / intracranial contents volume] × 100.
172-1	35815-35819	Each	_
172-2	35820-35826	volume	_
172-3	35827-35830	for	_
172-4	35831-35835	each	_
172-5	35836-35840	scan	_
172-6	35841-35843	is	_
172-7	35844-35853	expressed	_
172-8	35854-35856	as	_
172-9	35857-35865	relative	_
172-10	35866-35872	volume	_
172-11	35872-35873	,	_
172-12	35874-35879	given	_
172-13	35880-35882	as	_
172-14	35883-35884	a	_
172-15	35885-35895	percentage	_
172-16	35896-35899	and	_
172-17	35900-35910	calculated	_
172-18	35911-35913	as	_
172-19	35914-35915	(	_
172-20	35915-35923	Absolute	_
172-21	35924-35930	volume	_
172-22	35931-35932	/	_
172-23	35933-35945	intracranial	_
172-24	35946-35954	contents	_
172-25	35955-35961	volume	_
172-26	35961-35962	]	_
172-27	35963-35964	×	_
172-28	35965-35968	100	_
172-29	35968-35969	.	_

#Text=Each ROI shows each subject’s volume at baseline (first scan) and 1.5 years later (second scan) with a line connecting first and second scan values.
173-1	35970-35974	Each	_
173-2	35975-35978	ROI	_
173-3	35979-35984	shows	_
173-4	35985-35989	each	_
173-5	35990-35997	subject	_
173-6	35997-35998	’	_
173-7	35998-35999	s	_
173-8	36000-36006	volume	_
173-9	36007-36009	at	_
173-10	36010-36018	baseline	_
173-11	36019-36020	(	_
173-12	36020-36025	first	_
173-13	36026-36030	scan	_
173-14	36030-36031	)	_
173-15	36032-36035	and	_
173-16	36036-36039	1.5	_
173-17	36040-36045	years	_
173-18	36046-36051	later	_
173-19	36052-36053	(	_
173-20	36053-36059	second	_
173-21	36060-36064	scan	_
173-22	36064-36065	)	_
173-23	36066-36070	with	_
173-24	36071-36072	a	_
173-25	36073-36077	line	_
173-26	36078-36088	connecting	_
173-27	36089-36094	first	_
173-28	36095-36098	and	_
173-29	36099-36105	second	_
173-30	36106-36110	scan	_
173-31	36111-36117	values	_
173-32	36117-36118	.	_

#Text=For each ROI the proportion of subjects with longitudinal volume decrease is presented at the top as a fraction of the total number of subjects.
174-1	36119-36122	For	_
174-2	36123-36127	each	_
174-3	36128-36131	ROI	_
174-4	36132-36135	the	_
174-5	36136-36146	proportion	_
174-6	36147-36149	of	_
174-7	36150-36158	subjects	_
174-8	36159-36163	with	_
174-9	36164-36176	longitudinal	_
174-10	36177-36183	volume	_
174-11	36184-36192	decrease	_
174-12	36193-36195	is	_
174-13	36196-36205	presented	_
174-14	36206-36208	at	_
174-15	36209-36212	the	_
174-16	36213-36216	top	_
174-17	36217-36219	as	_
174-18	36220-36221	a	_
174-19	36222-36230	fraction	_
174-20	36231-36233	of	_
174-21	36234-36237	the	_
174-22	36238-36243	total	_
174-23	36244-36250	number	_
174-24	36251-36253	of	_
174-25	36254-36262	subjects	_
174-26	36262-36263	.	_

#Text=Mean values are indicated by a horizontal black line.
175-1	36264-36268	Mean	_
175-2	36269-36275	values	_
175-3	36276-36279	are	_
175-4	36280-36289	indicated	_
175-5	36290-36292	by	_
175-6	36293-36294	a	_
175-7	36295-36305	horizontal	_
175-8	36306-36311	black	_
175-9	36312-36316	line	_
175-10	36316-36317	.	_

#Text=ROI Abbreviations: FP, frontal pole (FP); SFG, superior frontal gyrus; MFG, middle frontal gyrus, IFG, inferior frontal gyrus.
176-1	36318-36321	ROI	_
176-2	36322-36335	Abbreviations	_
176-3	36335-36336	:	_
176-4	36337-36339	FP	_
176-5	36339-36340	,	_
176-6	36341-36348	frontal	_
176-7	36349-36353	pole	_
176-8	36354-36355	(	_
176-9	36355-36357	FP	_
176-10	36357-36358	)	_
176-11	36358-36359	;	_
176-12	36360-36363	SFG	_
176-13	36363-36364	,	_
176-14	36365-36373	superior	_
176-15	36374-36381	frontal	_
176-16	36382-36387	gyrus	_
176-17	36387-36388	;	_
176-18	36389-36392	MFG	_
176-19	36392-36393	,	_
176-20	36394-36400	middle	_
176-21	36401-36408	frontal	_
176-22	36409-36414	gyrus	_
176-23	36414-36415	,	_
176-24	36416-36419	IFG	_
176-25	36419-36420	,	_
176-26	36421-36429	inferior	_
176-27	36430-36437	frontal	_
176-28	36438-36443	gyrus	_
176-29	36443-36444	.	_

#Text=†indicates P < 0.001 in comparisons of % change over time between each of the 2 groups by analysis of variance.
177-1	36445-36446	†	_
177-2	36446-36455	indicates	_
177-3	36456-36457	P	_
177-4	36458-36459	<	_
177-5	36460-36465	0.001	_
177-6	36466-36468	in	_
177-7	36469-36480	comparisons	_
177-8	36481-36483	of	_
177-9	36484-36485	%	_
177-10	36486-36492	change	_
177-11	36493-36497	over	_
177-12	36498-36502	time	_
177-13	36503-36510	between	_
177-14	36511-36515	each	_
177-15	36516-36518	of	_
177-16	36519-36522	the	_
177-17	36523-36524	2	_
177-18	36525-36531	groups	_
177-19	36532-36534	by	_
177-20	36535-36543	analysis	_
177-21	36544-36546	of	_
177-22	36547-36555	variance	_
177-23	36555-36556	.	_

#Text=Note that Fig. 2 is continued on a second image.
178-1	36557-36561	Note	_
178-2	36562-36566	that	_
178-3	36567-36570	Fig	_
178-4	36570-36571	.	_
178-5	36572-36573	2	_
178-6	36574-36576	is	_
178-7	36577-36586	continued	_
178-8	36587-36589	on	_
178-9	36590-36591	a	_
178-10	36592-36598	second	_
178-11	36599-36604	image	_
178-12	36604-36605	.	_

#Text=The correlations between relative volume percentage of change and symptom change in the Brief Psychiatric Rating Scale (BPRS).
179-1	36606-36609	The	_
179-2	36610-36622	correlations	_
179-3	36623-36630	between	_
179-4	36631-36639	relative	_
179-5	36640-36646	volume	_
179-6	36647-36657	percentage	_
179-7	36658-36660	of	_
179-8	36661-36667	change	_
179-9	36668-36671	and	_
179-10	36672-36679	symptom	_
179-11	36680-36686	change	_
179-12	36687-36689	in	_
179-13	36690-36693	the	_
179-14	36694-36699	Brief	_
179-15	36700-36711	Psychiatric	_
179-16	36712-36718	Rating	_
179-17	36719-36724	Scale	_
179-18	36725-36726	(	_
179-19	36726-36730	BPRS	_
179-20	36730-36731	)	_
179-21	36731-36732	.	_

#Text=On the X axis, positive values mean relative volume percentage of increase over time and negative values mean relative volume percentage of decrease; and on the Y axis positive values mean symptom exacerbation over time and negative values mean symptom improvement.
180-1	36733-36735	On	_
180-2	36736-36739	the	_
180-3	36740-36741	X	_
180-4	36742-36746	axis	_
180-5	36746-36747	,	_
180-6	36748-36756	positive	_
180-7	36757-36763	values	_
180-8	36764-36768	mean	_
180-9	36769-36777	relative	_
180-10	36778-36784	volume	_
180-11	36785-36795	percentage	_
180-12	36796-36798	of	_
180-13	36799-36807	increase	_
180-14	36808-36812	over	_
180-15	36813-36817	time	_
180-16	36818-36821	and	_
180-17	36822-36830	negative	_
180-18	36831-36837	values	_
180-19	36838-36842	mean	_
180-20	36843-36851	relative	_
180-21	36852-36858	volume	_
180-22	36859-36869	percentage	_
180-23	36870-36872	of	_
180-24	36873-36881	decrease	_
180-25	36881-36882	;	_
180-26	36883-36886	and	_
180-27	36887-36889	on	_
180-28	36890-36893	the	_
180-29	36894-36895	Y	_
180-30	36896-36900	axis	_
180-31	36901-36909	positive	_
180-32	36910-36916	values	_
180-33	36917-36921	mean	_
180-34	36922-36929	symptom	_
180-35	36930-36942	exacerbation	_
180-36	36943-36947	over	_
180-37	36948-36952	time	_
180-38	36953-36956	and	_
180-39	36957-36965	negative	_
180-40	36966-36972	values	_
180-41	36973-36977	mean	_
180-42	36978-36985	symptom	_
180-43	36986-36997	improvement	_
180-44	36997-36998	.	_

#Text=Note the associations between the degree of reduction of Middle Frontal Gyrus (MFG) or Inferior Frontal Gyrus (IFG) in subjects with first episode schizophrenia and poorer symptom outcomes.
181-1	36999-37003	Note	_
181-2	37004-37007	the	_
181-3	37008-37020	associations	_
181-4	37021-37028	between	_
181-5	37029-37032	the	_
181-6	37033-37039	degree	_
181-7	37040-37042	of	_
181-8	37043-37052	reduction	_
181-9	37053-37055	of	_
181-10	37056-37062	Middle	_
181-11	37063-37070	Frontal	_
181-12	37071-37076	Gyrus	_
181-13	37077-37078	(	_
181-14	37078-37081	MFG	_
181-15	37081-37082	)	_
181-16	37083-37085	or	_
181-17	37086-37094	Inferior	_
181-18	37095-37102	Frontal	_
181-19	37103-37108	Gyrus	_
181-20	37109-37110	(	_
181-21	37110-37113	IFG	_
181-22	37113-37114	)	_
181-23	37115-37117	in	_
181-24	37118-37126	subjects	_
181-25	37127-37131	with	_
181-26	37132-37137	first	_
181-27	37138-37145	episode	_
181-28	37146-37159	schizophrenia	_
181-29	37160-37163	and	_
181-30	37164-37170	poorer	_
181-31	37171-37178	symptom	_
181-32	37179-37187	outcomes	_
181-33	37187-37188	.	_

#Text=Spearman correlation coefficients rho and its p-value are indicated within each diagram.
182-1	37189-37197	Spearman	_
182-2	37198-37209	correlation	_
182-3	37210-37222	coefficients	_
182-4	37223-37226	rho	_
182-5	37227-37230	and	_
182-6	37231-37234	its	_
182-7	37235-37242	p-value	_
182-8	37243-37246	are	_
182-9	37247-37256	indicated	_
182-10	37257-37263	within	_
182-11	37264-37268	each	_
182-12	37269-37276	diagram	_
182-13	37276-37277	.	_

#Text=Demographic and Clinical Characteristics of Cross-sectional and Longitudinal Study Subjectsa
#Text=\tFE SZ group (n = 21)\tFE AFF group (n = 24)\tHC group (n = 23)\tStatistical Analysis\t \t\t \tF or t Testb\tdfc\tP Value\t \tAge, mean (SD) [range], y.\t25.5 (8.2) [18–45]\t23.3 (4.9) [18–42]\t23.0 (3.6) [18–34]\t1.184\t2,65\t0.313\t \tTime between scans, mo.\t17.2 (11.5)\t18.6 (10.2)\t16.4 (8.2)\t0.288\t2,65\t0.751\t \tSex, No.
183-1	37278-37289	Demographic	_
183-2	37290-37293	and	_
183-3	37294-37302	Clinical	_
183-4	37303-37318	Characteristics	_
183-5	37319-37321	of	_
183-6	37322-37337	Cross-sectional	_
183-7	37338-37341	and	_
183-8	37342-37354	Longitudinal	_
183-9	37355-37360	Study	_
183-10	37361-37370	Subjectsa	_
183-11	37372-37374	FE	_
183-12	37375-37377	SZ	_
183-13	37378-37383	group	_
183-14	37384-37385	(	_
183-15	37385-37386	n	_
183-16	37387-37388	=	_
183-17	37389-37391	21	_
183-18	37391-37392	)	_
183-19	37393-37395	FE	_
183-20	37396-37399	AFF	_
183-21	37400-37405	group	_
183-22	37406-37407	(	_
183-23	37407-37408	n	_
183-24	37409-37410	=	_
183-25	37411-37413	24	_
183-26	37413-37414	)	_
183-27	37415-37417	HC	_
183-28	37418-37423	group	_
183-29	37424-37425	(	_
183-30	37425-37426	n	_
183-31	37427-37428	=	_
183-32	37429-37431	23	_
183-33	37431-37432	)	_
183-34	37433-37444	Statistical	_
183-35	37445-37453	Analysis	_
183-36	37459-37460	F	_
183-37	37461-37463	or	_
183-38	37464-37465	t	_
183-39	37466-37471	Testb	_
183-40	37472-37475	dfc	_
183-41	37476-37477	P	_
183-42	37478-37483	Value	_
183-43	37486-37489	Age	_
183-44	37489-37490	,	_
183-45	37491-37495	mean	_
183-46	37496-37497	(	_
183-47	37497-37499	SD	_
183-48	37499-37500	)	_
183-49	37501-37502	[	_
183-50	37502-37507	range	_
183-51	37507-37508	]	_
183-52	37508-37509	,	_
183-53	37510-37511	y	_
183-54	37511-37512	.	_
183-55	37513-37517	25.5	_
183-56	37518-37519	(	_
183-57	37519-37522	8.2	_
183-58	37522-37523	)	_
183-59	37524-37525	[	_
183-60	37525-37527	18	_
183-61	37527-37528	–	_
183-62	37528-37530	45	_
183-63	37530-37531	]	_
183-64	37532-37536	23.3	_
183-65	37537-37538	(	_
183-66	37538-37541	4.9	_
183-67	37541-37542	)	_
183-68	37543-37544	[	_
183-69	37544-37546	18	_
183-70	37546-37547	–	_
183-71	37547-37549	42	_
183-72	37549-37550	]	_
183-73	37551-37555	23.0	_
183-74	37556-37557	(	_
183-75	37557-37560	3.6	_
183-76	37560-37561	)	_
183-77	37562-37563	[	_
183-78	37563-37565	18	_
183-79	37565-37566	–	_
183-80	37566-37568	34	_
183-81	37568-37569	]	_
183-82	37570-37575	1.184	_
183-83	37576-37580	2,65	_
183-84	37581-37586	0.313	_
183-85	37589-37593	Time	_
183-86	37594-37601	between	_
183-87	37602-37607	scans	_
183-88	37607-37608	,	_
183-89	37609-37611	mo	_
183-90	37611-37612	.	_
183-91	37613-37617	17.2	_
183-92	37618-37619	(	_
183-93	37619-37623	11.5	_
183-94	37623-37624	)	_
183-95	37625-37629	18.6	_
183-96	37630-37631	(	_
183-97	37631-37635	10.2	_
183-98	37635-37636	)	_
183-99	37637-37641	16.4	_
183-100	37642-37643	(	_
183-101	37643-37646	8.2	_
183-102	37646-37647	)	_
183-103	37648-37653	0.288	_
183-104	37654-37658	2,65	_
183-105	37659-37664	0.751	_
183-106	37667-37670	Sex	_
183-107	37670-37671	,	_
183-108	37672-37674	No	_
183-109	37674-37675	.	_

#Text=M/F d\t18 / 3\t20 / 4\t18 / 5\t\t\t\t \tHandedness e\t0.8 (0.1)\t0.7 (0.2)\t0.8 (0.2)\t1.792\t2,65\t0.175\t \tSES f\t3.4 (1.4)\t2.8 (1.2)\t2.2 (0.9)\t5.727\t2,65\t0.005\t \tParental SES f\t1.9 (0.7)\t1.5 (0.9)\t1.5 (0.6)\t1.46\t2,65\t0.24\t \tYears of education g\t12.9 (2.3)\t14.0 (1.6)\t14.8 (2.0)\t3.981\t2,65\t0.023\t \tWAIS-R Information, scaled baseline\t12.0 (3.2)\t13.3 (2.7)\t13.5 (2.5)\t1.947\t2,63\t0.151\t \tWAIS-R Digit Span, scaled baseline\t9.8 (2.4)\t10.5 (2.6)\t10.9 (2.6)\t0.951\t2,63\t0.392\t \tBPRS\t \t Baseline scan\t41.8 (12.3)\t33.0 (8.5)\tNA\t7.203\t1,40\t0.011\t \t Second scan\t28.3 (7.4)\t26.1 (7.5)\tNA\t0.856\t1,39\t0.36\t \tDuration of illness\t0.9 (2.8)\t0.2 (0.3)\tNA\t1.919\t1,43\t0.173\t \tMedication dosage at baseline, CPZ equiv. j\t276.1 (209.3)\t215.9 (158.1)\tNA\t1.127\t1,40\t0.295\t \tDuration of antipsychotic medication before baseline scan, median (range), wk.\t2 (0–50)\t1 (0–45)\tNA\tNA\tNA\tNA\t \tMedication use, No. of patients\t\t\t\t\t\t\t \t Neuroleptics, TYP/ATYP/overlap\t\t\t\t\t\t\t \t  At baseline scan\t9 / 15 / 4\t8 / 14 / 1\tNA\t\t\t\t \t  At second scan\t1 / 15 / 1\t2 / 11 / 1\tNA\t\t\t\t \t Mood stabilizer, lithiumk / VPA / overlap\t\t\t\t\t\t\t \t  At baseline scan\t2 / 2 / 0\t8 / 8 / 1\tNA\t\t\t\t \t  At second scan\t4 / 2 / 0\t6 / 8 / 0\tNA\t\t\t\t \t
#Text=Abbreviations: BPRS, Brief Psychiatric Rating Scale; CPZ equiv., chlorpromazine equivalent; FEAFF, first-episode affective psychosis; FESZ, first-episode schizophrenia; HC, healthy control; NA, data not applicable; SES, socioeconomic status; WAIS-R, Wechsler Adult Intelligence Scale–Revised.
184-1	37676-37677	M	_
184-2	37677-37678	/	_
184-3	37678-37679	F	_
184-4	37680-37681	d	_
184-5	37682-37684	18	_
184-6	37685-37686	/	_
184-7	37687-37688	3	_
184-8	37689-37691	20	_
184-9	37692-37693	/	_
184-10	37694-37695	4	_
184-11	37696-37698	18	_
184-12	37699-37700	/	_
184-13	37701-37702	5	_
184-14	37708-37718	Handedness	_
184-15	37719-37720	e	_
184-16	37721-37724	0.8	_
184-17	37725-37726	(	_
184-18	37726-37729	0.1	_
184-19	37729-37730	)	_
184-20	37731-37734	0.7	_
184-21	37735-37736	(	_
184-22	37736-37739	0.2	_
184-23	37739-37740	)	_
184-24	37741-37744	0.8	_
184-25	37745-37746	(	_
184-26	37746-37749	0.2	_
184-27	37749-37750	)	_
184-28	37751-37756	1.792	_
184-29	37757-37761	2,65	_
184-30	37762-37767	0.175	_
184-31	37770-37773	SES	_
184-32	37774-37775	f	_
184-33	37776-37779	3.4	_
184-34	37780-37781	(	_
184-35	37781-37784	1.4	_
184-36	37784-37785	)	_
184-37	37786-37789	2.8	_
184-38	37790-37791	(	_
184-39	37791-37794	1.2	_
184-40	37794-37795	)	_
184-41	37796-37799	2.2	_
184-42	37800-37801	(	_
184-43	37801-37804	0.9	_
184-44	37804-37805	)	_
184-45	37806-37811	5.727	_
184-46	37812-37816	2,65	_
184-47	37817-37822	0.005	_
184-48	37825-37833	Parental	_
184-49	37834-37837	SES	_
184-50	37838-37839	f	_
184-51	37840-37843	1.9	_
184-52	37844-37845	(	_
184-53	37845-37848	0.7	_
184-54	37848-37849	)	_
184-55	37850-37853	1.5	_
184-56	37854-37855	(	_
184-57	37855-37858	0.9	_
184-58	37858-37859	)	_
184-59	37860-37863	1.5	_
184-60	37864-37865	(	_
184-61	37865-37868	0.6	_
184-62	37868-37869	)	_
184-63	37870-37874	1.46	_
184-64	37875-37879	2,65	_
184-65	37880-37884	0.24	_
184-66	37887-37892	Years	_
184-67	37893-37895	of	_
184-68	37896-37905	education	_
184-69	37906-37907	g	_
184-70	37908-37912	12.9	_
184-71	37913-37914	(	_
184-72	37914-37917	2.3	_
184-73	37917-37918	)	_
184-74	37919-37923	14.0	_
184-75	37924-37925	(	_
184-76	37925-37928	1.6	_
184-77	37928-37929	)	_
184-78	37930-37934	14.8	_
184-79	37935-37936	(	_
184-80	37936-37939	2.0	_
184-81	37939-37940	)	_
184-82	37941-37946	3.981	_
184-83	37947-37951	2,65	_
184-84	37952-37957	0.023	_
184-85	37960-37966	WAIS-R	_
184-86	37967-37978	Information	_
184-87	37978-37979	,	_
184-88	37980-37986	scaled	_
184-89	37987-37995	baseline	_
184-90	37996-38000	12.0	_
184-91	38001-38002	(	_
184-92	38002-38005	3.2	_
184-93	38005-38006	)	_
184-94	38007-38011	13.3	_
184-95	38012-38013	(	_
184-96	38013-38016	2.7	_
184-97	38016-38017	)	_
184-98	38018-38022	13.5	_
184-99	38023-38024	(	_
184-100	38024-38027	2.5	_
184-101	38027-38028	)	_
184-102	38029-38034	1.947	_
184-103	38035-38039	2,63	_
184-104	38040-38045	0.151	_
184-105	38048-38054	WAIS-R	_
184-106	38055-38060	Digit	_
184-107	38061-38065	Span	_
184-108	38065-38066	,	_
184-109	38067-38073	scaled	_
184-110	38074-38082	baseline	_
184-111	38083-38086	9.8	_
184-112	38087-38088	(	_
184-113	38088-38091	2.4	_
184-114	38091-38092	)	_
184-115	38093-38097	10.5	_
184-116	38098-38099	(	_
184-117	38099-38102	2.6	_
184-118	38102-38103	)	_
184-119	38104-38108	10.9	_
184-120	38109-38110	(	_
184-121	38110-38113	2.6	_
184-122	38113-38114	)	_
184-123	38115-38120	0.951	_
184-124	38121-38125	2,63	_
184-125	38126-38131	0.392	_
184-126	38134-38138	BPRS	_
184-127	38142-38150	Baseline	_
184-128	38151-38155	scan	_
184-129	38156-38160	41.8	_
184-130	38161-38162	(	_
184-131	38162-38166	12.3	_
184-132	38166-38167	)	_
184-133	38168-38172	33.0	_
184-134	38173-38174	(	_
184-135	38174-38177	8.5	_
184-136	38177-38178	)	_
184-137	38179-38181	NA	_
184-138	38182-38187	7.203	_
184-139	38188-38192	1,40	_
184-140	38193-38198	0.011	_
184-141	38202-38208	Second	_
184-142	38209-38213	scan	_
184-143	38214-38218	28.3	_
184-144	38219-38220	(	_
184-145	38220-38223	7.4	_
184-146	38223-38224	)	_
184-147	38225-38229	26.1	_
184-148	38230-38231	(	_
184-149	38231-38234	7.5	_
184-150	38234-38235	)	_
184-151	38236-38238	NA	_
184-152	38239-38244	0.856	_
184-153	38245-38249	1,39	_
184-154	38250-38254	0.36	_
184-155	38257-38265	Duration	_
184-156	38266-38268	of	_
184-157	38269-38276	illness	_
184-158	38277-38280	0.9	_
184-159	38281-38282	(	_
184-160	38282-38285	2.8	_
184-161	38285-38286	)	_
184-162	38287-38290	0.2	_
184-163	38291-38292	(	_
184-164	38292-38295	0.3	_
184-165	38295-38296	)	_
184-166	38297-38299	NA	_
184-167	38300-38305	1.919	_
184-168	38306-38310	1,43	_
184-169	38311-38316	0.173	_
184-170	38319-38329	Medication	_
184-171	38330-38336	dosage	_
184-172	38337-38339	at	_
184-173	38340-38348	baseline	_
184-174	38348-38349	,	_
184-175	38350-38353	CPZ	_
184-176	38354-38359	equiv	_
184-177	38359-38360	.	_
184-178	38361-38362	j	_
184-179	38363-38368	276.1	_
184-180	38369-38370	(	_
184-181	38370-38375	209.3	_
184-182	38375-38376	)	_
184-183	38377-38382	215.9	_
184-184	38383-38384	(	_
184-185	38384-38389	158.1	_
184-186	38389-38390	)	_
184-187	38391-38393	NA	_
184-188	38394-38399	1.127	_
184-189	38400-38404	1,40	_
184-190	38405-38410	0.295	_
184-191	38413-38421	Duration	_
184-192	38422-38424	of	_
184-193	38425-38438	antipsychotic	_
184-194	38439-38449	medication	_
184-195	38450-38456	before	_
184-196	38457-38465	baseline	_
184-197	38466-38470	scan	_
184-198	38470-38471	,	_
184-199	38472-38478	median	_
184-200	38479-38480	(	_
184-201	38480-38485	range	_
184-202	38485-38486	)	_
184-203	38486-38487	,	_
184-204	38488-38490	wk	_
184-205	38490-38491	.	_
184-206	38492-38493	2	_
184-207	38494-38495	(	_
184-208	38495-38496	0	_
184-209	38496-38497	–	_
184-210	38497-38499	50	_
184-211	38499-38500	)	_
184-212	38501-38502	1	_
184-213	38503-38504	(	_
184-214	38504-38505	0	_
184-215	38505-38506	–	_
184-216	38506-38508	45	_
184-217	38508-38509	)	_
184-218	38510-38512	NA	_
184-219	38513-38515	NA	_
184-220	38516-38518	NA	_
184-221	38519-38521	NA	_
184-222	38524-38534	Medication	_
184-223	38535-38538	use	_
184-224	38538-38539	,	_
184-225	38540-38542	No	_
184-226	38542-38543	.	_
184-227	38544-38546	of	_
184-228	38547-38555	patients	_
184-229	38565-38577	Neuroleptics	_
184-230	38577-38578	,	_
184-231	38579-38582	TYP	_
184-232	38582-38583	/	_
184-233	38583-38587	ATYP	_
184-234	38587-38588	/	_
184-235	38588-38595	overlap	_
184-236	38606-38608	At	_
184-237	38609-38617	baseline	_
184-238	38618-38622	scan	_
184-239	38623-38624	9	_
184-240	38625-38626	/	_
184-241	38627-38629	15	_
184-242	38630-38631	/	_
184-243	38632-38633	4	_
184-244	38634-38635	8	_
184-245	38636-38637	/	_
184-246	38638-38640	14	_
184-247	38641-38642	/	_
184-248	38643-38644	1	_
184-249	38645-38647	NA	_
184-250	38655-38657	At	_
184-251	38658-38664	second	_
184-252	38665-38669	scan	_
184-253	38670-38671	1	_
184-254	38672-38673	/	_
184-255	38674-38676	15	_
184-256	38677-38678	/	_
184-257	38679-38680	1	_
184-258	38681-38682	2	_
184-259	38683-38684	/	_
184-260	38685-38687	11	_
184-261	38688-38689	/	_
184-262	38690-38691	1	_
184-263	38692-38694	NA	_
184-264	38701-38705	Mood	_
184-265	38706-38716	stabilizer	_
184-266	38716-38717	,	_
184-267	38718-38726	lithiumk	_
184-268	38727-38728	/	_
184-269	38729-38732	VPA	_
184-270	38733-38734	/	_
184-271	38735-38742	overlap	_
184-272	38753-38755	At	_
184-273	38756-38764	baseline	_
184-274	38765-38769	scan	_
184-275	38770-38771	2	_
184-276	38772-38773	/	_
184-277	38774-38775	2	_
184-278	38776-38777	/	_
184-279	38778-38779	0	_
184-280	38780-38781	8	_
184-281	38782-38783	/	_
184-282	38784-38785	8	_
184-283	38786-38787	/	_
184-284	38788-38789	1	_
184-285	38790-38792	NA	_
184-286	38800-38802	At	_
184-287	38803-38809	second	_
184-288	38810-38814	scan	_
184-289	38815-38816	4	_
184-290	38817-38818	/	_
184-291	38819-38820	2	_
184-292	38821-38822	/	_
184-293	38823-38824	0	_
184-294	38825-38826	6	_
184-295	38827-38828	/	_
184-296	38829-38830	8	_
184-297	38831-38832	/	_
184-298	38833-38834	0	_
184-299	38835-38837	NA	_
184-300	38844-38857	Abbreviations	_
184-301	38857-38858	:	_
184-302	38859-38863	BPRS	_
184-303	38863-38864	,	_
184-304	38865-38870	Brief	_
184-305	38871-38882	Psychiatric	_
184-306	38883-38889	Rating	_
184-307	38890-38895	Scale	_
184-308	38895-38896	;	_
184-309	38897-38900	CPZ	_
184-310	38901-38906	equiv	_
184-311	38906-38907	.	_
184-312	38907-38908	,	_
184-313	38909-38923	chlorpromazine	_
184-314	38924-38934	equivalent	_
184-315	38934-38935	;	_
184-316	38936-38941	FEAFF	_
184-317	38941-38942	,	_
184-318	38943-38956	first-episode	_
184-319	38957-38966	affective	_
184-320	38967-38976	psychosis	_
184-321	38976-38977	;	_
184-322	38978-38982	FESZ	_
184-323	38982-38983	,	_
184-324	38984-38997	first-episode	_
184-325	38998-39011	schizophrenia	_
184-326	39011-39012	;	_
184-327	39013-39015	HC	_
184-328	39015-39016	,	_
184-329	39017-39024	healthy	_
184-330	39025-39032	control	_
184-331	39032-39033	;	_
184-332	39034-39036	NA	_
184-333	39036-39037	,	_
184-334	39038-39042	data	_
184-335	39043-39046	not	_
184-336	39047-39057	applicable	_
184-337	39057-39058	;	_
184-338	39059-39062	SES	_
184-339	39062-39063	,	_
184-340	39064-39077	socioeconomic	_
184-341	39078-39084	status	_
184-342	39084-39085	;	_
184-343	39086-39092	WAIS-R	_
184-344	39092-39093	,	_
184-345	39094-39102	Wechsler	_
184-346	39103-39108	Adult	_
184-347	39109-39121	Intelligence	_
184-348	39122-39135	Scale–Revised	_
184-349	39135-39136	.	_

#Text=Of 24 patients with FEAFF, 22 had bipolar disorder in a manic phase and 2 had bipolar disorder in a depressive phase with psychotic features.
185-1	39137-39139	Of	_
185-2	39140-39142	24	_
185-3	39143-39151	patients	_
185-4	39152-39156	with	_
185-5	39157-39162	FEAFF	_
185-6	39162-39163	,	_
185-7	39164-39166	22	_
185-8	39167-39170	had	_
185-9	39171-39178	bipolar	_
185-10	39179-39187	disorder	_
185-11	39188-39190	in	_
185-12	39191-39192	a	_
185-13	39193-39198	manic	_
185-14	39199-39204	phase	_
185-15	39205-39208	and	_
185-16	39209-39210	2	_
185-17	39211-39214	had	_
185-18	39215-39222	bipolar	_
185-19	39223-39231	disorder	_
185-20	39232-39234	in	_
185-21	39235-39236	a	_
185-22	39237-39247	depressive	_
185-23	39248-39253	phase	_
185-24	39254-39258	with	_
185-25	39259-39268	psychotic	_
185-26	39269-39277	features	_
185-27	39277-39278	.	_

#Text=Unless otherwise indicated, data are expressed as mean (SD).
186-1	39279-39285	Unless	_
186-2	39286-39295	otherwise	_
186-3	39296-39305	indicated	_
186-4	39305-39306	,	_
186-5	39307-39311	data	_
186-6	39312-39315	are	_
186-7	39316-39325	expressed	_
186-8	39326-39328	as	_
186-9	39329-39333	mean	_
186-10	39334-39335	(	_
186-11	39335-39337	SD	_
186-12	39337-39338	)	_
186-13	39338-39339	.	_

#Text=The F tests (1-way analysis of variance) were performed among FESZ, FEAFF, and HC groups for age, handedness, SES, parental SES, WAIS-R Information and Digit Span scaled scores, and MMSE scores.
187-1	39340-39343	The	_
187-2	39344-39345	F	_
187-3	39346-39351	tests	_
187-4	39352-39353	(	_
187-5	39353-39354	1	_
187-6	39354-39355	-	_
187-7	39355-39358	way	_
187-8	39359-39367	analysis	_
187-9	39368-39370	of	_
187-10	39371-39379	variance	_
187-11	39379-39380	)	_
187-12	39381-39385	were	_
187-13	39386-39395	performed	_
187-14	39396-39401	among	_
187-15	39402-39406	FESZ	_
187-16	39406-39407	,	_
187-17	39408-39413	FEAFF	_
187-18	39413-39414	,	_
187-19	39415-39418	and	_
187-20	39419-39421	HC	_
187-21	39422-39428	groups	_
187-22	39429-39432	for	_
187-23	39433-39436	age	_
187-24	39436-39437	,	_
187-25	39438-39448	handedness	_
187-26	39448-39449	,	_
187-27	39450-39453	SES	_
187-28	39453-39454	,	_
187-29	39455-39463	parental	_
187-30	39464-39467	SES	_
187-31	39467-39468	,	_
187-32	39469-39475	WAIS-R	_
187-33	39476-39487	Information	_
187-34	39488-39491	and	_
187-35	39492-39497	Digit	_
187-36	39498-39502	Span	_
187-37	39503-39509	scaled	_
187-38	39510-39516	scores	_
187-39	39516-39517	,	_
187-40	39518-39521	and	_
187-41	39522-39526	MMSE	_
187-42	39527-39533	scores	_
187-43	39533-39534	.	_

#Text=The t tests were performed between FESZ and FEAFF groups for duration of illness, medication dosage, BPRS scores, and GAS scores.
188-1	39535-39538	The	_
188-2	39539-39540	t	_
188-3	39541-39546	tests	_
188-4	39547-39551	were	_
188-5	39552-39561	performed	_
188-6	39562-39569	between	_
188-7	39570-39574	FESZ	_
188-8	39575-39578	and	_
188-9	39579-39584	FEAFF	_
188-10	39585-39591	groups	_
188-11	39592-39595	for	_
188-12	39596-39604	duration	_
188-13	39605-39607	of	_
188-14	39608-39615	illness	_
188-15	39615-39616	,	_
188-16	39617-39627	medication	_
188-17	39628-39634	dosage	_
188-18	39634-39635	,	_
188-19	39636-39640	BPRS	_
188-20	39641-39647	scores	_
188-21	39647-39648	,	_
188-22	39649-39652	and	_
188-23	39653-39656	GAS	_
188-24	39657-39663	scores	_
188-25	39663-39664	.	_

#Text=The degrees of freedom differ among variables owing to unavailability of data in some participants.
#Text=χ2 test (F2 = 0.080; P = 0.44) showed no difference in sex ratio among the 3 groups.
189-1	39665-39668	The	_
189-2	39669-39676	degrees	_
189-3	39677-39679	of	_
189-4	39680-39687	freedom	_
189-5	39688-39694	differ	_
189-6	39695-39700	among	_
189-7	39701-39710	variables	_
189-8	39711-39716	owing	_
189-9	39717-39719	to	_
189-10	39720-39734	unavailability	_
189-11	39735-39737	of	_
189-12	39738-39742	data	_
189-13	39743-39745	in	_
189-14	39746-39750	some	_
189-15	39751-39763	participants	_
189-16	39763-39764	.	_
189-17	39765-39767	χ2	_
189-18	39768-39772	test	_
189-19	39773-39774	(	_
189-20	39774-39776	F2	_
189-21	39777-39778	=	_
189-22	39779-39784	0.080	_
189-23	39784-39785	;	_
189-24	39786-39787	P	_
189-25	39788-39789	=	_
189-26	39790-39794	0.44	_
189-27	39794-39795	)	_
189-28	39796-39802	showed	_
189-29	39803-39805	no	_
189-30	39806-39816	difference	_
189-31	39817-39819	in	_
189-32	39820-39823	sex	_
189-33	39824-39829	ratio	_
189-34	39830-39835	among	_
189-35	39836-39839	the	_
189-36	39840-39841	3	_
189-37	39842-39848	groups	_
189-38	39848-39849	.	_

#Text=Evaluated using the Edinburgh Handedness Inventory as ([right hand-left hand] × 100) / (right hand + left hand); scores > 0 indicate right-handedness.
190-1	39850-39859	Evaluated	_
190-2	39860-39865	using	_
190-3	39866-39869	the	_
190-4	39870-39879	Edinburgh	_
190-5	39880-39890	Handedness	_
190-6	39891-39900	Inventory	_
190-7	39901-39903	as	_
190-8	39904-39905	(	_
190-9	39905-39906	[	_
190-10	39906-39911	right	_
190-11	39912-39921	hand-left	_
190-12	39922-39926	hand	_
190-13	39926-39927	]	_
190-14	39928-39929	×	_
190-15	39930-39933	100	_
190-16	39933-39934	)	_
190-17	39935-39936	/	_
190-18	39937-39938	(	_
190-19	39938-39943	right	_
190-20	39944-39948	hand	_
190-21	39949-39950	+	_
190-22	39951-39955	left	_
190-23	39956-39960	hand	_
190-24	39960-39961	)	_
190-25	39961-39962	;	_
190-26	39963-39969	scores	_
190-27	39970-39971	>	_
190-28	39972-39973	0	_
190-29	39974-39982	indicate	_
190-30	39983-39999	right-handedness	_
190-31	39999-40000	.	_

#Text=Higher numbers represent lower SES, based on the Hollingshead 2-factor index of SES.
191-1	40001-40007	Higher	_
191-2	40008-40015	numbers	_
191-3	40016-40025	represent	_
191-4	40026-40031	lower	_
191-5	40032-40035	SES	_
191-6	40035-40036	,	_
191-7	40037-40042	based	_
191-8	40043-40045	on	_
191-9	40046-40049	the	_
191-10	40050-40062	Hollingshead	_
191-11	40063-40064	2	_
191-12	40064-40065	-	_
191-13	40065-40071	factor	_
191-14	40072-40077	index	_
191-15	40078-40080	of	_
191-16	40081-40084	SES	_
191-17	40084-40085	.	_

#Text=The FESZ group showed a significantly lower SES than the HC group in Tukey Honestly Significant Difference [HSD] test, P = 0.004.
192-1	40086-40089	The	_
192-2	40090-40094	FESZ	_
192-3	40095-40100	group	_
192-4	40101-40107	showed	_
192-5	40108-40109	a	_
192-6	40110-40123	significantly	_
192-7	40124-40129	lower	_
192-8	40130-40133	SES	_
192-9	40134-40138	than	_
192-10	40139-40142	the	_
192-11	40143-40145	HC	_
192-12	40146-40151	group	_
192-13	40152-40154	in	_
192-14	40155-40160	Tukey	_
192-15	40161-40169	Honestly	_
192-16	40170-40181	Significant	_
192-17	40182-40192	Difference	_
192-18	40193-40194	[	_
192-19	40194-40197	HSD	_
192-20	40197-40198	]	_
192-21	40199-40203	test	_
192-22	40203-40204	,	_
192-23	40205-40206	P	_
192-24	40207-40208	=	_
192-25	40209-40214	0.004	_
192-26	40214-40215	.	_

#Text=The FESZ (P = 0.022) group showed significantly fewer years of education than the HC group in Tukey HSD tests.
193-1	40216-40219	The	_
193-2	40220-40224	FESZ	_
193-3	40225-40226	(	_
193-4	40226-40227	P	_
193-5	40228-40229	=	_
193-6	40230-40235	0.022	_
193-7	40235-40236	)	_
193-8	40237-40242	group	_
193-9	40243-40249	showed	_
193-10	40250-40263	significantly	_
193-11	40264-40269	fewer	_
193-12	40270-40275	years	_
193-13	40276-40278	of	_
193-14	40279-40288	education	_
193-15	40289-40293	than	_
193-16	40294-40297	the	_
193-17	40298-40300	HC	_
193-18	40301-40306	group	_
193-19	40307-40309	in	_
193-20	40310-40315	Tukey	_
193-21	40316-40319	HSD	_
193-22	40320-40325	tests	_
193-23	40325-40326	.	_

#Text=The FESZ (P = 0.041) group showed significantly lower score than the FEAFF group in Tukey HSD tests.
194-1	40327-40330	The	_
194-2	40331-40335	FESZ	_
194-3	40336-40337	(	_
194-4	40337-40338	P	_
194-5	40339-40340	=	_
194-6	40341-40346	0.041	_
194-7	40346-40347	)	_
194-8	40348-40353	group	_
194-9	40354-40360	showed	_
194-10	40361-40374	significantly	_
194-11	40375-40380	lower	_
194-12	40381-40386	score	_
194-13	40387-40391	than	_
194-14	40392-40395	the	_
194-15	40396-40401	FEAFF	_
194-16	40402-40407	group	_
194-17	40408-40410	in	_
194-18	40411-40416	Tukey	_
194-19	40417-40420	HSD	_
194-20	40421-40426	tests	_
194-21	40426-40427	.	_

#Text=The FESZ (P = 0.003) group showed significantly lower score than the FEAFF group, and the FESZ (P = 0.022) group also showed significantly lower score than the HC group in Tukey HSD tests.
195-1	40428-40431	The	_
195-2	40432-40436	FESZ	_
195-3	40437-40438	(	_
195-4	40438-40439	P	_
195-5	40440-40441	=	_
195-6	40442-40447	0.003	_
195-7	40447-40448	)	_
195-8	40449-40454	group	_
195-9	40455-40461	showed	_
195-10	40462-40475	significantly	_
195-11	40476-40481	lower	_
195-12	40482-40487	score	_
195-13	40488-40492	than	_
195-14	40493-40496	the	_
195-15	40497-40502	FEAFF	_
195-16	40503-40508	group	_
195-17	40508-40509	,	_
195-18	40510-40513	and	_
195-19	40514-40517	the	_
195-20	40518-40522	FESZ	_
195-21	40523-40524	(	_
195-22	40524-40525	P	_
195-23	40526-40527	=	_
195-24	40528-40533	0.022	_
195-25	40533-40534	)	_
195-26	40535-40540	group	_
195-27	40541-40545	also	_
195-28	40546-40552	showed	_
195-29	40553-40566	significantly	_
195-30	40567-40572	lower	_
195-31	40573-40578	score	_
195-32	40579-40583	than	_
195-33	40584-40587	the	_
195-34	40588-40590	HC	_
195-35	40591-40596	group	_
195-36	40597-40599	in	_
195-37	40600-40605	Tukey	_
195-38	40606-40609	HSD	_
195-39	40610-40615	tests	_
195-40	40615-40616	.	_

#Text=The t tests were performed between 2 groups.
196-1	40617-40620	The	_
196-2	40621-40622	t	_
196-3	40623-40628	tests	_
196-4	40629-40633	were	_
196-5	40634-40643	performed	_
196-6	40644-40651	between	_
196-7	40652-40653	2	_
196-8	40654-40660	groups	_
196-9	40660-40661	.	_

#Text=Before magnetic resonance imaging scanning, one patient with FESZ and none with FEAFF was neuroleptic naive.
197-1	40662-40668	Before	_
197-2	40669-40677	magnetic	_
197-3	40678-40687	resonance	_
197-4	40688-40695	imaging	_
197-5	40696-40704	scanning	_
197-6	40704-40705	,	_
197-7	40706-40709	one	_
197-8	40710-40717	patient	_
197-9	40718-40722	with	_
197-10	40723-40727	FESZ	_
197-11	40728-40731	and	_
197-12	40732-40736	none	_
197-13	40737-40741	with	_
197-14	40742-40747	FEAFF	_
197-15	40748-40751	was	_
197-16	40752-40763	neuroleptic	_
197-17	40764-40769	naive	_
197-18	40769-40770	.	_

#Text=Duration of neuroleptic therapy was less than 4 weeks in 17 patients with FESZ (including typical neuroleptics (TYP) in 7, atypical neuroleptics (ATYP) in 12, and both in 2) and 19 patients with FEAFF (including TYP in 7, ATYP in 13, and both in 1) and 4 to 15 weeks in 1 patient with FESZ (including TYP in 1, ATYP in 1, and both in 1) and 1 patient with FEAFF (including TYP in none, ATYP in 1).
198-1	40771-40779	Duration	_
198-2	40780-40782	of	_
198-3	40783-40794	neuroleptic	_
198-4	40795-40802	therapy	_
198-5	40803-40806	was	_
198-6	40807-40811	less	_
198-7	40812-40816	than	_
198-8	40817-40818	4	_
198-9	40819-40824	weeks	_
198-10	40825-40827	in	_
198-11	40828-40830	17	_
198-12	40831-40839	patients	_
198-13	40840-40844	with	_
198-14	40845-40849	FESZ	_
198-15	40850-40851	(	_
198-16	40851-40860	including	_
198-17	40861-40868	typical	_
198-18	40869-40881	neuroleptics	_
198-19	40882-40883	(	_
198-20	40883-40886	TYP	_
198-21	40886-40887	)	_
198-22	40888-40890	in	_
198-23	40891-40892	7	_
198-24	40892-40893	,	_
198-25	40894-40902	atypical	_
198-26	40903-40915	neuroleptics	_
198-27	40916-40917	(	_
198-28	40917-40921	ATYP	_
198-29	40921-40922	)	_
198-30	40923-40925	in	_
198-31	40926-40928	12	_
198-32	40928-40929	,	_
198-33	40930-40933	and	_
198-34	40934-40938	both	_
198-35	40939-40941	in	_
198-36	40942-40943	2	_
198-37	40943-40944	)	_
198-38	40945-40948	and	_
198-39	40949-40951	19	_
198-40	40952-40960	patients	_
198-41	40961-40965	with	_
198-42	40966-40971	FEAFF	_
198-43	40972-40973	(	_
198-44	40973-40982	including	_
198-45	40983-40986	TYP	_
198-46	40987-40989	in	_
198-47	40990-40991	7	_
198-48	40991-40992	,	_
198-49	40993-40997	ATYP	_
198-50	40998-41000	in	_
198-51	41001-41003	13	_
198-52	41003-41004	,	_
198-53	41005-41008	and	_
198-54	41009-41013	both	_
198-55	41014-41016	in	_
198-56	41017-41018	1	_
198-57	41018-41019	)	_
198-58	41020-41023	and	_
198-59	41024-41025	4	_
198-60	41026-41028	to	_
198-61	41029-41031	15	_
198-62	41032-41037	weeks	_
198-63	41038-41040	in	_
198-64	41041-41042	1	_
198-65	41043-41050	patient	_
198-66	41051-41055	with	_
198-67	41056-41060	FESZ	_
198-68	41061-41062	(	_
198-69	41062-41071	including	_
198-70	41072-41075	TYP	_
198-71	41076-41078	in	_
198-72	41079-41080	1	_
198-73	41080-41081	,	_
198-74	41082-41086	ATYP	_
198-75	41087-41089	in	_
198-76	41090-41091	1	_
198-77	41091-41092	,	_
198-78	41093-41096	and	_
198-79	41097-41101	both	_
198-80	41102-41104	in	_
198-81	41105-41106	1	_
198-82	41106-41107	)	_
198-83	41108-41111	and	_
198-84	41112-41113	1	_
198-85	41114-41121	patient	_
198-86	41122-41126	with	_
198-87	41127-41132	FEAFF	_
198-88	41133-41134	(	_
198-89	41134-41143	including	_
198-90	41144-41147	TYP	_
198-91	41148-41150	in	_
198-92	41151-41155	none	_
198-93	41155-41156	,	_
198-94	41157-41161	ATYP	_
198-95	41162-41164	in	_
198-96	41165-41166	1	_
198-97	41166-41167	)	_
198-98	41167-41168	.	_

#Text=For mood stabilizers (MS), including lithium carbonate and valproic acid, 4of 21 patients with FESZ (19.0%) and 11 of 24 with FEAFF (45.8%) were treated at their first-episode hospitalization.
199-1	41169-41172	For	_
199-2	41173-41177	mood	_
199-3	41178-41189	stabilizers	_
199-4	41190-41191	(	_
199-5	41191-41193	MS	_
199-6	41193-41194	)	_
199-7	41194-41195	,	_
199-8	41196-41205	including	_
199-9	41206-41213	lithium	_
199-10	41214-41223	carbonate	_
199-11	41224-41227	and	_
199-12	41228-41236	valproic	_
199-13	41237-41241	acid	_
199-14	41241-41242	,	_
199-15	41243-41246	4of	_
199-16	41247-41249	21	_
199-17	41250-41258	patients	_
199-18	41259-41263	with	_
199-19	41264-41268	FESZ	_
199-20	41269-41270	(	_
199-21	41270-41275	19.0%	_
199-22	41275-41276	)	_
199-23	41277-41280	and	_
199-24	41281-41283	11	_
199-25	41284-41286	of	_
199-26	41287-41289	24	_
199-27	41290-41294	with	_
199-28	41295-41300	FEAFF	_
199-29	41301-41302	(	_
199-30	41302-41307	45.8%	_
199-31	41307-41308	)	_
199-32	41309-41313	were	_
199-33	41314-41321	treated	_
199-34	41322-41324	at	_
199-35	41325-41330	their	_
199-36	41331-41344	first-episode	_
199-37	41345-41360	hospitalization	_
199-38	41360-41361	.	_

#Text=None of these MS-treated patients with FESZ and FEAFF received MS for more than 4 weeks before the magnetic resonance imaging.
200-1	41362-41366	None	_
200-2	41367-41369	of	_
200-3	41370-41375	these	_
200-4	41376-41386	MS-treated	_
200-5	41387-41395	patients	_
200-6	41396-41400	with	_
200-7	41401-41405	FESZ	_
200-8	41406-41409	and	_
200-9	41410-41415	FEAFF	_
200-10	41416-41424	received	_
200-11	41425-41427	MS	_
200-12	41428-41431	for	_
200-13	41432-41436	more	_
200-14	41437-41441	than	_
200-15	41442-41443	4	_
200-16	41444-41449	weeks	_
200-17	41450-41456	before	_
200-18	41457-41460	the	_
200-19	41461-41469	magnetic	_
200-20	41470-41479	resonance	_
200-21	41480-41487	imaging	_
200-22	41487-41488	.	_

#Text=Indicates lithium carbonate.
201-1	41489-41498	Indicates	_
201-2	41499-41506	lithium	_
201-3	41507-41516	carbonate	_
201-4	41516-41517	.	_

#Text=Relative Volumes of Prefrontal Cortex Gray Matter at Baseline (Time 1) and 1.5 Year later (Time 2) and Percentage of Change in the FESZ, FEAFF, and HC Groups.
202-1	41518-41526	Relative	_
202-2	41527-41534	Volumes	_
202-3	41535-41537	of	_
202-4	41538-41548	Prefrontal	_
202-5	41549-41555	Cortex	_
202-6	41556-41560	Gray	_
202-7	41561-41567	Matter	_
202-8	41568-41570	at	_
202-9	41571-41579	Baseline	_
202-10	41580-41581	(	_
202-11	41581-41585	Time	_
202-12	41586-41587	1	_
202-13	41587-41588	)	_
202-14	41589-41592	and	_
202-15	41593-41596	1.5	_
202-16	41597-41601	Year	_
202-17	41602-41607	later	_
202-18	41608-41609	(	_
202-19	41609-41613	Time	_
202-20	41614-41615	2	_
202-21	41615-41616	)	_
202-22	41617-41620	and	_
202-23	41621-41631	Percentage	_
202-24	41632-41634	of	_
202-25	41635-41641	Change	_
202-26	41642-41644	in	_
202-27	41645-41648	the	_
202-28	41649-41653	FESZ	_
202-29	41653-41654	,	_
202-30	41655-41660	FEAFF	_
202-31	41660-41661	,	_
202-32	41662-41665	and	_
202-33	41666-41668	HC	_
202-34	41669-41675	Groups	_
202-35	41675-41676	.	_

#Text=RegionandVolume\tFESZ Group (n= 21)\tFEAFF Group (n= 24)\tHC Group (n= 23)\tOverall 3-GroupComparison ofPercentage ofChange (1-FactorANOVA byGroup)b\t2-GroupComparison TukeyHSD PostHocTests\t \t\t \tTime1,Mean(SD)\tTime2,Mean(SD)\tChange,%(SED)a\tTime1,Mean(SD)\tTime2,Mean(SD)\tChange,%(SED)a\tTime1,Mean(SD)\tTime2,Mean(SD)\tChange,%(SED)a\t \t\t \tF2,65\tPValue\t \tFP\t \t Left, %\t0.530 (0.088)\t0.526 (0.093)\t−0.892 (3.152)\t0.547 (0.082)\t0.544 (0.083)\t−0.506 (4.247)\t0.548 (0.080)\t0.542 (0.078)\t−0.965 (4.670)\t0.085\t0.919\tFESZ = FEAFF = HC\t \t Right, %\t0.603 (0.109)\t0.595 (0.110)\t−1.333 (2.057)\t0.610 (0.066)\t0.606 (0.072)\t−0.643 (5.662)\t0.605 (0.049)\t0.599 (0.056)\t−1.030 (4.446)\t0.139\t0.870\tFESZ = FEAFF = HC\t \t Left + right, %\t1.132 (0.166)\t1.120 (0.173)\t−2.225 (4.228)\t1.157 (0.133)\t1.149 (0.140)\t−1.149 (8.079)\t1.153 (0.114)\t1.141 (0.121)\t−1.995 (7.899)\t0.148\t0.862\tFESZ = FEAFF = HC\t \tSFG\t \t Left, %\t0.902 (0.138)\t0.852 (0.134)\t−5.636 (2.996)\t0.905 (0.133)\t0.899 (0.133)\t−0.673 (2.688)\t0.960 (0.112)\t0.955 (0.119)\t−0.510 (3.172)\t21.173\t<0.001\tFESZ < FEAFF = HC d\t \t Right, %\t0.869 (0.136)\t0.840 (0.131)\t−3.229 (4.170)\t0.853 (0.124)\t0.846 (0.126)\t−0.873 (4.304)\t0.941 (0.153)\t0.933 (0.144)\t−0.637 (2.614)\t3.141\t0.050\tFESZ = FEAFF = HC\t \t Left + right, %\t1.771 (0.262)\t1.692 (0.253)\t−8.865 (4.521)\t1.759 (0.234)\t1.745 (0.235)\t−1.546 (5.570)\t1.901 (0.234)\t1.889 (0.227)\t−1.147 (4.584)\t16.849\t<0.001\tFESZ < FEAFF = HC c\t \tMFG\t \t Left, %\t0.792 (0.149)\t0.734 (0.131)\t−7.159 (3.776)\t0.811 (0.120)\t0.807 (0.123)\t−0.616 (3.095)\t0.844 (0.112)\t0.840 (0.110)\t−0.365 (1.980)\t35.458\t<0.001\tFESZ < FEAFF = HC f\t \t Right, %\t0.784 (0.120)\t0.728 (0.120)\t−7.309 (3.615)\t0.802 (0.119)\t0.796 (0.119)\t−0.737 (4.259)\t0.838 (0.185)\t0.833 (0.180)\t−0.479 (2.920)\t24.466\t<0.001\tFESZ < FEAFF = HC g\t \t Left + right, %\t1.577 (0.247)\t1.462 (0.231)\t−14.468 (6.535)\t1.614 (0.214)\t1.602 (0.216)\t−1.354 (6.145)\t1.682 (0.276)\t1.673 (0.266)\t−0.844 (3.973)\t40.745\t<0.001\tFESZ < FEAFF = HC e\t \tIFG\t \t Left, %\t0.554 (0.098)\t0.508 (0.087)\t−8.073 (4.220)\t0.514 (0.088)\t0.501 (0.095)\t−2.787 (4.619)\t0.551 (0.124)\t0.548 (0.123)\t−0.450 (1.654)\t23.789\t<0.001\tFESZ < FEAFF = HC i\t \t Right, %\t0.596 (0.127)\t0.546 (0.115)\t−8.379 (4.084)\t0.551 (0.126)\t0.546 (0.122)\t−0.619 (6.520)\t0.609 (0.116)\t0.607 (0.119)\t−0.457 (2.896)\t19.391\t<0.001\tFESZ < FEAFF = HC j\t \t Left + right, %\t1.150 (0.201)\t1.054 (0.180)\t−16.452 (7.549)\t1.065 (0.178)\t1.047 (0.177)\t−3.407 (9.722)\t1.160 (0.206)\t1.155 (0.207)\t−0.907 (3.179)\t27.834\t<0.001\tFESZ < FEAFF = HC h\t \t
#Text=Abbreviations: FP: frontal pole; SFG: superior frontal gyrus; MFG: middle frontal gyrus; IFG: inferior frontal gyrus; ANOVA, analysis of variance; FEAFF, first-episode affective psychosis; FESZ, first-episode schizophrenia; HCs, healthy control subjects; HSD, Honestly Significant Difference; ICC, intracranial contents; SED, standard error of the difference.
203-1	41677-41692	RegionandVolume	_
203-2	41693-41697	FESZ	_
203-3	41698-41703	Group	_
203-4	41704-41705	(	_
203-5	41705-41706	n	_
203-6	41706-41707	=	_
203-7	41708-41710	21	_
203-8	41710-41711	)	_
203-9	41712-41717	FEAFF	_
203-10	41718-41723	Group	_
203-11	41724-41725	(	_
203-12	41725-41726	n	_
203-13	41726-41727	=	_
203-14	41728-41730	24	_
203-15	41730-41731	)	_
203-16	41732-41734	HC	_
203-17	41735-41740	Group	_
203-18	41741-41742	(	_
203-19	41742-41743	n	_
203-20	41743-41744	=	_
203-21	41745-41747	23	_
203-22	41747-41748	)	_
203-23	41749-41756	Overall	_
203-24	41757-41758	3	_
203-25	41758-41759	-	_
203-26	41759-41774	GroupComparison	_
203-27	41775-41787	ofPercentage	_
203-28	41788-41796	ofChange	_
203-29	41797-41798	(	_
203-30	41798-41799	1	_
203-31	41799-41800	-	_
203-32	41800-41811	FactorANOVA	_
203-33	41812-41819	byGroup	_
203-34	41819-41820	)	_
203-35	41820-41821	b	_
203-36	41822-41823	2	_
203-37	41823-41824	-	_
203-38	41824-41839	GroupComparison	_
203-39	41840-41848	TukeyHSD	_
203-40	41849-41861	PostHocTests	_
203-41	41867-41872	Time1	_
203-42	41872-41873	,	_
203-43	41873-41877	Mean	_
203-44	41877-41878	(	_
203-45	41878-41880	SD	_
203-46	41880-41881	)	_
203-47	41882-41887	Time2	_
203-48	41887-41888	,	_
203-49	41888-41892	Mean	_
203-50	41892-41893	(	_
203-51	41893-41895	SD	_
203-52	41895-41896	)	_
203-53	41897-41903	Change	_
203-54	41903-41904	,	_
203-55	41904-41905	%	_
203-56	41905-41906	(	_
203-57	41906-41909	SED	_
203-58	41909-41910	)	_
203-59	41910-41911	a	_
203-60	41912-41917	Time1	_
203-61	41917-41918	,	_
203-62	41918-41922	Mean	_
203-63	41922-41923	(	_
203-64	41923-41925	SD	_
203-65	41925-41926	)	_
203-66	41927-41932	Time2	_
203-67	41932-41933	,	_
203-68	41933-41937	Mean	_
203-69	41937-41938	(	_
203-70	41938-41940	SD	_
203-71	41940-41941	)	_
203-72	41942-41948	Change	_
203-73	41948-41949	,	_
203-74	41949-41950	%	_
203-75	41950-41951	(	_
203-76	41951-41954	SED	_
203-77	41954-41955	)	_
203-78	41955-41956	a	_
203-79	41957-41962	Time1	_
203-80	41962-41963	,	_
203-81	41963-41967	Mean	_
203-82	41967-41968	(	_
203-83	41968-41970	SD	_
203-84	41970-41971	)	_
203-85	41972-41977	Time2	_
203-86	41977-41978	,	_
203-87	41978-41982	Mean	_
203-88	41982-41983	(	_
203-89	41983-41985	SD	_
203-90	41985-41986	)	_
203-91	41987-41993	Change	_
203-92	41993-41994	,	_
203-93	41994-41995	%	_
203-94	41995-41996	(	_
203-95	41996-41999	SED	_
203-96	41999-42000	)	_
203-97	42000-42001	a	_
203-98	42007-42012	F2,65	_
203-99	42013-42019	PValue	_
203-100	42022-42024	FP	_
203-101	42028-42032	Left	_
203-102	42032-42033	,	_
203-103	42034-42035	%	_
203-104	42036-42041	0.530	_
203-105	42042-42043	(	_
203-106	42043-42048	0.088	_
203-107	42048-42049	)	_
203-108	42050-42055	0.526	_
203-109	42056-42057	(	_
203-110	42057-42062	0.093	_
203-111	42062-42063	)	_
203-112	42064-42065	−	_
203-113	42065-42070	0.892	_
203-114	42071-42072	(	_
203-115	42072-42077	3.152	_
203-116	42077-42078	)	_
203-117	42079-42084	0.547	_
203-118	42085-42086	(	_
203-119	42086-42091	0.082	_
203-120	42091-42092	)	_
203-121	42093-42098	0.544	_
203-122	42099-42100	(	_
203-123	42100-42105	0.083	_
203-124	42105-42106	)	_
203-125	42107-42108	−	_
203-126	42108-42113	0.506	_
203-127	42114-42115	(	_
203-128	42115-42120	4.247	_
203-129	42120-42121	)	_
203-130	42122-42127	0.548	_
203-131	42128-42129	(	_
203-132	42129-42134	0.080	_
203-133	42134-42135	)	_
203-134	42136-42141	0.542	_
203-135	42142-42143	(	_
203-136	42143-42148	0.078	_
203-137	42148-42149	)	_
203-138	42150-42151	−	_
203-139	42151-42156	0.965	_
203-140	42157-42158	(	_
203-141	42158-42163	4.670	_
203-142	42163-42164	)	_
203-143	42165-42170	0.085	_
203-144	42171-42176	0.919	_
203-145	42177-42181	FESZ	_
203-146	42182-42183	=	_
203-147	42184-42189	FEAFF	_
203-148	42190-42191	=	_
203-149	42192-42194	HC	_
203-150	42198-42203	Right	_
203-151	42203-42204	,	_
203-152	42205-42206	%	_
203-153	42207-42212	0.603	_
203-154	42213-42214	(	_
203-155	42214-42219	0.109	_
203-156	42219-42220	)	_
203-157	42221-42226	0.595	_
203-158	42227-42228	(	_
203-159	42228-42233	0.110	_
203-160	42233-42234	)	_
203-161	42235-42236	−	_
203-162	42236-42241	1.333	_
203-163	42242-42243	(	_
203-164	42243-42248	2.057	_
203-165	42248-42249	)	_
203-166	42250-42255	0.610	_
203-167	42256-42257	(	_
203-168	42257-42262	0.066	_
203-169	42262-42263	)	_
203-170	42264-42269	0.606	_
203-171	42270-42271	(	_
203-172	42271-42276	0.072	_
203-173	42276-42277	)	_
203-174	42278-42279	−	_
203-175	42279-42284	0.643	_
203-176	42285-42286	(	_
203-177	42286-42291	5.662	_
203-178	42291-42292	)	_
203-179	42293-42298	0.605	_
203-180	42299-42300	(	_
203-181	42300-42305	0.049	_
203-182	42305-42306	)	_
203-183	42307-42312	0.599	_
203-184	42313-42314	(	_
203-185	42314-42319	0.056	_
203-186	42319-42320	)	_
203-187	42321-42322	−	_
203-188	42322-42327	1.030	_
203-189	42328-42329	(	_
203-190	42329-42334	4.446	_
203-191	42334-42335	)	_
203-192	42336-42341	0.139	_
203-193	42342-42347	0.870	_
203-194	42348-42352	FESZ	_
203-195	42353-42354	=	_
203-196	42355-42360	FEAFF	_
203-197	42361-42362	=	_
203-198	42363-42365	HC	_
203-199	42369-42373	Left	_
203-200	42374-42375	+	_
203-201	42376-42381	right	_
203-202	42381-42382	,	_
203-203	42383-42384	%	_
203-204	42385-42390	1.132	_
203-205	42391-42392	(	_
203-206	42392-42397	0.166	_
203-207	42397-42398	)	_
203-208	42399-42404	1.120	_
203-209	42405-42406	(	_
203-210	42406-42411	0.173	_
203-211	42411-42412	)	_
203-212	42413-42414	−	_
203-213	42414-42419	2.225	_
203-214	42420-42421	(	_
203-215	42421-42426	4.228	_
203-216	42426-42427	)	_
203-217	42428-42433	1.157	_
203-218	42434-42435	(	_
203-219	42435-42440	0.133	_
203-220	42440-42441	)	_
203-221	42442-42447	1.149	_
203-222	42448-42449	(	_
203-223	42449-42454	0.140	_
203-224	42454-42455	)	_
203-225	42456-42457	−	_
203-226	42457-42462	1.149	_
203-227	42463-42464	(	_
203-228	42464-42469	8.079	_
203-229	42469-42470	)	_
203-230	42471-42476	1.153	_
203-231	42477-42478	(	_
203-232	42478-42483	0.114	_
203-233	42483-42484	)	_
203-234	42485-42490	1.141	_
203-235	42491-42492	(	_
203-236	42492-42497	0.121	_
203-237	42497-42498	)	_
203-238	42499-42500	−	_
203-239	42500-42505	1.995	_
203-240	42506-42507	(	_
203-241	42507-42512	7.899	_
203-242	42512-42513	)	_
203-243	42514-42519	0.148	_
203-244	42520-42525	0.862	_
203-245	42526-42530	FESZ	_
203-246	42531-42532	=	_
203-247	42533-42538	FEAFF	_
203-248	42539-42540	=	_
203-249	42541-42543	HC	_
203-250	42546-42549	SFG	_
203-251	42553-42557	Left	_
203-252	42557-42558	,	_
203-253	42559-42560	%	_
203-254	42561-42566	0.902	_
203-255	42567-42568	(	_
203-256	42568-42573	0.138	_
203-257	42573-42574	)	_
203-258	42575-42580	0.852	_
203-259	42581-42582	(	_
203-260	42582-42587	0.134	_
203-261	42587-42588	)	_
203-262	42589-42590	−	_
203-263	42590-42595	5.636	_
203-264	42596-42597	(	_
203-265	42597-42602	2.996	_
203-266	42602-42603	)	_
203-267	42604-42609	0.905	_
203-268	42610-42611	(	_
203-269	42611-42616	0.133	_
203-270	42616-42617	)	_
203-271	42618-42623	0.899	_
203-272	42624-42625	(	_
203-273	42625-42630	0.133	_
203-274	42630-42631	)	_
203-275	42632-42633	−	_
203-276	42633-42638	0.673	_
203-277	42639-42640	(	_
203-278	42640-42645	2.688	_
203-279	42645-42646	)	_
203-280	42647-42652	0.960	_
203-281	42653-42654	(	_
203-282	42654-42659	0.112	_
203-283	42659-42660	)	_
203-284	42661-42666	0.955	_
203-285	42667-42668	(	_
203-286	42668-42673	0.119	_
203-287	42673-42674	)	_
203-288	42675-42676	−	_
203-289	42676-42681	0.510	_
203-290	42682-42683	(	_
203-291	42683-42688	3.172	_
203-292	42688-42689	)	_
203-293	42690-42696	21.173	_
203-294	42697-42698	<	_
203-295	42698-42703	0.001	_
203-296	42704-42708	FESZ	_
203-297	42709-42710	<	_
203-298	42711-42716	FEAFF	_
203-299	42717-42718	=	_
203-300	42719-42721	HC	_
203-301	42722-42723	d	_
203-302	42727-42732	Right	_
203-303	42732-42733	,	_
203-304	42734-42735	%	_
203-305	42736-42741	0.869	_
203-306	42742-42743	(	_
203-307	42743-42748	0.136	_
203-308	42748-42749	)	_
203-309	42750-42755	0.840	_
203-310	42756-42757	(	_
203-311	42757-42762	0.131	_
203-312	42762-42763	)	_
203-313	42764-42765	−	_
203-314	42765-42770	3.229	_
203-315	42771-42772	(	_
203-316	42772-42777	4.170	_
203-317	42777-42778	)	_
203-318	42779-42784	0.853	_
203-319	42785-42786	(	_
203-320	42786-42791	0.124	_
203-321	42791-42792	)	_
203-322	42793-42798	0.846	_
203-323	42799-42800	(	_
203-324	42800-42805	0.126	_
203-325	42805-42806	)	_
203-326	42807-42808	−	_
203-327	42808-42813	0.873	_
203-328	42814-42815	(	_
203-329	42815-42820	4.304	_
203-330	42820-42821	)	_
203-331	42822-42827	0.941	_
203-332	42828-42829	(	_
203-333	42829-42834	0.153	_
203-334	42834-42835	)	_
203-335	42836-42841	0.933	_
203-336	42842-42843	(	_
203-337	42843-42848	0.144	_
203-338	42848-42849	)	_
203-339	42850-42851	−	_
203-340	42851-42856	0.637	_
203-341	42857-42858	(	_
203-342	42858-42863	2.614	_
203-343	42863-42864	)	_
203-344	42865-42870	3.141	_
203-345	42871-42876	0.050	_
203-346	42877-42881	FESZ	_
203-347	42882-42883	=	_
203-348	42884-42889	FEAFF	_
203-349	42890-42891	=	_
203-350	42892-42894	HC	_
203-351	42898-42902	Left	_
203-352	42903-42904	+	_
203-353	42905-42910	right	_
203-354	42910-42911	,	_
203-355	42912-42913	%	_
203-356	42914-42919	1.771	_
203-357	42920-42921	(	_
203-358	42921-42926	0.262	_
203-359	42926-42927	)	_
203-360	42928-42933	1.692	_
203-361	42934-42935	(	_
203-362	42935-42940	0.253	_
203-363	42940-42941	)	_
203-364	42942-42943	−	_
203-365	42943-42948	8.865	_
203-366	42949-42950	(	_
203-367	42950-42955	4.521	_
203-368	42955-42956	)	_
203-369	42957-42962	1.759	_
203-370	42963-42964	(	_
203-371	42964-42969	0.234	_
203-372	42969-42970	)	_
203-373	42971-42976	1.745	_
203-374	42977-42978	(	_
203-375	42978-42983	0.235	_
203-376	42983-42984	)	_
203-377	42985-42986	−	_
203-378	42986-42991	1.546	_
203-379	42992-42993	(	_
203-380	42993-42998	5.570	_
203-381	42998-42999	)	_
203-382	43000-43005	1.901	_
203-383	43006-43007	(	_
203-384	43007-43012	0.234	_
203-385	43012-43013	)	_
203-386	43014-43019	1.889	_
203-387	43020-43021	(	_
203-388	43021-43026	0.227	_
203-389	43026-43027	)	_
203-390	43028-43029	−	_
203-391	43029-43034	1.147	_
203-392	43035-43036	(	_
203-393	43036-43041	4.584	_
203-394	43041-43042	)	_
203-395	43043-43049	16.849	_
203-396	43050-43051	<	_
203-397	43051-43056	0.001	_
203-398	43057-43061	FESZ	_
203-399	43062-43063	<	_
203-400	43064-43069	FEAFF	_
203-401	43070-43071	=	_
203-402	43072-43074	HC	_
203-403	43075-43076	c	_
203-404	43079-43082	MFG	_
203-405	43086-43090	Left	_
203-406	43090-43091	,	_
203-407	43092-43093	%	_
203-408	43094-43099	0.792	_
203-409	43100-43101	(	_
203-410	43101-43106	0.149	_
203-411	43106-43107	)	_
203-412	43108-43113	0.734	_
203-413	43114-43115	(	_
203-414	43115-43120	0.131	_
203-415	43120-43121	)	_
203-416	43122-43123	−	_
203-417	43123-43128	7.159	_
203-418	43129-43130	(	_
203-419	43130-43135	3.776	_
203-420	43135-43136	)	_
203-421	43137-43142	0.811	_
203-422	43143-43144	(	_
203-423	43144-43149	0.120	_
203-424	43149-43150	)	_
203-425	43151-43156	0.807	_
203-426	43157-43158	(	_
203-427	43158-43163	0.123	_
203-428	43163-43164	)	_
203-429	43165-43166	−	_
203-430	43166-43171	0.616	_
203-431	43172-43173	(	_
203-432	43173-43178	3.095	_
203-433	43178-43179	)	_
203-434	43180-43185	0.844	_
203-435	43186-43187	(	_
203-436	43187-43192	0.112	_
203-437	43192-43193	)	_
203-438	43194-43199	0.840	_
203-439	43200-43201	(	_
203-440	43201-43206	0.110	_
203-441	43206-43207	)	_
203-442	43208-43209	−	_
203-443	43209-43214	0.365	_
203-444	43215-43216	(	_
203-445	43216-43221	1.980	_
203-446	43221-43222	)	_
203-447	43223-43229	35.458	_
203-448	43230-43231	<	_
203-449	43231-43236	0.001	_
203-450	43237-43241	FESZ	_
203-451	43242-43243	<	_
203-452	43244-43249	FEAFF	_
203-453	43250-43251	=	_
203-454	43252-43254	HC	_
203-455	43255-43256	f	_
203-456	43260-43265	Right	_
203-457	43265-43266	,	_
203-458	43267-43268	%	_
203-459	43269-43274	0.784	_
203-460	43275-43276	(	_
203-461	43276-43281	0.120	_
203-462	43281-43282	)	_
203-463	43283-43288	0.728	_
203-464	43289-43290	(	_
203-465	43290-43295	0.120	_
203-466	43295-43296	)	_
203-467	43297-43298	−	_
203-468	43298-43303	7.309	_
203-469	43304-43305	(	_
203-470	43305-43310	3.615	_
203-471	43310-43311	)	_
203-472	43312-43317	0.802	_
203-473	43318-43319	(	_
203-474	43319-43324	0.119	_
203-475	43324-43325	)	_
203-476	43326-43331	0.796	_
203-477	43332-43333	(	_
203-478	43333-43338	0.119	_
203-479	43338-43339	)	_
203-480	43340-43341	−	_
203-481	43341-43346	0.737	_
203-482	43347-43348	(	_
203-483	43348-43353	4.259	_
203-484	43353-43354	)	_
203-485	43355-43360	0.838	_
203-486	43361-43362	(	_
203-487	43362-43367	0.185	_
203-488	43367-43368	)	_
203-489	43369-43374	0.833	_
203-490	43375-43376	(	_
203-491	43376-43381	0.180	_
203-492	43381-43382	)	_
203-493	43383-43384	−	_
203-494	43384-43389	0.479	_
203-495	43390-43391	(	_
203-496	43391-43396	2.920	_
203-497	43396-43397	)	_
203-498	43398-43404	24.466	_
203-499	43405-43406	<	_
203-500	43406-43411	0.001	_
203-501	43412-43416	FESZ	_
203-502	43417-43418	<	_
203-503	43419-43424	FEAFF	_
203-504	43425-43426	=	_
203-505	43427-43429	HC	_
203-506	43430-43431	g	_
203-507	43435-43439	Left	_
203-508	43440-43441	+	_
203-509	43442-43447	right	_
203-510	43447-43448	,	_
203-511	43449-43450	%	_
203-512	43451-43456	1.577	_
203-513	43457-43458	(	_
203-514	43458-43463	0.247	_
203-515	43463-43464	)	_
203-516	43465-43470	1.462	_
203-517	43471-43472	(	_
203-518	43472-43477	0.231	_
203-519	43477-43478	)	_
203-520	43479-43480	−	_
203-521	43480-43486	14.468	_
203-522	43487-43488	(	_
203-523	43488-43493	6.535	_
203-524	43493-43494	)	_
203-525	43495-43500	1.614	_
203-526	43501-43502	(	_
203-527	43502-43507	0.214	_
203-528	43507-43508	)	_
203-529	43509-43514	1.602	_
203-530	43515-43516	(	_
203-531	43516-43521	0.216	_
203-532	43521-43522	)	_
203-533	43523-43524	−	_
203-534	43524-43529	1.354	_
203-535	43530-43531	(	_
203-536	43531-43536	6.145	_
203-537	43536-43537	)	_
203-538	43538-43543	1.682	_
203-539	43544-43545	(	_
203-540	43545-43550	0.276	_
203-541	43550-43551	)	_
203-542	43552-43557	1.673	_
203-543	43558-43559	(	_
203-544	43559-43564	0.266	_
203-545	43564-43565	)	_
203-546	43566-43567	−	_
203-547	43567-43572	0.844	_
203-548	43573-43574	(	_
203-549	43574-43579	3.973	_
203-550	43579-43580	)	_
203-551	43581-43587	40.745	_
203-552	43588-43589	<	_
203-553	43589-43594	0.001	_
203-554	43595-43599	FESZ	_
203-555	43600-43601	<	_
203-556	43602-43607	FEAFF	_
203-557	43608-43609	=	_
203-558	43610-43612	HC	_
203-559	43613-43614	e	_
203-560	43617-43620	IFG	_
203-561	43624-43628	Left	_
203-562	43628-43629	,	_
203-563	43630-43631	%	_
203-564	43632-43637	0.554	_
203-565	43638-43639	(	_
203-566	43639-43644	0.098	_
203-567	43644-43645	)	_
203-568	43646-43651	0.508	_
203-569	43652-43653	(	_
203-570	43653-43658	0.087	_
203-571	43658-43659	)	_
203-572	43660-43661	−	_
203-573	43661-43666	8.073	_
203-574	43667-43668	(	_
203-575	43668-43673	4.220	_
203-576	43673-43674	)	_
203-577	43675-43680	0.514	_
203-578	43681-43682	(	_
203-579	43682-43687	0.088	_
203-580	43687-43688	)	_
203-581	43689-43694	0.501	_
203-582	43695-43696	(	_
203-583	43696-43701	0.095	_
203-584	43701-43702	)	_
203-585	43703-43704	−	_
203-586	43704-43709	2.787	_
203-587	43710-43711	(	_
203-588	43711-43716	4.619	_
203-589	43716-43717	)	_
203-590	43718-43723	0.551	_
203-591	43724-43725	(	_
203-592	43725-43730	0.124	_
203-593	43730-43731	)	_
203-594	43732-43737	0.548	_
203-595	43738-43739	(	_
203-596	43739-43744	0.123	_
203-597	43744-43745	)	_
203-598	43746-43747	−	_
203-599	43747-43752	0.450	_
203-600	43753-43754	(	_
203-601	43754-43759	1.654	_
203-602	43759-43760	)	_
203-603	43761-43767	23.789	_
203-604	43768-43769	<	_
203-605	43769-43774	0.001	_
203-606	43775-43779	FESZ	_
203-607	43780-43781	<	_
203-608	43782-43787	FEAFF	_
203-609	43788-43789	=	_
203-610	43790-43792	HC	_
203-611	43793-43794	i	_
203-612	43798-43803	Right	_
203-613	43803-43804	,	_
203-614	43805-43806	%	_
203-615	43807-43812	0.596	_
203-616	43813-43814	(	_
203-617	43814-43819	0.127	_
203-618	43819-43820	)	_
203-619	43821-43826	0.546	_
203-620	43827-43828	(	_
203-621	43828-43833	0.115	_
203-622	43833-43834	)	_
203-623	43835-43836	−	_
203-624	43836-43841	8.379	_
203-625	43842-43843	(	_
203-626	43843-43848	4.084	_
203-627	43848-43849	)	_
203-628	43850-43855	0.551	_
203-629	43856-43857	(	_
203-630	43857-43862	0.126	_
203-631	43862-43863	)	_
203-632	43864-43869	0.546	_
203-633	43870-43871	(	_
203-634	43871-43876	0.122	_
203-635	43876-43877	)	_
203-636	43878-43879	−	_
203-637	43879-43884	0.619	_
203-638	43885-43886	(	_
203-639	43886-43891	6.520	_
203-640	43891-43892	)	_
203-641	43893-43898	0.609	_
203-642	43899-43900	(	_
203-643	43900-43905	0.116	_
203-644	43905-43906	)	_
203-645	43907-43912	0.607	_
203-646	43913-43914	(	_
203-647	43914-43919	0.119	_
203-648	43919-43920	)	_
203-649	43921-43922	−	_
203-650	43922-43927	0.457	_
203-651	43928-43929	(	_
203-652	43929-43934	2.896	_
203-653	43934-43935	)	_
203-654	43936-43942	19.391	_
203-655	43943-43944	<	_
203-656	43944-43949	0.001	_
203-657	43950-43954	FESZ	_
203-658	43955-43956	<	_
203-659	43957-43962	FEAFF	_
203-660	43963-43964	=	_
203-661	43965-43967	HC	_
203-662	43968-43969	j	_
203-663	43973-43977	Left	_
203-664	43978-43979	+	_
203-665	43980-43985	right	_
203-666	43985-43986	,	_
203-667	43987-43988	%	_
203-668	43989-43994	1.150	_
203-669	43995-43996	(	_
203-670	43996-44001	0.201	_
203-671	44001-44002	)	_
203-672	44003-44008	1.054	_
203-673	44009-44010	(	_
203-674	44010-44015	0.180	_
203-675	44015-44016	)	_
203-676	44017-44018	−	_
203-677	44018-44024	16.452	_
203-678	44025-44026	(	_
203-679	44026-44031	7.549	_
203-680	44031-44032	)	_
203-681	44033-44038	1.065	_
203-682	44039-44040	(	_
203-683	44040-44045	0.178	_
203-684	44045-44046	)	_
203-685	44047-44052	1.047	_
203-686	44053-44054	(	_
203-687	44054-44059	0.177	_
203-688	44059-44060	)	_
203-689	44061-44062	−	_
203-690	44062-44067	3.407	_
203-691	44068-44069	(	_
203-692	44069-44074	9.722	_
203-693	44074-44075	)	_
203-694	44076-44081	1.160	_
203-695	44082-44083	(	_
203-696	44083-44088	0.206	_
203-697	44088-44089	)	_
203-698	44090-44095	1.155	_
203-699	44096-44097	(	_
203-700	44097-44102	0.207	_
203-701	44102-44103	)	_
203-702	44104-44105	−	_
203-703	44105-44110	0.907	_
203-704	44111-44112	(	_
203-705	44112-44117	3.179	_
203-706	44117-44118	)	_
203-707	44119-44125	27.834	_
203-708	44126-44127	<	_
203-709	44127-44132	0.001	_
203-710	44133-44137	FESZ	_
203-711	44138-44139	<	_
203-712	44140-44145	FEAFF	_
203-713	44146-44147	=	_
203-714	44148-44150	HC	_
203-715	44151-44152	h	_
203-716	44156-44169	Abbreviations	_
203-717	44169-44170	:	_
203-718	44171-44173	FP	_
203-719	44173-44174	:	_
203-720	44175-44182	frontal	_
203-721	44183-44187	pole	_
203-722	44187-44188	;	_
203-723	44189-44192	SFG	_
203-724	44192-44193	:	_
203-725	44194-44202	superior	_
203-726	44203-44210	frontal	_
203-727	44211-44216	gyrus	_
203-728	44216-44217	;	_
203-729	44218-44221	MFG	_
203-730	44221-44222	:	_
203-731	44223-44229	middle	_
203-732	44230-44237	frontal	_
203-733	44238-44243	gyrus	_
203-734	44243-44244	;	_
203-735	44245-44248	IFG	_
203-736	44248-44249	:	_
203-737	44250-44258	inferior	_
203-738	44259-44266	frontal	_
203-739	44267-44272	gyrus	_
203-740	44272-44273	;	_
203-741	44274-44279	ANOVA	_
203-742	44279-44280	,	_
203-743	44281-44289	analysis	_
203-744	44290-44292	of	_
203-745	44293-44301	variance	_
203-746	44301-44302	;	_
203-747	44303-44308	FEAFF	_
203-748	44308-44309	,	_
203-749	44310-44323	first-episode	_
203-750	44324-44333	affective	_
203-751	44334-44343	psychosis	_
203-752	44343-44344	;	_
203-753	44345-44349	FESZ	_
203-754	44349-44350	,	_
203-755	44351-44364	first-episode	_
203-756	44365-44378	schizophrenia	_
203-757	44378-44379	;	_
203-758	44380-44383	HCs	_
203-759	44383-44384	,	_
203-760	44385-44392	healthy	_
203-761	44393-44400	control	_
203-762	44401-44409	subjects	_
203-763	44409-44410	;	_
203-764	44411-44414	HSD	_
203-765	44414-44415	,	_
203-766	44416-44424	Honestly	_
203-767	44425-44436	Significant	_
203-768	44437-44447	Difference	_
203-769	44447-44448	;	_
203-770	44449-44452	ICC	_
203-771	44452-44453	,	_
203-772	44454-44466	intracranial	_
203-773	44467-44475	contents	_
203-774	44475-44476	;	_
203-775	44477-44480	SED	_
203-776	44480-44481	,	_
203-777	44482-44490	standard	_
203-778	44491-44496	error	_
203-779	44497-44499	of	_
203-780	44500-44503	the	_
203-781	44504-44514	difference	_
203-782	44514-44515	.	_

#Text=Percentage of change is calculated as ((volume at second scan–volume at baseline scan) / volume at baseline scan) × 100.
204-1	44516-44526	Percentage	_
204-2	44527-44529	of	_
204-3	44530-44536	change	_
204-4	44537-44539	is	_
204-5	44540-44550	calculated	_
204-6	44551-44553	as	_
204-7	44554-44555	(	_
204-8	44555-44556	(	_
204-9	44556-44562	volume	_
204-10	44563-44565	at	_
204-11	44566-44572	second	_
204-12	44573-44584	scan–volume	_
204-13	44585-44587	at	_
204-14	44588-44596	baseline	_
204-15	44597-44601	scan	_
204-16	44601-44602	)	_
204-17	44603-44604	/	_
204-18	44605-44611	volume	_
204-19	44612-44614	at	_
204-20	44615-44623	baseline	_
204-21	44624-44628	scan	_
204-22	44628-44629	)	_
204-23	44630-44631	×	_
204-24	44632-44635	100	_
204-25	44635-44636	.	_

#Text=Repeated-measures ANOVA of relative volume difference (percentage of change) with group (FESZ, FEAFF, and HC) as the between-subjects factor and hemisphere (left vs right) and region (FP, SFG, MFG, and IFG) as the within-subjects factors revealed a significant main effect for group (F2,65 = 35.832; P < 0.001) and region (F2.882,187.354 = 10.502; P < 0.001).
205-1	44637-44654	Repeated-measures	_
205-2	44655-44660	ANOVA	_
205-3	44661-44663	of	_
205-4	44664-44672	relative	_
205-5	44673-44679	volume	_
205-6	44680-44690	difference	_
205-7	44691-44692	(	_
205-8	44692-44702	percentage	_
205-9	44703-44705	of	_
205-10	44706-44712	change	_
205-11	44712-44713	)	_
205-12	44714-44718	with	_
205-13	44719-44724	group	_
205-14	44725-44726	(	_
205-15	44726-44730	FESZ	_
205-16	44730-44731	,	_
205-17	44732-44737	FEAFF	_
205-18	44737-44738	,	_
205-19	44739-44742	and	_
205-20	44743-44745	HC	_
205-21	44745-44746	)	_
205-22	44747-44749	as	_
205-23	44750-44753	the	_
205-24	44754-44770	between-subjects	_
205-25	44771-44777	factor	_
205-26	44778-44781	and	_
205-27	44782-44792	hemisphere	_
205-28	44793-44794	(	_
205-29	44794-44798	left	_
205-30	44799-44801	vs	_
205-31	44802-44807	right	_
205-32	44807-44808	)	_
205-33	44809-44812	and	_
205-34	44813-44819	region	_
205-35	44820-44821	(	_
205-36	44821-44823	FP	_
205-37	44823-44824	,	_
205-38	44825-44828	SFG	_
205-39	44828-44829	,	_
205-40	44830-44833	MFG	_
205-41	44833-44834	,	_
205-42	44835-44838	and	_
205-43	44839-44842	IFG	_
205-44	44842-44843	)	_
205-45	44844-44846	as	_
205-46	44847-44850	the	_
205-47	44851-44866	within-subjects	_
205-48	44867-44874	factors	_
205-49	44875-44883	revealed	_
205-50	44884-44885	a	_
205-51	44886-44897	significant	_
205-52	44898-44902	main	_
205-53	44903-44909	effect	_
205-54	44910-44913	for	_
205-55	44914-44919	group	_
205-56	44920-44921	(	_
205-57	44921-44926	F2,65	_
205-58	44927-44928	=	_
205-59	44929-44935	35.832	_
205-60	44935-44936	;	_
205-61	44937-44938	P	_
205-62	44939-44940	<	_
205-63	44941-44946	0.001	_
205-64	44946-44947	)	_
205-65	44948-44951	and	_
205-66	44952-44958	region	_
205-67	44959-44960	(	_
205-68	44960-44974	F2.882,187.354	_
205-69	44975-44976	=	_
205-70	44977-44983	10.502	_
205-71	44983-44984	;	_
205-72	44985-44986	P	_
205-73	44987-44988	<	_
205-74	44989-44994	0.001	_
205-75	44994-44995	)	_
205-76	44995-44996	.	_

#Text=There was no significant effect for hemisphere (F1,65 = 0.696; P = 0.407).
206-1	44997-45002	There	_
206-2	45003-45006	was	_
206-3	45007-45009	no	_
206-4	45010-45021	significant	_
206-5	45022-45028	effect	_
206-6	45029-45032	for	_
206-7	45033-45043	hemisphere	_
206-8	45044-45045	(	_
206-9	45045-45050	F1,65	_
206-10	45051-45052	=	_
206-11	45053-45058	0.696	_
206-12	45058-45059	;	_
206-13	45060-45061	P	_
206-14	45062-45063	=	_
206-15	45064-45069	0.407	_
206-16	45069-45070	)	_
206-17	45070-45071	.	_

#Text=There was a significant interaction of region × group (F5.765,187.354 = 9.394; P < 0.001).
207-1	45072-45077	There	_
207-2	45078-45081	was	_
207-3	45082-45083	a	_
207-4	45084-45095	significant	_
207-5	45096-45107	interaction	_
207-6	45108-45110	of	_
207-7	45111-45117	region	_
207-8	45118-45119	×	_
207-9	45120-45125	group	_
207-10	45126-45127	(	_
207-11	45127-45141	F5.765,187.354	_
207-12	45142-45143	=	_
207-13	45144-45149	9.394	_
207-14	45149-45150	;	_
207-15	45151-45152	P	_
207-16	45153-45154	<	_
207-17	45155-45160	0.001	_
207-18	45160-45161	)	_
207-19	45161-45162	.	_

#Text=However, there was no significant interaction of hemisphere × group (F2,65 = 0.312; P = 0.733), region × hemisphere (F3,195 = 0.871; P = 0.457), or region × hemisphere × group (F6,195 = 1.561; P = 0.160) (Hyunh-Feldt ε: 0.961 with region, 1.0 with hemisphere, and 1.0 with region-by-hemisphere).
208-1	45163-45170	However	_
208-2	45170-45171	,	_
208-3	45172-45177	there	_
208-4	45178-45181	was	_
208-5	45182-45184	no	_
208-6	45185-45196	significant	_
208-7	45197-45208	interaction	_
208-8	45209-45211	of	_
208-9	45212-45222	hemisphere	_
208-10	45223-45224	×	_
208-11	45225-45230	group	_
208-12	45231-45232	(	_
208-13	45232-45237	F2,65	_
208-14	45238-45239	=	_
208-15	45240-45245	0.312	_
208-16	45245-45246	;	_
208-17	45247-45248	P	_
208-18	45249-45250	=	_
208-19	45251-45256	0.733	_
208-20	45256-45257	)	_
208-21	45257-45258	,	_
208-22	45259-45265	region	_
208-23	45266-45267	×	_
208-24	45268-45278	hemisphere	_
208-25	45279-45280	(	_
208-26	45280-45286	F3,195	_
208-27	45287-45288	=	_
208-28	45289-45294	0.871	_
208-29	45294-45295	;	_
208-30	45296-45297	P	_
208-31	45298-45299	=	_
208-32	45300-45305	0.457	_
208-33	45305-45306	)	_
208-34	45306-45307	,	_
208-35	45308-45310	or	_
208-36	45311-45317	region	_
208-37	45318-45319	×	_
208-38	45320-45330	hemisphere	_
208-39	45331-45332	×	_
208-40	45333-45338	group	_
208-41	45339-45340	(	_
208-42	45340-45346	F6,195	_
208-43	45347-45348	=	_
208-44	45349-45354	1.561	_
208-45	45354-45355	;	_
208-46	45356-45357	P	_
208-47	45358-45359	=	_
208-48	45360-45365	0.160	_
208-49	45365-45366	)	_
208-50	45367-45368	(	_
208-51	45368-45379	Hyunh-Feldt	_
208-52	45380-45381	ε	_
208-53	45381-45382	:	_
208-54	45383-45388	0.961	_
208-55	45389-45393	with	_
208-56	45394-45400	region	_
208-57	45400-45401	,	_
208-58	45402-45405	1.0	_
208-59	45406-45410	with	_
208-60	45411-45421	hemisphere	_
208-61	45421-45422	,	_
208-62	45423-45426	and	_
208-63	45427-45430	1.0	_
208-64	45431-45435	with	_
208-65	45436-45456	region-by-hemisphere	_
208-66	45456-45457	)	_
208-67	45457-45458	.	_

#Text=Post hoc Tukey HSD tests indicated that entire SFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
209-1	45459-45463	Post	_
209-2	45464-45467	hoc	_
209-3	45468-45473	Tukey	_
209-4	45474-45477	HSD	_
209-5	45478-45483	tests	_
209-6	45484-45493	indicated	_
209-7	45494-45498	that	_
209-8	45499-45505	entire	_
209-9	45506-45509	SFG	_
209-10	45510-45518	relative	_
209-11	45519-45525	volume	_
209-12	45526-45537	percentages	_
209-13	45538-45540	of	_
209-14	45541-45547	change	_
209-15	45548-45550	of	_
209-16	45551-45554	the	_
209-17	45555-45559	FESZ	_
209-18	45560-45565	group	_
209-19	45566-45570	were	_
209-20	45571-45584	significantly	_
209-21	45585-45591	bigger	_
209-22	45592-45596	than	_
209-23	45597-45602	those	_
209-24	45603-45605	of	_
209-25	45606-45609	the	_
209-26	45610-45612	HC	_
209-27	45613-45614	(	_
209-28	45614-45615	P	_
209-29	45616-45617	<	_
209-30	45618-45623	0.001	_
209-31	45623-45624	)	_
209-32	45625-45628	and	_
209-33	45629-45634	FEAFF	_
209-34	45635-45636	(	_
209-35	45636-45637	P	_
209-36	45638-45639	<	_
209-37	45640-45645	0.001	_
209-38	45645-45646	)	_
209-39	45647-45653	groups	_
209-40	45653-45654	.	_

#Text=Post hoc Tukey HSD tests indicated that left SFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
210-1	45655-45659	Post	_
210-2	45660-45663	hoc	_
210-3	45664-45669	Tukey	_
210-4	45670-45673	HSD	_
210-5	45674-45679	tests	_
210-6	45680-45689	indicated	_
210-7	45690-45694	that	_
210-8	45695-45699	left	_
210-9	45700-45703	SFG	_
210-10	45704-45712	relative	_
210-11	45713-45719	volume	_
210-12	45720-45731	percentages	_
210-13	45732-45734	of	_
210-14	45735-45741	change	_
210-15	45742-45744	of	_
210-16	45745-45748	the	_
210-17	45749-45753	FESZ	_
210-18	45754-45759	group	_
210-19	45760-45764	were	_
210-20	45765-45778	significantly	_
210-21	45779-45785	bigger	_
210-22	45786-45790	than	_
210-23	45791-45796	those	_
210-24	45797-45799	of	_
210-25	45800-45803	the	_
210-26	45804-45806	HC	_
210-27	45807-45808	(	_
210-28	45808-45809	P	_
210-29	45810-45811	<	_
210-30	45812-45817	0.001	_
210-31	45817-45818	)	_
210-32	45819-45822	and	_
210-33	45823-45828	FEAFF	_
210-34	45829-45830	(	_
210-35	45830-45831	P	_
210-36	45832-45833	<	_
210-37	45834-45839	0.001	_
210-38	45839-45840	)	_
210-39	45841-45847	groups	_
210-40	45847-45848	.	_

#Text=Post hoc Tukey HSD tests indicated that entire MFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
211-1	45849-45853	Post	_
211-2	45854-45857	hoc	_
211-3	45858-45863	Tukey	_
211-4	45864-45867	HSD	_
211-5	45868-45873	tests	_
211-6	45874-45883	indicated	_
211-7	45884-45888	that	_
211-8	45889-45895	entire	_
211-9	45896-45899	MFG	_
211-10	45900-45908	relative	_
211-11	45909-45915	volume	_
211-12	45916-45927	percentages	_
211-13	45928-45930	of	_
211-14	45931-45937	change	_
211-15	45938-45940	of	_
211-16	45941-45944	the	_
211-17	45945-45949	FESZ	_
211-18	45950-45955	group	_
211-19	45956-45960	were	_
211-20	45961-45974	significantly	_
211-21	45975-45981	bigger	_
211-22	45982-45986	than	_
211-23	45987-45992	those	_
211-24	45993-45995	of	_
211-25	45996-45999	the	_
211-26	46000-46002	HC	_
211-27	46003-46004	(	_
211-28	46004-46005	P	_
211-29	46006-46007	<	_
211-30	46008-46013	0.001	_
211-31	46013-46014	)	_
211-32	46015-46018	and	_
211-33	46019-46024	FEAFF	_
211-34	46025-46026	(	_
211-35	46026-46027	P	_
211-36	46028-46029	<	_
211-37	46030-46035	0.001	_
211-38	46035-46036	)	_
211-39	46037-46043	groups	_
211-40	46043-46044	.	_

#Text=Post hoc Tukey HSD tests indicated that left MFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
212-1	46045-46049	Post	_
212-2	46050-46053	hoc	_
212-3	46054-46059	Tukey	_
212-4	46060-46063	HSD	_
212-5	46064-46069	tests	_
212-6	46070-46079	indicated	_
212-7	46080-46084	that	_
212-8	46085-46089	left	_
212-9	46090-46093	MFG	_
212-10	46094-46102	relative	_
212-11	46103-46109	volume	_
212-12	46110-46121	percentages	_
212-13	46122-46124	of	_
212-14	46125-46131	change	_
212-15	46132-46134	of	_
212-16	46135-46138	the	_
212-17	46139-46143	FESZ	_
212-18	46144-46149	group	_
212-19	46150-46154	were	_
212-20	46155-46168	significantly	_
212-21	46169-46175	bigger	_
212-22	46176-46180	than	_
212-23	46181-46186	those	_
212-24	46187-46189	of	_
212-25	46190-46193	the	_
212-26	46194-46196	HC	_
212-27	46197-46198	(	_
212-28	46198-46199	P	_
212-29	46200-46201	<	_
212-30	46202-46207	0.001	_
212-31	46207-46208	)	_
212-32	46209-46212	and	_
212-33	46213-46218	FEAFF	_
212-34	46219-46220	(	_
212-35	46220-46221	P	_
212-36	46222-46223	<	_
212-37	46224-46229	0.001	_
212-38	46229-46230	)	_
212-39	46231-46237	groups	_
212-40	46237-46238	.	_

#Text=Post hoc Tukey HSD tests indicated that right MFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
213-1	46239-46243	Post	_
213-2	46244-46247	hoc	_
213-3	46248-46253	Tukey	_
213-4	46254-46257	HSD	_
213-5	46258-46263	tests	_
213-6	46264-46273	indicated	_
213-7	46274-46278	that	_
213-8	46279-46284	right	_
213-9	46285-46288	MFG	_
213-10	46289-46297	relative	_
213-11	46298-46304	volume	_
213-12	46305-46316	percentages	_
213-13	46317-46319	of	_
213-14	46320-46326	change	_
213-15	46327-46329	of	_
213-16	46330-46333	the	_
213-17	46334-46338	FESZ	_
213-18	46339-46344	group	_
213-19	46345-46349	were	_
213-20	46350-46363	significantly	_
213-21	46364-46370	bigger	_
213-22	46371-46375	than	_
213-23	46376-46381	those	_
213-24	46382-46384	of	_
213-25	46385-46388	the	_
213-26	46389-46391	HC	_
213-27	46392-46393	(	_
213-28	46393-46394	P	_
213-29	46395-46396	<	_
213-30	46397-46402	0.001	_
213-31	46402-46403	)	_
213-32	46404-46407	and	_
213-33	46408-46413	FEAFF	_
213-34	46414-46415	(	_
213-35	46415-46416	P	_
213-36	46417-46418	<	_
213-37	46419-46424	0.001	_
213-38	46424-46425	)	_
213-39	46426-46432	groups	_
213-40	46432-46433	.	_

#Text=Post hoc Tukey HSD tests indicated that entire IFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
214-1	46434-46438	Post	_
214-2	46439-46442	hoc	_
214-3	46443-46448	Tukey	_
214-4	46449-46452	HSD	_
214-5	46453-46458	tests	_
214-6	46459-46468	indicated	_
214-7	46469-46473	that	_
214-8	46474-46480	entire	_
214-9	46481-46484	IFG	_
214-10	46485-46493	relative	_
214-11	46494-46500	volume	_
214-12	46501-46512	percentages	_
214-13	46513-46515	of	_
214-14	46516-46522	change	_
214-15	46523-46525	of	_
214-16	46526-46529	the	_
214-17	46530-46534	FESZ	_
214-18	46535-46540	group	_
214-19	46541-46545	were	_
214-20	46546-46559	significantly	_
214-21	46560-46566	bigger	_
214-22	46567-46571	than	_
214-23	46572-46577	those	_
214-24	46578-46580	of	_
214-25	46581-46584	the	_
214-26	46585-46587	HC	_
214-27	46588-46589	(	_
214-28	46589-46590	P	_
214-29	46591-46592	<	_
214-30	46593-46598	0.001	_
214-31	46598-46599	)	_
214-32	46600-46603	and	_
214-33	46604-46609	FEAFF	_
214-34	46610-46611	(	_
214-35	46611-46612	P	_
214-36	46613-46614	<	_
214-37	46615-46620	0.001	_
214-38	46620-46621	)	_
214-39	46622-46628	groups	_
214-40	46628-46629	.	_

#Text=Post hoc Tukey HSD tests indicated that left IFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
215-1	46630-46634	Post	_
215-2	46635-46638	hoc	_
215-3	46639-46644	Tukey	_
215-4	46645-46648	HSD	_
215-5	46649-46654	tests	_
215-6	46655-46664	indicated	_
215-7	46665-46669	that	_
215-8	46670-46674	left	_
215-9	46675-46678	IFG	_
215-10	46679-46687	relative	_
215-11	46688-46694	volume	_
215-12	46695-46706	percentages	_
215-13	46707-46709	of	_
215-14	46710-46716	change	_
215-15	46717-46719	of	_
215-16	46720-46723	the	_
215-17	46724-46728	FESZ	_
215-18	46729-46734	group	_
215-19	46735-46739	were	_
215-20	46740-46753	significantly	_
215-21	46754-46760	bigger	_
215-22	46761-46765	than	_
215-23	46766-46771	those	_
215-24	46772-46774	of	_
215-25	46775-46778	the	_
215-26	46779-46781	HC	_
215-27	46782-46783	(	_
215-28	46783-46784	P	_
215-29	46785-46786	<	_
215-30	46787-46792	0.001	_
215-31	46792-46793	)	_
215-32	46794-46797	and	_
215-33	46798-46803	FEAFF	_
215-34	46804-46805	(	_
215-35	46805-46806	P	_
215-36	46807-46808	<	_
215-37	46809-46814	0.001	_
215-38	46814-46815	)	_
215-39	46816-46822	groups	_
215-40	46822-46823	.	_

#Text=Post hoc Tukey HSD tests indicated that right IFG relative volume percentages of change of the FESZ group were significantly bigger than those of the HC (P < 0.001) and FEAFF (P < 0.001) groups.
216-1	46824-46828	Post	_
216-2	46829-46832	hoc	_
216-3	46833-46838	Tukey	_
216-4	46839-46842	HSD	_
216-5	46843-46848	tests	_
216-6	46849-46858	indicated	_
216-7	46859-46863	that	_
216-8	46864-46869	right	_
216-9	46870-46873	IFG	_
216-10	46874-46882	relative	_
216-11	46883-46889	volume	_
216-12	46890-46901	percentages	_
216-13	46902-46904	of	_
216-14	46905-46911	change	_
216-15	46912-46914	of	_
216-16	46915-46918	the	_
216-17	46919-46923	FESZ	_
216-18	46924-46929	group	_
216-19	46930-46934	were	_
216-20	46935-46948	significantly	_
216-21	46949-46955	bigger	_
216-22	46956-46960	than	_
216-23	46961-46966	those	_
216-24	46967-46969	of	_
216-25	46970-46973	the	_
216-26	46974-46976	HC	_
216-27	46977-46978	(	_
216-28	46978-46979	P	_
216-29	46980-46981	<	_
216-30	46982-46987	0.001	_
216-31	46987-46988	)	_
216-32	46989-46992	and	_
216-33	46993-46998	FEAFF	_
216-34	46999-47000	(	_
216-35	47000-47001	P	_
216-36	47002-47003	<	_
216-37	47004-47009	0.001	_
216-38	47009-47010	)	_
216-39	47011-47017	groups	_
216-40	47017-47018	.	_

#Text=Percentage of Change of Prefrontal Cortex Gray Matter in Patients Sub-grouped by Medication Type, Compared with HCs.
217-1	47019-47029	Percentage	_
217-2	47030-47032	of	_
217-3	47033-47039	Change	_
217-4	47040-47042	of	_
217-5	47043-47053	Prefrontal	_
217-6	47054-47060	Cortex	_
217-7	47061-47065	Gray	_
217-8	47066-47072	Matter	_
217-9	47073-47075	in	_
217-10	47076-47084	Patients	_
217-11	47085-47096	Sub-grouped	_
217-12	47097-47099	by	_
217-13	47100-47110	Medication	_
217-14	47111-47115	Type	_
217-15	47115-47116	,	_
217-16	47117-47125	Compared	_
217-17	47126-47130	with	_
217-18	47131-47134	HCs	_
217-19	47134-47135	.	_

#Text=Change, % (SD)a\tFESZ Group (n = 21)b\tFEAFF Group (n = 24)\tHC Group (n = 23)\tOverall Group Comparison of Percentage of Changes (1-Factor ANOVA by Group)c\tPost Hoc Tukey HDS Test\t \t\t\t \t+TYP (n = 3)d\t+ATYP (n = 19)d\tBOTH (n = 2)d\t+MS (n = 20)e\t−MS (n = 4)e\tF5,65\tP Value\t \tLeft FP\t−0.508\t−1.168\t−3.346\t−0.275\t−1.661\t−0.965\t0.225\t.95\t\t \t2.774\t3.309\t6.499\t4.242\t4.712\t4.670\t\t\t\t \tRight FP\t−1.836\t−1.390\t−1.897\t−1.067\t−1.475\t−1.030\t0.335\t.89\t\t \t1.979\t2.236\t0.919\t5.856\t4.631\t4.446\t\t\t\t \tLeft SFG\t−3.775\t−5.994\t−8.596\t−0.925\t−0.588\t−0.510\t9.683\t<.001\tFESZ+ATYP = FESZ+TYP = HC, FESZ+ATYP < HCf\t \t3.971\t2.608\t0.528\t2.569\t3.325\t3.172\t\t\tFEAFF+MS = FEAFF-MS = HCg\t \tRight SFG\t−4.340\t−3.417\t−2.367\t−1.092\t−0.223\t−0.637\t1.801\t.125\t\t \t4.437\t4.464\t2.359\t4.614\t2.284\t2.614\t\t\t\t \tLeft MFG\t−7.370\t−7.654\t−3.932\t−0.944\t−1.020\t−0.365\t15.695\t<.001\tFESZ+TYP = FESZ+ATYP < HCh\t \t4.670\t4.001\t3.075\t3.137\t2.610\t1.980\t\t\tFEAFF+MS =FEAFF-MS = HCi\t \tRight MFG\t−9.328\t−7.492\t−9.470\t−1.342\t−2.285\t−0.479\t13.583\t<.001\tFESZ+TYP = FESZ+ATYP < HCj\t \t2.366\t3.799\t2.718\t3.960\t5.010\t2.920\t\t\tFEAFF+MS = FEAFF-MS = HCk\t \tLeft IFG\t−7.356\t−8.722\t−7.983\t−2.977\t−1.841\t−0.450\t10.677\t<.001\tFESZ+ATYP = FESZ+TYP = HC, FESZ+ATYP < HCl\t \t4.460\t4.620\t1.339\t4.970\t2.394\t1.654\t\t\tFEAFF+MS = FEAFF-MS = HCm\t \tRight IFG\t−9.594\t−8.651\t−8.477\t−0.503\t−1.200\t−0.457\t8.919\t<.001\tFESZ+ATYP = FESZ+TYP = HC, FESZ+ATYP < HCn\t \t2.916\t4.567\t1.289\t6.709\t6.345\t2.896\t\t\tFEAFF+MS = FEAFF-MS = HCo\t \t
#Text=Abbreviations: +ATY, with atypical neuroleptic treatment without exposure to typical neuroleptics at times 1 and 2 magnetic resonance imaging (MRI); FEAFF, first episode affective psychosis; FESZ, first episode schizophrenia; HCs, healthy comparison subjects; +/−MS, with/without mood stabilizer treatment; SED, standard error of the difference; +TYP, with typical neuroleptic treatment; +ATYP, with atypical neuroleptic treatment.
218-1	47136-47142	Change	_
218-2	47142-47143	,	_
218-3	47144-47145	%	_
218-4	47146-47147	(	_
218-5	47147-47149	SD	_
218-6	47149-47150	)	_
218-7	47150-47151	a	_
218-8	47152-47156	FESZ	_
218-9	47157-47162	Group	_
218-10	47163-47164	(	_
218-11	47164-47165	n	_
218-12	47166-47167	=	_
218-13	47168-47170	21	_
218-14	47170-47171	)	_
218-15	47171-47172	b	_
218-16	47173-47178	FEAFF	_
218-17	47179-47184	Group	_
218-18	47185-47186	(	_
218-19	47186-47187	n	_
218-20	47188-47189	=	_
218-21	47190-47192	24	_
218-22	47192-47193	)	_
218-23	47194-47196	HC	_
218-24	47197-47202	Group	_
218-25	47203-47204	(	_
218-26	47204-47205	n	_
218-27	47206-47207	=	_
218-28	47208-47210	23	_
218-29	47210-47211	)	_
218-30	47212-47219	Overall	_
218-31	47220-47225	Group	_
218-32	47226-47236	Comparison	_
218-33	47237-47239	of	_
218-34	47240-47250	Percentage	_
218-35	47251-47253	of	_
218-36	47254-47261	Changes	_
218-37	47262-47263	(	_
218-38	47263-47264	1	_
218-39	47264-47265	-	_
218-40	47265-47271	Factor	_
218-41	47272-47277	ANOVA	_
218-42	47278-47280	by	_
218-43	47281-47286	Group	_
218-44	47286-47287	)	_
218-45	47287-47288	c	_
218-46	47289-47293	Post	_
218-47	47294-47297	Hoc	_
218-48	47298-47303	Tukey	_
218-49	47304-47307	HDS	_
218-50	47308-47312	Test	_
218-51	47319-47320	+	_
218-52	47320-47323	TYP	_
218-53	47324-47325	(	_
218-54	47325-47326	n	_
218-55	47327-47328	=	_
218-56	47329-47330	3	_
218-57	47330-47331	)	_
218-58	47331-47332	d	_
218-59	47333-47334	+	_
218-60	47334-47338	ATYP	_
218-61	47339-47340	(	_
218-62	47340-47341	n	_
218-63	47342-47343	=	_
218-64	47344-47346	19	_
218-65	47346-47347	)	_
218-66	47347-47348	d	_
218-67	47349-47353	BOTH	_
218-68	47354-47355	(	_
218-69	47355-47356	n	_
218-70	47357-47358	=	_
218-71	47359-47360	2	_
218-72	47360-47361	)	_
218-73	47361-47362	d	_
218-74	47363-47364	+	_
218-75	47364-47366	MS	_
218-76	47367-47368	(	_
218-77	47368-47369	n	_
218-78	47370-47371	=	_
218-79	47372-47374	20	_
218-80	47374-47375	)	_
218-81	47375-47376	e	_
218-82	47377-47378	−	_
218-83	47378-47380	MS	_
218-84	47381-47382	(	_
218-85	47382-47383	n	_
218-86	47384-47385	=	_
218-87	47386-47387	4	_
218-88	47387-47388	)	_
218-89	47388-47389	e	_
218-90	47390-47395	F5,65	_
218-91	47396-47397	P	_
218-92	47398-47403	Value	_
218-93	47406-47410	Left	_
218-94	47411-47413	FP	_
218-95	47414-47415	−	_
218-96	47415-47420	0.508	_
218-97	47421-47422	−	_
218-98	47422-47427	1.168	_
218-99	47428-47429	−	_
218-100	47429-47434	3.346	_
218-101	47435-47436	−	_
218-102	47436-47441	0.275	_
218-103	47442-47443	−	_
218-104	47443-47448	1.661	_
218-105	47449-47450	−	_
218-106	47450-47455	0.965	_
218-107	47456-47461	0.225	_
218-108	47462-47465	.95	_
218-109	47469-47474	2.774	_
218-110	47475-47480	3.309	_
218-111	47481-47486	6.499	_
218-112	47487-47492	4.242	_
218-113	47493-47498	4.712	_
218-114	47499-47504	4.670	_
218-115	47510-47515	Right	_
218-116	47516-47518	FP	_
218-117	47519-47520	−	_
218-118	47520-47525	1.836	_
218-119	47526-47527	−	_
218-120	47527-47532	1.390	_
218-121	47533-47534	−	_
218-122	47534-47539	1.897	_
218-123	47540-47541	−	_
218-124	47541-47546	1.067	_
218-125	47547-47548	−	_
218-126	47548-47553	1.475	_
218-127	47554-47555	−	_
218-128	47555-47560	1.030	_
218-129	47561-47566	0.335	_
218-130	47567-47570	.89	_
218-131	47574-47579	1.979	_
218-132	47580-47585	2.236	_
218-133	47586-47591	0.919	_
218-134	47592-47597	5.856	_
218-135	47598-47603	4.631	_
218-136	47604-47609	4.446	_
218-137	47615-47619	Left	_
218-138	47620-47623	SFG	_
218-139	47624-47625	−	_
218-140	47625-47630	3.775	_
218-141	47631-47632	−	_
218-142	47632-47637	5.994	_
218-143	47638-47639	−	_
218-144	47639-47644	8.596	_
218-145	47645-47646	−	_
218-146	47646-47651	0.925	_
218-147	47652-47653	−	_
218-148	47653-47658	0.588	_
218-149	47659-47660	−	_
218-150	47660-47665	0.510	_
218-151	47666-47671	9.683	_
218-152	47672-47673	<	_
218-153	47673-47677	.001	_
218-154	47678-47682	FESZ	_
218-155	47682-47683	+	_
218-156	47683-47687	ATYP	_
218-157	47688-47689	=	_
218-158	47690-47694	FESZ	_
218-159	47694-47695	+	_
218-160	47695-47698	TYP	_
218-161	47699-47700	=	_
218-162	47701-47703	HC	_
218-163	47703-47704	,	_
218-164	47705-47709	FESZ	_
218-165	47709-47710	+	_
218-166	47710-47714	ATYP	_
218-167	47715-47716	<	_
218-168	47717-47720	HCf	_
218-169	47723-47728	3.971	_
218-170	47729-47734	2.608	_
218-171	47735-47740	0.528	_
218-172	47741-47746	2.569	_
218-173	47747-47752	3.325	_
218-174	47753-47758	3.172	_
218-175	47761-47766	FEAFF	_
218-176	47766-47767	+	_
218-177	47767-47769	MS	_
218-178	47770-47771	=	_
218-179	47772-47780	FEAFF-MS	_
218-180	47781-47782	=	_
218-181	47783-47786	HCg	_
218-182	47789-47794	Right	_
218-183	47795-47798	SFG	_
218-184	47799-47800	−	_
218-185	47800-47805	4.340	_
218-186	47806-47807	−	_
218-187	47807-47812	3.417	_
218-188	47813-47814	−	_
218-189	47814-47819	2.367	_
218-190	47820-47821	−	_
218-191	47821-47826	1.092	_
218-192	47827-47828	−	_
218-193	47828-47833	0.223	_
218-194	47834-47835	−	_
218-195	47835-47840	0.637	_
218-196	47841-47846	1.801	_
218-197	47847-47851	.125	_
218-198	47855-47860	4.437	_
218-199	47861-47866	4.464	_
218-200	47867-47872	2.359	_
218-201	47873-47878	4.614	_
218-202	47879-47884	2.284	_
218-203	47885-47890	2.614	_
218-204	47896-47900	Left	_
218-205	47901-47904	MFG	_
218-206	47905-47906	−	_
218-207	47906-47911	7.370	_
218-208	47912-47913	−	_
218-209	47913-47918	7.654	_
218-210	47919-47920	−	_
218-211	47920-47925	3.932	_
218-212	47926-47927	−	_
218-213	47927-47932	0.944	_
218-214	47933-47934	−	_
218-215	47934-47939	1.020	_
218-216	47940-47941	−	_
218-217	47941-47946	0.365	_
218-218	47947-47953	15.695	_
218-219	47954-47955	<	_
218-220	47955-47959	.001	_
218-221	47960-47964	FESZ	_
218-222	47964-47965	+	_
218-223	47965-47968	TYP	_
218-224	47969-47970	=	_
218-225	47971-47975	FESZ	_
218-226	47975-47976	+	_
218-227	47976-47980	ATYP	_
218-228	47981-47982	<	_
218-229	47983-47986	HCh	_
218-230	47989-47994	4.670	_
218-231	47995-48000	4.001	_
218-232	48001-48006	3.075	_
218-233	48007-48012	3.137	_
218-234	48013-48018	2.610	_
218-235	48019-48024	1.980	_
218-236	48027-48032	FEAFF	_
218-237	48032-48033	+	_
218-238	48033-48035	MS	_
218-239	48036-48037	=	_
218-240	48037-48045	FEAFF-MS	_
218-241	48046-48047	=	_
218-242	48048-48051	HCi	_
218-243	48054-48059	Right	_
218-244	48060-48063	MFG	_
218-245	48064-48065	−	_
218-246	48065-48070	9.328	_
218-247	48071-48072	−	_
218-248	48072-48077	7.492	_
218-249	48078-48079	−	_
218-250	48079-48084	9.470	_
218-251	48085-48086	−	_
218-252	48086-48091	1.342	_
218-253	48092-48093	−	_
218-254	48093-48098	2.285	_
218-255	48099-48100	−	_
218-256	48100-48105	0.479	_
218-257	48106-48112	13.583	_
218-258	48113-48114	<	_
218-259	48114-48118	.001	_
218-260	48119-48123	FESZ	_
218-261	48123-48124	+	_
218-262	48124-48127	TYP	_
218-263	48128-48129	=	_
218-264	48130-48134	FESZ	_
218-265	48134-48135	+	_
218-266	48135-48139	ATYP	_
218-267	48140-48141	<	_
218-268	48142-48145	HCj	_
218-269	48148-48153	2.366	_
218-270	48154-48159	3.799	_
218-271	48160-48165	2.718	_
218-272	48166-48171	3.960	_
218-273	48172-48177	5.010	_
218-274	48178-48183	2.920	_
218-275	48186-48191	FEAFF	_
218-276	48191-48192	+	_
218-277	48192-48194	MS	_
218-278	48195-48196	=	_
218-279	48197-48205	FEAFF-MS	_
218-280	48206-48207	=	_
218-281	48208-48211	HCk	_
218-282	48214-48218	Left	_
218-283	48219-48222	IFG	_
218-284	48223-48224	−	_
218-285	48224-48229	7.356	_
218-286	48230-48231	−	_
218-287	48231-48236	8.722	_
218-288	48237-48238	−	_
218-289	48238-48243	7.983	_
218-290	48244-48245	−	_
218-291	48245-48250	2.977	_
218-292	48251-48252	−	_
218-293	48252-48257	1.841	_
218-294	48258-48259	−	_
218-295	48259-48264	0.450	_
218-296	48265-48271	10.677	_
218-297	48272-48273	<	_
218-298	48273-48277	.001	_
218-299	48278-48282	FESZ	_
218-300	48282-48283	+	_
218-301	48283-48287	ATYP	_
218-302	48288-48289	=	_
218-303	48290-48294	FESZ	_
218-304	48294-48295	+	_
218-305	48295-48298	TYP	_
218-306	48299-48300	=	_
218-307	48301-48303	HC	_
218-308	48303-48304	,	_
218-309	48305-48309	FESZ	_
218-310	48309-48310	+	_
218-311	48310-48314	ATYP	_
218-312	48315-48316	<	_
218-313	48317-48320	HCl	_
218-314	48323-48328	4.460	_
218-315	48329-48334	4.620	_
218-316	48335-48340	1.339	_
218-317	48341-48346	4.970	_
218-318	48347-48352	2.394	_
218-319	48353-48358	1.654	_
218-320	48361-48366	FEAFF	_
218-321	48366-48367	+	_
218-322	48367-48369	MS	_
218-323	48370-48371	=	_
218-324	48372-48380	FEAFF-MS	_
218-325	48381-48382	=	_
218-326	48383-48386	HCm	_
218-327	48389-48394	Right	_
218-328	48395-48398	IFG	_
218-329	48399-48400	−	_
218-330	48400-48405	9.594	_
218-331	48406-48407	−	_
218-332	48407-48412	8.651	_
218-333	48413-48414	−	_
218-334	48414-48419	8.477	_
218-335	48420-48421	−	_
218-336	48421-48426	0.503	_
218-337	48427-48428	−	_
218-338	48428-48433	1.200	_
218-339	48434-48435	−	_
218-340	48435-48440	0.457	_
218-341	48441-48446	8.919	_
218-342	48447-48448	<	_
218-343	48448-48452	.001	_
218-344	48453-48457	FESZ	_
218-345	48457-48458	+	_
218-346	48458-48462	ATYP	_
218-347	48463-48464	=	_
218-348	48465-48469	FESZ	_
218-349	48469-48470	+	_
218-350	48470-48473	TYP	_
218-351	48474-48475	=	_
218-352	48476-48478	HC	_
218-353	48478-48479	,	_
218-354	48480-48484	FESZ	_
218-355	48484-48485	+	_
218-356	48485-48489	ATYP	_
218-357	48490-48491	<	_
218-358	48492-48495	HCn	_
218-359	48498-48503	2.916	_
218-360	48504-48509	4.567	_
218-361	48510-48515	1.289	_
218-362	48516-48521	6.709	_
218-363	48522-48527	6.345	_
218-364	48528-48533	2.896	_
218-365	48536-48541	FEAFF	_
218-366	48541-48542	+	_
218-367	48542-48544	MS	_
218-368	48545-48546	=	_
218-369	48547-48555	FEAFF-MS	_
218-370	48556-48557	=	_
218-371	48558-48561	HCo	_
218-372	48565-48578	Abbreviations	_
218-373	48578-48579	:	_
218-374	48580-48581	+	_
218-375	48581-48584	ATY	_
218-376	48584-48585	,	_
218-377	48586-48590	with	_
218-378	48591-48599	atypical	_
218-379	48600-48611	neuroleptic	_
218-380	48612-48621	treatment	_
218-381	48622-48629	without	_
218-382	48630-48638	exposure	_
218-383	48639-48641	to	_
218-384	48642-48649	typical	_
218-385	48650-48662	neuroleptics	_
218-386	48663-48665	at	_
218-387	48666-48671	times	_
218-388	48672-48673	1	_
218-389	48674-48677	and	_
218-390	48678-48679	2	_
218-391	48680-48688	magnetic	_
218-392	48689-48698	resonance	_
218-393	48699-48706	imaging	_
218-394	48707-48708	(	_
218-395	48708-48711	MRI	_
218-396	48711-48712	)	_
218-397	48712-48713	;	_
218-398	48714-48719	FEAFF	_
218-399	48719-48720	,	_
218-400	48721-48726	first	_
218-401	48727-48734	episode	_
218-402	48735-48744	affective	_
218-403	48745-48754	psychosis	_
218-404	48754-48755	;	_
218-405	48756-48760	FESZ	_
218-406	48760-48761	,	_
218-407	48762-48767	first	_
218-408	48768-48775	episode	_
218-409	48776-48789	schizophrenia	_
218-410	48789-48790	;	_
218-411	48791-48794	HCs	_
218-412	48794-48795	,	_
218-413	48796-48803	healthy	_
218-414	48804-48814	comparison	_
218-415	48815-48823	subjects	_
218-416	48823-48824	;	_
218-417	48825-48826	+	_
218-418	48826-48827	/	_
218-419	48827-48828	−	_
218-420	48828-48830	MS	_
218-421	48830-48831	,	_
218-422	48832-48836	with	_
218-423	48836-48837	/	_
218-424	48837-48844	without	_
218-425	48845-48849	mood	_
218-426	48850-48860	stabilizer	_
218-427	48861-48870	treatment	_
218-428	48870-48871	;	_
218-429	48872-48875	SED	_
218-430	48875-48876	,	_
218-431	48877-48885	standard	_
218-432	48886-48891	error	_
218-433	48892-48894	of	_
218-434	48895-48898	the	_
218-435	48899-48909	difference	_
218-436	48909-48910	;	_
218-437	48911-48912	+	_
218-438	48912-48915	TYP	_
218-439	48915-48916	,	_
218-440	48917-48921	with	_
218-441	48922-48929	typical	_
218-442	48930-48941	neuroleptic	_
218-443	48942-48951	treatment	_
218-444	48951-48952	;	_
218-445	48953-48954	+	_
218-446	48954-48958	ATYP	_
218-447	48958-48959	,	_
218-448	48960-48964	with	_
218-449	48965-48973	atypical	_
218-450	48974-48985	neuroleptic	_
218-451	48986-48995	treatment	_
218-452	48995-48996	.	_

#Text=Calculated as ((volume at second MRI - volume at baseline MRI) / volume at baseline MRI) x 100.
219-1	48997-49007	Calculated	_
219-2	49008-49010	as	_
219-3	49011-49012	(	_
219-4	49012-49013	(	_
219-5	49013-49019	volume	_
219-6	49020-49022	at	_
219-7	49023-49029	second	_
219-8	49030-49033	MRI	_
219-9	49034-49035	-	_
219-10	49036-49042	volume	_
219-11	49043-49045	at	_
219-12	49046-49054	baseline	_
219-13	49055-49058	MRI	_
219-14	49058-49059	)	_
219-15	49060-49061	/	_
219-16	49062-49068	volume	_
219-17	49069-49071	at	_
219-18	49072-49080	baseline	_
219-19	49081-49084	MRI	_
219-20	49084-49085	)	_
219-21	49086-49087	x	_
219-22	49088-49091	100	_
219-23	49091-49092	.	_

#Text=One of the 21 FESZ subjects was not prescribed typical and atypical neuroleptics (only prescribed Gabapentin).
220-1	49093-49096	One	_
220-2	49097-49099	of	_
220-3	49100-49103	the	_
220-4	49104-49106	21	_
220-5	49107-49111	FESZ	_
220-6	49112-49120	subjects	_
220-7	49121-49124	was	_
220-8	49125-49128	not	_
220-9	49129-49139	prescribed	_
220-10	49140-49147	typical	_
220-11	49148-49151	and	_
220-12	49152-49160	atypical	_
220-13	49161-49173	neuroleptics	_
220-14	49174-49175	(	_
220-15	49175-49179	only	_
220-16	49180-49190	prescribed	_
220-17	49191-49201	Gabapentin	_
220-18	49201-49202	)	_
220-19	49202-49203	.	_

#Text=Calculated using one-way analysis of variance (ANOVA) by group for the percentages of change of prefrontal cortex gray matter relative volumes in each region.
221-1	49204-49214	Calculated	_
221-2	49215-49220	using	_
221-3	49221-49228	one-way	_
221-4	49229-49237	analysis	_
221-5	49238-49240	of	_
221-6	49241-49249	variance	_
221-7	49250-49251	(	_
221-8	49251-49256	ANOVA	_
221-9	49256-49257	)	_
221-10	49258-49260	by	_
221-11	49261-49266	group	_
221-12	49267-49270	for	_
221-13	49271-49274	the	_
221-14	49275-49286	percentages	_
221-15	49287-49289	of	_
221-16	49290-49296	change	_
221-17	49297-49299	of	_
221-18	49300-49310	prefrontal	_
221-19	49311-49317	cortex	_
221-20	49318-49322	gray	_
221-21	49323-49329	matter	_
221-22	49330-49338	relative	_
221-23	49339-49346	volumes	_
221-24	49347-49349	in	_
221-25	49350-49354	each	_
221-26	49355-49361	region	_
221-27	49361-49362	.	_

#Text=The groups include the 6 given in the Table (FESZ +TYP, FESZ +ATYP, FESZ BOTH, FEAFF +MS, FEAFF −MS, and HC).
222-1	49363-49366	The	_
222-2	49367-49373	groups	_
222-3	49374-49381	include	_
222-4	49382-49385	the	_
222-5	49386-49387	6	_
222-6	49388-49393	given	_
222-7	49394-49396	in	_
222-8	49397-49400	the	_
222-9	49401-49406	Table	_
222-10	49407-49408	(	_
222-11	49408-49412	FESZ	_
222-12	49413-49414	+	_
222-13	49414-49417	TYP	_
222-14	49417-49418	,	_
222-15	49419-49423	FESZ	_
222-16	49424-49425	+	_
222-17	49425-49429	ATYP	_
222-18	49429-49430	,	_
222-19	49431-49435	FESZ	_
222-20	49436-49440	BOTH	_
222-21	49440-49441	,	_
222-22	49442-49447	FEAFF	_
222-23	49448-49449	+	_
222-24	49449-49451	MS	_
222-25	49451-49452	,	_
222-26	49453-49458	FEAFF	_
222-27	49459-49460	−	_
222-28	49460-49462	MS	_
222-29	49462-49463	,	_
222-30	49464-49467	and	_
222-31	49468-49470	HC	_
222-32	49470-49471	)	_
222-33	49471-49472	.	_

#Text=Number of subjects who received the medication from the baseline scan to the second scan.
223-1	49473-49479	Number	_
223-2	49480-49482	of	_
223-3	49483-49491	subjects	_
223-4	49492-49495	who	_
223-5	49496-49504	received	_
223-6	49505-49508	the	_
223-7	49509-49519	medication	_
223-8	49520-49524	from	_
223-9	49525-49528	the	_
223-10	49529-49537	baseline	_
223-11	49538-49542	scan	_
223-12	49543-49545	to	_
223-13	49546-49549	the	_
223-14	49550-49556	second	_
223-15	49557-49561	scan	_
223-16	49561-49562	.	_

#Text=Number of subjects who received the medication from the baseline scan to the second scan.
224-1	49563-49569	Number	_
224-2	49570-49572	of	_
224-3	49573-49581	subjects	_
224-4	49582-49585	who	_
224-5	49586-49594	received	_
224-6	49595-49598	the	_
224-7	49599-49609	medication	_
224-8	49610-49614	from	_
224-9	49615-49618	the	_
224-10	49619-49627	baseline	_
224-11	49628-49632	scan	_
224-12	49633-49635	to	_
224-13	49636-49639	the	_
224-14	49640-49646	second	_
224-15	49647-49651	scan	_
224-16	49651-49652	.	_

#Text=Mood stabilizer includes lithium or valproic acid.
225-1	49653-49657	Mood	_
225-2	49658-49668	stabilizer	_
225-3	49669-49677	includes	_
225-4	49678-49685	lithium	_
225-5	49686-49688	or	_
225-6	49689-49697	valproic	_
225-7	49698-49702	acid	_
225-8	49702-49703	.	_

#Text=P = 1.000 between the FESZ+ATYP and FESZ+TYP groups, P = 1.000 between the FESZ+TYP and HC groups, and P < .001 between FESZ+ATYP and HC groups.
226-1	49704-49705	P	_
226-2	49706-49707	=	_
226-3	49708-49713	1.000	_
226-4	49714-49721	between	_
226-5	49722-49725	the	_
226-6	49726-49730	FESZ	_
226-7	49730-49731	+	_
226-8	49731-49735	ATYP	_
226-9	49736-49739	and	_
226-10	49740-49744	FESZ	_
226-11	49744-49745	+	_
226-12	49745-49748	TYP	_
226-13	49749-49755	groups	_
226-14	49755-49756	,	_
226-15	49757-49758	P	_
226-16	49759-49760	=	_
226-17	49761-49766	1.000	_
226-18	49767-49774	between	_
226-19	49775-49778	the	_
226-20	49779-49783	FESZ	_
226-21	49783-49784	+	_
226-22	49784-49787	TYP	_
226-23	49788-49791	and	_
226-24	49792-49794	HC	_
226-25	49795-49801	groups	_
226-26	49801-49802	,	_
226-27	49803-49806	and	_
226-28	49807-49808	P	_
226-29	49809-49810	<	_
226-30	49811-49815	.001	_
226-31	49816-49823	between	_
226-32	49824-49828	FESZ	_
226-33	49828-49829	+	_
226-34	49829-49833	ATYP	_
226-35	49834-49837	and	_
226-36	49838-49840	HC	_
226-37	49841-49847	groups	_
226-38	49847-49848	.	_

#Text=P = 1.000 between the FEAFF +MS and FEAFF −MS groups, P = 1.000 between the FEAFF +MS and HC groups, and P = 1.000 between the FEAFF −MS and HC groups
#Text=P = 1.000 between the FESZ+TYP and FESZ+ATYP groups, P = .010 between the FESZ+TYP and HC groups, and P < .001 between the FESZ+ATYP and HC groups.
227-1	49849-49850	P	_
227-2	49851-49852	=	_
227-3	49853-49858	1.000	_
227-4	49859-49866	between	_
227-5	49867-49870	the	_
227-6	49871-49876	FEAFF	_
227-7	49877-49878	+	_
227-8	49878-49880	MS	_
227-9	49881-49884	and	_
227-10	49885-49890	FEAFF	_
227-11	49891-49892	−	_
227-12	49892-49894	MS	_
227-13	49895-49901	groups	_
227-14	49901-49902	,	_
227-15	49903-49904	P	_
227-16	49905-49906	=	_
227-17	49907-49912	1.000	_
227-18	49913-49920	between	_
227-19	49921-49924	the	_
227-20	49925-49930	FEAFF	_
227-21	49931-49932	+	_
227-22	49932-49934	MS	_
227-23	49935-49938	and	_
227-24	49939-49941	HC	_
227-25	49942-49948	groups	_
227-26	49948-49949	,	_
227-27	49950-49953	and	_
227-28	49954-49955	P	_
227-29	49956-49957	=	_
227-30	49958-49963	1.000	_
227-31	49964-49971	between	_
227-32	49972-49975	the	_
227-33	49976-49981	FEAFF	_
227-34	49982-49983	−	_
227-35	49983-49985	MS	_
227-36	49986-49989	and	_
227-37	49990-49992	HC	_
227-38	49993-49999	groups	_
227-39	50000-50001	P	_
227-40	50002-50003	=	_
227-41	50004-50009	1.000	_
227-42	50010-50017	between	_
227-43	50018-50021	the	_
227-44	50022-50026	FESZ	_
227-45	50026-50027	+	_
227-46	50027-50030	TYP	_
227-47	50031-50034	and	_
227-48	50035-50039	FESZ	_
227-49	50039-50040	+	_
227-50	50040-50044	ATYP	_
227-51	50045-50051	groups	_
227-52	50051-50052	,	_
227-53	50053-50054	P	_
227-54	50055-50056	=	_
227-55	50057-50061	.010	_
227-56	50062-50069	between	_
227-57	50070-50073	the	_
227-58	50074-50078	FESZ	_
227-59	50078-50079	+	_
227-60	50079-50082	TYP	_
227-61	50083-50086	and	_
227-62	50087-50089	HC	_
227-63	50090-50096	groups	_
227-64	50096-50097	,	_
227-65	50098-50101	and	_
227-66	50102-50103	P	_
227-67	50104-50105	<	_
227-68	50106-50110	.001	_
227-69	50111-50118	between	_
227-70	50119-50122	the	_
227-71	50123-50127	FESZ	_
227-72	50127-50128	+	_
227-73	50128-50132	ATYP	_
227-74	50133-50136	and	_
227-75	50137-50139	HC	_
227-76	50140-50146	groups	_
227-77	50146-50147	.	_

#Text=P = 1.000 between the FEAFF +MS and FEAFF −MS groups, P = 1.000 between the FEAFF +MS and HC groups, and P = 1.000 FEAFF −MS and HC groups.
228-1	50148-50149	P	_
228-2	50150-50151	=	_
228-3	50152-50157	1.000	_
228-4	50158-50165	between	_
228-5	50166-50169	the	_
228-6	50170-50175	FEAFF	_
228-7	50176-50177	+	_
228-8	50177-50179	MS	_
228-9	50180-50183	and	_
228-10	50184-50189	FEAFF	_
228-11	50190-50191	−	_
228-12	50191-50193	MS	_
228-13	50194-50200	groups	_
228-14	50200-50201	,	_
228-15	50202-50203	P	_
228-16	50204-50205	=	_
228-17	50206-50211	1.000	_
228-18	50212-50219	between	_
228-19	50220-50223	the	_
228-20	50224-50229	FEAFF	_
228-21	50230-50231	+	_
228-22	50231-50233	MS	_
228-23	50234-50237	and	_
228-24	50238-50240	HC	_
228-25	50241-50247	groups	_
228-26	50247-50248	,	_
228-27	50249-50252	and	_
228-28	50253-50254	P	_
228-29	50255-50256	=	_
228-30	50257-50262	1.000	_
228-31	50263-50268	FEAFF	_
228-32	50269-50270	−	_
228-33	50270-50272	MS	_
228-34	50273-50276	and	_
228-35	50277-50279	HC	_
228-36	50280-50286	groups	_
228-37	50286-50287	.	_

#Text=P = 1.000 between the FESZ+TYP and FESZ+ATYP groups, P = .002 between the FESZ+TYP and HC groups, and P <.001 between the FESZ+ATYP and HC groups.
229-1	50288-50289	P	_
229-2	50290-50291	=	_
229-3	50292-50297	1.000	_
229-4	50298-50305	between	_
229-5	50306-50309	the	_
229-6	50310-50314	FESZ	_
229-7	50314-50315	+	_
229-8	50315-50318	TYP	_
229-9	50319-50322	and	_
229-10	50323-50327	FESZ	_
229-11	50327-50328	+	_
229-12	50328-50332	ATYP	_
229-13	50333-50339	groups	_
229-14	50339-50340	,	_
229-15	50341-50342	P	_
229-16	50343-50344	=	_
229-17	50345-50349	.002	_
229-18	50350-50357	between	_
229-19	50358-50361	the	_
229-20	50362-50366	FESZ	_
229-21	50366-50367	+	_
229-22	50367-50370	TYP	_
229-23	50371-50374	and	_
229-24	50375-50377	HC	_
229-25	50378-50384	groups	_
229-26	50384-50385	,	_
229-27	50386-50389	and	_
229-28	50390-50391	P	_
229-29	50392-50393	<	_
229-30	50393-50397	.001	_
229-31	50398-50405	between	_
229-32	50406-50409	the	_
229-33	50410-50414	FESZ	_
229-34	50414-50415	+	_
229-35	50415-50419	ATYP	_
229-36	50420-50423	and	_
229-37	50424-50426	HC	_
229-38	50427-50433	groups	_
229-39	50433-50434	.	_

#Text=P = 1.000 between the FEAFF+MS and FEAFF-MS groups, P = 1.000 between the FEAFF+MS and HC groups, and P = 1.000 between the FEAFF-MS and HC groups
#Text=P = 1.000 between the FESZ+TYP and FESZ+ATYP groups, P = .085 between the FESZ+TYP and HC groups, and P < .001 between the FESZ+ATYP and HC groups.
230-1	50435-50436	P	_
230-2	50437-50438	=	_
230-3	50439-50444	1.000	_
230-4	50445-50452	between	_
230-5	50453-50456	the	_
230-6	50457-50462	FEAFF	_
230-7	50462-50463	+	_
230-8	50463-50465	MS	_
230-9	50466-50469	and	_
230-10	50470-50478	FEAFF-MS	_
230-11	50479-50485	groups	_
230-12	50485-50486	,	_
230-13	50487-50488	P	_
230-14	50489-50490	=	_
230-15	50491-50496	1.000	_
230-16	50497-50504	between	_
230-17	50505-50508	the	_
230-18	50509-50514	FEAFF	_
230-19	50514-50515	+	_
230-20	50515-50517	MS	_
230-21	50518-50521	and	_
230-22	50522-50524	HC	_
230-23	50525-50531	groups	_
230-24	50531-50532	,	_
230-25	50533-50536	and	_
230-26	50537-50538	P	_
230-27	50539-50540	=	_
230-28	50541-50546	1.000	_
230-29	50547-50554	between	_
230-30	50555-50558	the	_
230-31	50559-50567	FEAFF-MS	_
230-32	50568-50571	and	_
230-33	50572-50574	HC	_
230-34	50575-50581	groups	_
230-35	50582-50583	P	_
230-36	50584-50585	=	_
230-37	50586-50591	1.000	_
230-38	50592-50599	between	_
230-39	50600-50603	the	_
230-40	50604-50608	FESZ	_
230-41	50608-50609	+	_
230-42	50609-50612	TYP	_
230-43	50613-50616	and	_
230-44	50617-50621	FESZ	_
230-45	50621-50622	+	_
230-46	50622-50626	ATYP	_
230-47	50627-50633	groups	_
230-48	50633-50634	,	_
230-49	50635-50636	P	_
230-50	50637-50638	=	_
230-51	50639-50643	.085	_
230-52	50644-50651	between	_
230-53	50652-50655	the	_
230-54	50656-50660	FESZ	_
230-55	50660-50661	+	_
230-56	50661-50664	TYP	_
230-57	50665-50668	and	_
230-58	50669-50671	HC	_
230-59	50672-50678	groups	_
230-60	50678-50679	,	_
230-61	50680-50683	and	_
230-62	50684-50685	P	_
230-63	50686-50687	<	_
230-64	50688-50692	.001	_
230-65	50693-50700	between	_
230-66	50701-50704	the	_
230-67	50705-50709	FESZ	_
230-68	50709-50710	+	_
230-69	50710-50714	ATYP	_
230-70	50715-50718	and	_
230-71	50719-50721	HC	_
230-72	50722-50728	groups	_
230-73	50728-50729	.	_

#Text=P = 1.000 between the FEAFF+MS and FEAFF-MS groups, P = .591 between the FEAFF+MS and HC groups, and P = 1.000 between the FEAFF-MS and HC groups
#Text=P = 1.000 between the FESZ+ATYP and FESZ+TYP groups, P = .050 between the FESZ+TYP and HC groups, and P < .001 between the FESZ+AYP and HC groups
#Text=P = 1.000 between the FEAFF +MS and FEAFF -MS groups, P = 1.000 between the FEAFF +MS and HC groups, and P = 1.000 between the FEAFF −MS and HC groups
231-1	50730-50731	P	_
231-2	50732-50733	=	_
231-3	50734-50739	1.000	_
231-4	50740-50747	between	_
231-5	50748-50751	the	_
231-6	50752-50757	FEAFF	_
231-7	50757-50758	+	_
231-8	50758-50760	MS	_
231-9	50761-50764	and	_
231-10	50765-50773	FEAFF-MS	_
231-11	50774-50780	groups	_
231-12	50780-50781	,	_
231-13	50782-50783	P	_
231-14	50784-50785	=	_
231-15	50786-50790	.591	_
231-16	50791-50798	between	_
231-17	50799-50802	the	_
231-18	50803-50808	FEAFF	_
231-19	50808-50809	+	_
231-20	50809-50811	MS	_
231-21	50812-50815	and	_
231-22	50816-50818	HC	_
231-23	50819-50825	groups	_
231-24	50825-50826	,	_
231-25	50827-50830	and	_
231-26	50831-50832	P	_
231-27	50833-50834	=	_
231-28	50835-50840	1.000	_
231-29	50841-50848	between	_
231-30	50849-50852	the	_
231-31	50853-50861	FEAFF-MS	_
231-32	50862-50865	and	_
231-33	50866-50868	HC	_
231-34	50869-50875	groups	_
231-35	50876-50877	P	_
231-36	50878-50879	=	_
231-37	50880-50885	1.000	_
231-38	50886-50893	between	_
231-39	50894-50897	the	_
231-40	50898-50902	FESZ	_
231-41	50902-50903	+	_
231-42	50903-50907	ATYP	_
231-43	50908-50911	and	_
231-44	50912-50916	FESZ	_
231-45	50916-50917	+	_
231-46	50917-50920	TYP	_
231-47	50921-50927	groups	_
231-48	50927-50928	,	_
231-49	50929-50930	P	_
231-50	50931-50932	=	_
231-51	50933-50937	.050	_
231-52	50938-50945	between	_
231-53	50946-50949	the	_
231-54	50950-50954	FESZ	_
231-55	50954-50955	+	_
231-56	50955-50958	TYP	_
231-57	50959-50962	and	_
231-58	50963-50965	HC	_
231-59	50966-50972	groups	_
231-60	50972-50973	,	_
231-61	50974-50977	and	_
231-62	50978-50979	P	_
231-63	50980-50981	<	_
231-64	50982-50986	.001	_
231-65	50987-50994	between	_
231-66	50995-50998	the	_
231-67	50999-51003	FESZ	_
231-68	51003-51004	+	_
231-69	51004-51007	AYP	_
231-70	51008-51011	and	_
231-71	51012-51014	HC	_
231-72	51015-51021	groups	_
231-73	51022-51023	P	_
231-74	51024-51025	=	_
231-75	51026-51031	1.000	_
231-76	51032-51039	between	_
231-77	51040-51043	the	_
231-78	51044-51049	FEAFF	_
231-79	51050-51051	+	_
231-80	51051-51053	MS	_
231-81	51054-51057	and	_
231-82	51058-51063	FEAFF	_
231-83	51064-51065	-	_
231-84	51065-51067	MS	_
231-85	51068-51074	groups	_
231-86	51074-51075	,	_
231-87	51076-51077	P	_
231-88	51078-51079	=	_
231-89	51080-51085	1.000	_
231-90	51086-51093	between	_
231-91	51094-51097	the	_
231-92	51098-51103	FEAFF	_
231-93	51104-51105	+	_
231-94	51105-51107	MS	_
231-95	51108-51111	and	_
231-96	51112-51114	HC	_
231-97	51115-51121	groups	_
231-98	51121-51122	,	_
231-99	51123-51126	and	_
231-100	51127-51128	P	_
231-101	51129-51130	=	_
231-102	51131-51136	1.000	_
231-103	51137-51144	between	_
231-104	51145-51148	the	_
231-105	51149-51154	FEAFF	_
231-106	51155-51156	−	_
231-107	51156-51158	MS	_
231-108	51159-51162	and	_
231-109	51163-51165	HC	_
231-110	51166-51172	groups	_
